<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:50.3pt;left:124.0pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">sease 53 (2016) 1209&#x2013;1230</span></p>
<p style="top:50.0pt;left:477.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1209</span></p>
<p style="top:97.6pt;left:117.0pt;line-height:24.9pt"><span style="font-family:Times New Roman,serif;font-size:24.9pt">g from the Dish to the Clinical</span></p>
<p style="top:127.5pt;left:120.1pt;line-height:24.9pt"><span style="font-family:Times New Roman,serif;font-size:24.9pt">e: A Decade of Lessons</span></p>
<p style="top:157.4pt;left:118.1pt;line-height:24.9pt"><span style="font-family:Times New Roman,serif;font-size:24.9pt">rspectives from the Pre-Clinical</span></p>
<p style="top:187.3pt;left:123.6pt;line-height:24.9pt"><span style="font-family:Times New Roman,serif;font-size:24.9pt">nical Stem Cell Studies</span></p>
<p style="top:217.2pt;left:122.2pt;line-height:24.9pt"><span style="font-family:Times New Roman,serif;font-size:24.9pt">heimer&#x2019;s Disease</span></p>
<p style="top:267.7pt;left:125.0pt;line-height:7.7pt"><span style="font-family:Times New Roman,serif;font-size:7.7pt">b</span><span style="font-family:Times New Roman,serif;font-size:11.0pt">, Natalia Pessoa Rocha</span><span style="font-family:Times New Roman,serif;font-size:7.7pt">a</span><span style="font-family:Times New Roman,serif;font-size:11.0pt">, Gabriela Delevati Colpo</span><span style="font-family:Times New Roman,serif;font-size:7.7pt">a</span><span style="font-family:Times New Roman,serif;font-size:11.0pt"> and Antonio Lucio Teixeira</span><span style="font-family:Times New Roman,serif;font-size:7.7pt">a</span><i><span style="font-family:MTMI,serif;font-size:7.7pt">,</span></i><span style="font-family:MTSY,serif;font-size:7.7pt">&#x2217;</span></p>
<p style="top:281.9pt;left:125.3pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">ychiatry and Behavioral Sciences, Neuropsychiatry Program, McGovern Medical School,</span></i></p>
<p style="top:293.9pt;left:122.5pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Texas Health Science Center, Houston, TX, USA</span></i></p>
<p style="top:305.8pt;left:122.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">dicine Program, University of L&#xa8;ubeck, Schleswig-Holstein, Germany</span></i></p>
<p style="top:372.6pt;left:125.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ere is no de&#xfb01;nitive treatment for Alzheimer&#x2019;s disease (AD). The realm of stem cells is very promising in</span></p>
<p style="top:383.5pt;left:125.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">e, particularly neurodegenerative disorders. Various types of stem cells have been used in multiple trials</span></p>
<p style="top:394.5pt;left:121.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ng to &#xfb01;nd an innovative management of this disease. In this systematic review, we trace the published</span></p>
<p style="top:405.5pt;left:122.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cal data throughout the last decade, to show how much knowledge we gained so far in this &#xfb01;eld and the</span></p>
<p style="top:416.4pt;left:125.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">f stem cells in AD treatment.</span></p>
<p style="top:437.2pt;left:123.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">er&#x2019;s disease, clinical trails, neurodegenerative diseases, preclinical trials, stem cells</span></p>
<p style="top:480.3pt;left:123.2pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">N</span></b></p>
<p style="top:504.2pt;left:124.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pment of the cell theory by Mattias</span></p>
<p style="top:516.1pt;left:123.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eodor Schwann in 1839, and after</span></p>
<p style="top:528.1pt;left:123.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">opularized the slogan: Omnis cel-</span></p>
<p style="top:540.0pt;left:128.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cells come from cells) in 1855,</span></p>
<p style="top:552.0pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">en considered the most fundamen-</span></p>
<p style="top:563.9pt;left:125.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">development of living organisms</span></p>
<p style="top:575.9pt;left:124.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">goes diverse processes throughout</span></p>
<p style="top:587.9pt;left:125.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nsures maintenance of organs and</span></p>
<p style="top:599.8pt;left:124.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">, 3].</span></p>
<p style="top:636.1pt;left:127.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Antonio Lucio Teixeira, MD, PhD, Neu-</span></p>
<p style="top:646.0pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Department of Psychiatry and Behavioral</span></p>
<p style="top:656.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Medical School, The University of Texas</span></p>
<p style="top:666.0pt;left:128.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">BBSB 3140, 1941 East Road, Houston,</span></p>
<p style="top:675.9pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">+1 713 486 2555; Fax: +1 713 486 2553;</span></p>
<p style="top:685.9pt;left:125.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">com/Antonio.L.Teixeira@uth.tmc.edu.</span></p>
<p style="top:480.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In order to sustain a balance between cell loss and</span></p>
<p style="top:492.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">replacement, cells should be capable of self-renewal</span></p>
<p style="top:504.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as well as differentiation. Stem/progenitor cells &#xfb01;rst</span></p>
<p style="top:516.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">described in 1964, lying at the heart of this process as</span></p>
<p style="top:528.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the functional units of regeneration, are clonogenic</span></p>
<p style="top:540.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">populations that can give rise to various cell lin-</span></p>
<p style="top:552.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eages [4, 5]. As their therapeutic potential has already</span></p>
<p style="top:563.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">been demonstrated in different settings, stem cells</span></p>
<p style="top:575.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">novel applications for clinical and preclinical trials</span></p>
<p style="top:587.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are of great interest, which will hopefully enable the</span></p>
<p style="top:599.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">promise of regenerative medicine to be accomplished</span></p>
<p style="top:611.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[6, 7].</span></p>
<p style="top:623.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Currently, the incurable neurodegenerative dis-</span></p>
<p style="top:635.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eases reached a staggering prevalence [8]. For</span></p>
<p style="top:647.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">example, in the United States, the prevalence of</span></p>
<p style="top:659.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Alzheimer&#x2019;s disease (AD) is estimated at 4.7 million</span></p>
<p style="top:671.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cases and is expected to continue increasing dramat-</span></p>
<p style="top:683.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ically [9]. The lack of de&#xfb01;nitive treatment to such</span></p>
<p style="top:715.9pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">5.00 &#xa9; 2016 &#x2013; IOS Press and the authors. All rights reserved</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:74.6pt;left:121.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mperativefornewinnovativeforms</span></p>
<p style="top:86.5pt;left:128.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ameliorate their crippling effects</span></p>
<p style="top:110.5pt;left:123.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ommonformofneurodegenerative</span></p>
<p style="top:122.4pt;left:123.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ng for about 60% to 70% of cases.</span></p>
<p style="top:134.4pt;left:124.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with several distinct neuropatho-</span></p>
<p style="top:146.3pt;left:120.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mainly extracellular amyloid-beta</span></p>
<p style="top:158.3pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ques, intracellular neuro&#xfb01;brillary</span></p>
<p style="top:170.2pt;left:121.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">osition of hyperphosphorylated tau</span></p>
<p style="top:182.2pt;left:122.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on loss with degeneration of the</span></p>
<p style="top:194.1pt;left:124.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ietal lobe, and parts of the frontal</span></p>
<p style="top:206.1pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ate gyrus. Clinically, it shows a</span></p>
<p style="top:218.1pt;left:123.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rment of learning, memory, lan-</span></p>
<p style="top:230.0pt;left:122.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sorientation, behavioral problems,</span></p>
<p style="top:242.0pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cline, and ultimately death. Sev-</span></p>
<p style="top:253.9pt;left:122.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">entioned risk factors related to AD</span></p>
<p style="top:265.9pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as genetics, neurotransmitters mal-</span></p>
<p style="top:277.8pt;left:123.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ronmental factors, including head</span></p>
<p style="top:289.8pt;left:125.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">. Currently, treatment for AD is</span></p>
<p style="top:301.7pt;left:123.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and there are no disease-modifying</span></p>
<p style="top:325.6pt;left:123.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oncept, stem cells appeared to be</span></p>
<p style="top:337.6pt;left:122.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eld of AD. The multifactorial com-</span></p>
<p style="top:349.6pt;left:119.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">D pathogenesis, in addition to the</span></p>
<p style="top:361.5pt;left:128.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the current pharmacological and</span></p>
<p style="top:373.5pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ategies, increased the necessity for</span></p>
<p style="top:385.4pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tackle the disease. This led to the</span></p>
<p style="top:397.4pt;left:124.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ious forms of stem cell lines in</span></p>
<p style="top:409.3pt;left:128.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ranging from basic lab research</span></p>
<p style="top:421.3pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">es and clinical trials, hoping for an</span></p>
<p style="top:433.2pt;left:124.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ll treatment for AD [14].</span></p>
<p style="top:445.2pt;left:121.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vely evolving nature of both stem</span></p>
<p style="top:457.2pt;left:127.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurogenesis research, we per-</span></p>
<p style="top:469.1pt;left:125.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the-art review tracing preclinical</span></p>
<p style="top:481.1pt;left:125.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">s that dealt with stem cells ther-</span></p>
<p style="top:493.0pt;left:124.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">D. Here, we aimed to highlight</span></p>
<p style="top:505.0pt;left:124.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">s: How far did we progress? What</span></p>
<p style="top:516.9pt;left:129.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we still have? Which cell lines</span></p>
<p style="top:528.9pt;left:121.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ng? Are we ready for a de&#xfb01;nitive</span></p>
<p style="top:590.1pt;left:124.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">f-the-art review of published data</span></p>
<p style="top:602.0pt;left:127.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">use of stem cells in AD treatment.</span></p>
<p style="top:625.5pt;left:123.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">usion criteria</span></i></p>
<p style="top:648.4pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">riteria entailed all scienti&#xfb01;c peer-</span></p>
<p style="top:660.4pt;left:127.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">articles (preclinical and clinical</span></p>
<p style="top:672.3pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">om 2006 until February 2016. As</span></p>
<p style="top:684.3pt;left:124.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we omitted all bench side studies,</span></p>
<p style="top:74.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reviews, editorials, communications, opinions, let-</span></p>
<p style="top:86.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ters, news, and reports. Also, any study that used</span></p>
<p style="top:98.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">concomitant treatment with stem cells or entailed</span></p>
<p style="top:110.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">indirect cell use (e.g., cells&#x2019; medium, endogenous</span></p>
<p style="top:122.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stemcellpopulationactivationorin&#xfb02;ammatorymedi-</span></p>
<p style="top:134.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ators derived from the cells) was excluded. This</span></p>
<p style="top:146.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">systematic review focused on direct cells application</span></p>
<p style="top:158.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies only. We used several electronic databases</span></p>
<p style="top:170.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(PubMed, Google Scholar, Elsevier ScienceDirect,</span></p>
<p style="top:182.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SpringerLink and PsycINFO) and the keywords</span></p>
<p style="top:194.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#x201c;STEM CELLS, NEURODEGENERATIVE DISE-</span></p>
<p style="top:206.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ASES, ALZHEIMER&#x2019;S, PRECLINICAL, CLINIAL</span></p>
<p style="top:218.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">TRIALS&#x201d; for search. In addition, we searched the</span></p>
<p style="top:230.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">http://www.clinicaltrials.gov website to compare the</span></p>
<p style="top:242.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">results of our search with the existing ongoing or &#xfb01;n-</span></p>
<p style="top:253.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ished clinical trials (Table 2). All the results were</span></p>
<p style="top:265.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">double checked to ensure they meet the mentioned</span></p>
<p style="top:277.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">criteria.</span></p>
<p style="top:289.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">It is should be noted that almost all trials regard-</span></p>
<p style="top:301.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing the use of the pluripotent stem cells are bench</span></p>
<p style="top:313.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">side studies. Thus, we decided to include some bench</span></p>
<p style="top:325.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">side studies in a short paragraph on the topic about</span></p>
<p style="top:337.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pluripotent cells to be more comprehensive regarding</span></p>
<p style="top:349.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">all the potentially bene&#xfb01;cial stem cells types.</span></p>
<p style="top:380.2pt;left:284.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Data handling</span></i></p>
<p style="top:403.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Different levels of categorizations were done. We</span></p>
<p style="top:415.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">divided the articles into clinical and preclinical, then</span></p>
<p style="top:427.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we further categorized them according to four impor-</span></p>
<p style="top:439.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tant parameters (variables): year of publication, AD</span></p>
<p style="top:451.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">model (animal or human subjects), type of stem cells</span></p>
<p style="top:462.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">used, and route of cells administration. Published</span></p>
<p style="top:474.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">articles from the same research group that present</span></p>
<p style="top:486.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">different data regarding a research trial are treated as</span></p>
<p style="top:498.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">separate articles.</span></p>
<p style="top:528.9pt;left:284.8pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">RESULTS</span></b></p>
<p style="top:552.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Our search yielded 65 articles published between</span></p>
<p style="top:564.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2006 and 2016 ful&#xfb01;lling our criteria (Fig. 1),</span></p>
<p style="top:576.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in addition to 13 listed clinical trials on http://</span></p>
<p style="top:588.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinicaltrials.gov(listedinTable2).Oneofthestudies</span></p>
<p style="top:600.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compared the use of two separate groups of animals</span></p>
<p style="top:612.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with two different routes of cells injection each with</span></p>
<p style="top:624.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">its own control group (4 groups in total), therefore</span></p>
<p style="top:636.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">this study was considered as two independent stud-</span></p>
<p style="top:648.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ies. Collectively after adjustment, 66 studies were</span></p>
<p style="top:660.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">further analyzed (Table 1). Only one clinical study</span></p>
<p style="top:672.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was found, while the remaining studies were all pre-</span></p>
<p style="top:684.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical ones.</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1211</span></p>
<img style="position:absolute;transform:matrix(.48010598,0,-0,.47954426,-90.15997,-72)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.120000008,0,-0,.119998,-1448.248,-1070.9813)" src="data:image/png;base64,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">
<p style="top:329.2pt;left:125.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">. Histogram comparing number of publications per each year starting from 2006 until early 2016.</span></p>
<p style="top:420.0pt;left:122.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sed different types of stem cells</span></p>
<p style="top:431.9pt;left:128.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(Fig. 2). We found that the most</span></p>
<p style="top:443.9pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">e mesenchymal stem cells (MSCs,</span></p>
<p style="top:455.8pt;left:122.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nal stem cells (NSCs, 36.4%).</span></p>
<p style="top:467.8pt;left:125.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">em cells.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> The MSCs are the most</span></p>
<p style="top:479.7pt;left:119.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">m cell type since their discovery</span></p>
<p style="top:491.7pt;left:122.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nd co-workers, especially in age-</span></p>
<p style="top:503.6pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[15]. First identi&#xfb01;ed in the bone</span></p>
<p style="top:515.6pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cs are currently being harvested</span></p>
<p style="top:527.6pt;left:125.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sues, such as adipose tissue [17],</span></p>
<p style="top:539.5pt;left:124.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">], placenta [19], cord blood [20],</span></p>
<p style="top:551.5pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[21]. Upon transplantation, MSCs</span></p>
<p style="top:563.4pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">y to rapidly home to ischemic sites</span></p>
<p style="top:575.4pt;left:121.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ng proven ability to trigger immune</span></p>
<p style="top:587.3pt;left:122.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">croglia activation in various AD</span></p>
<p style="top:599.3pt;left:123.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">odels [23]. In a very elegant study,</span></p>
<p style="top:611.2pt;left:123.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">shown to modulate cytokines and</span></p>
<p style="top:623.2pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP/PS1 mice, and authors</span></p>
<p style="top:635.2pt;left:124.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">he &#xfb01;rst time the negative corre-</span></p>
<p style="top:647.1pt;left:123.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SC induced microglial activation</span></p>
<p style="top:659.1pt;left:122.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ammatory cytokines expression on</span></p>
<p style="top:671.0pt;left:126.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">deposits decrease and tau phos-</span></p>
<p style="top:683.0pt;left:125.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ion, mostly in the hippocampus,</span></p>
<p style="top:361.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on the other side [24]. In another debatable study,</span></p>
<p style="top:373.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">it was shown that MSCs direct transplantation into</span></p>
<p style="top:385.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the hippocampus can improve cognition in C57BL/6</span></p>
<p style="top:397.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mice, as well as augmentation of hippocampal neu-</span></p>
<p style="top:409.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rogenesis, allegedly through</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Wnt</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> signaling pathway,</span></p>
<p style="top:420.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">thus enhancing endogenous repair [25]. MSCs that</span></p>
<p style="top:432.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">overexpress the vascular endothelial growth factor</span></p>
<p style="top:444.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was shown to improve neovascularization and the</span></p>
<p style="top:456.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clearance of A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">, ultimately leading to memory and</span></p>
<p style="top:468.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">learning de&#xfb01;cits recovery in 2xTg-AD animals [26].</span></p>
<p style="top:480.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">However, a major concern in the study was that in</span></p>
<p style="top:492.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">older animals (12 months), the condition was wors-</span></p>
<p style="top:504.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ened by the accentuated neurodegeneration caused</span></p>
<p style="top:516.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by the AD genotype. Moreover, the robust effect</span></p>
<p style="top:528.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of the VEGF in improving social memory de&#xfb01;cit</span></p>
<p style="top:540.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">seen in younger animals was attenuated in older</span></p>
<p style="top:552.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animals and no reverse of the impairment of the</span></p>
<p style="top:564.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">social recognition memory was accomplished at that</span></p>
<p style="top:576.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">age.</span></p>
<p style="top:588.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In an interesting study set to investigate the poten-</span></p>
<p style="top:600.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tial role of MSCs in treating early AD, high-risk</span></p>
<p style="top:612.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pre-dementia A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP mice models were treated with</span></p>
<p style="top:624.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MSC from the bone marrow. Two months post injec-</span></p>
<p style="top:636.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion, a reduction in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> deposits and changes in</span></p>
<p style="top:648.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">key proteins required for synaptic transmission were</span></p>
<p style="top:660.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">detected, suggesting a potential early interventional</span></p>
<p style="top:672.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">therapy in prodromal AD by bone marrow-MSC</span></p>
<p style="top:683.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">transplantation [27].</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 1</span></p>
<p style="top:84.3pt;left:150.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Summary of evidence regarding the use of stem cells in Alzheimer&#x2019;s disease</span></p>
<p style="top:98.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell Type</span></p>
<p style="top:98.6pt;left:206.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell</span></p>
<p style="top:98.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Main &#xfb01;ndings</span></p>
<p style="top:98.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reference</span></p>
<p style="top:108.0pt;left:200.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Routing</span></p>
<p style="top:120.2pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:120.2pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:120.2pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human MSCs reduced the potentially neurotoxic 56</span></p>
<p style="top:129.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">kDa A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> oligomers, increased the endogenous</span></p>
<p style="top:139.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neurogenesis in the SVZ, and maintained the</span></p>
<p style="top:148.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">glutamate transport systems in the entorhinal</span></p>
<p style="top:158.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cortex, thus leading to a smaller working memory</span></p>
<p style="top:167.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">de&#xfb01;cit in AD models.</span></p>
<p style="top:120.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ruzicka et al.,</span></p>
<p style="top:129.6pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[110]</span></p>
<p style="top:176.9pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">UCBCs</span></p>
<p style="top:176.9pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:176.9pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">UCBCs reach several tissues including the brain</span></p>
<p style="top:186.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">following a single IV treatment. Low IV dose of</span></p>
<p style="top:195.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">UCBCs led to eventual loss of these cells in key</span></p>
<p style="top:205.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">organs, such as the spleen, thus the use of multiple</span></p>
<p style="top:214.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">low-dose infusions in AD models may be</span></p>
<p style="top:224.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">necessary to prolong the therapeutic bene&#xfb01;t of</span></p>
<p style="top:233.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">these cells.</span></p>
<p style="top:176.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ehrhart et al., [66]</span></p>
<p style="top:243.2pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:243.2pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:243.2pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Stereotactic administration of MSCs into the</span></p>
<p style="top:252.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hippocampus and precuneus of human subjects</span></p>
<p style="top:262.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">was feasible, safe, and well tolerated. A phase 1</span></p>
<p style="top:271.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">clinical trial.</span></p>
<p style="top:243.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim et al., [61]</span></p>
<p style="top:281.0pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:281.0pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:281.0pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wharton Jelly-derived cells led to a signi&#xfb01;cant</span></p>
<p style="top:290.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">reduction in A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposition and soluble A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> levels,</span></p>
<p style="top:300.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">with a signi&#xfb01;cantly increased expression of the</span></p>
<p style="top:309.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">anti-in&#xfb02;ammatory cytokine IL-10 and</span></p>
<p style="top:318.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">down-regulation of pro-in&#xfb02;ammatory cytokines</span></p>
<p style="top:328.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IL-1</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> and TNF-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">. Thus, improving the spatial</span></p>
<p style="top:337.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">learning and alleviated the memory decline.</span></p>
<p style="top:281.0pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Xie et al., [111]</span></p>
<p style="top:347.3pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">BMMNCs</span></p>
<p style="top:347.3pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:347.3pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Transplantation of BMMCs suppressed neuronal</span></p>
<p style="top:356.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">loss and reduced A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposition in the brain,</span></p>
<p style="top:366.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">leading to restoration of memory impairment of</span></p>
<p style="top:375.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">DAL transgenic mice to almost the same level as</span></p>
<p style="top:385.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in wild-type mice.</span></p>
<p style="top:347.3pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kanamaru et al.,</span></p>
<p style="top:356.8pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[28]</span></p>
<p style="top:394.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">iPSCs derived</span></p>
<p style="top:404.1pt;left:140.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neural cells</span></p>
<p style="top:394.6pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:394.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ChAT-positive neurons and alpha7 nicotinic</span></p>
<p style="top:404.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">acetylcholine receptor (</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">7nAChR)-positive</span></p>
<p style="top:413.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neurons were signi&#xfb01;cantly increased in the cortex</span></p>
<p style="top:423.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and hippocampus with signi&#xfb01;cantly increased</span></p>
<p style="top:432.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">number of GABA receptor-positive neurons of</span></p>
<p style="top:441.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">both human origin and mouse origin compared</span></p>
<p style="top:451.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">with those in the vehicle-injected mouse cortex.</span></p>
<p style="top:394.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Fujiwara et al.,</span></p>
<p style="top:404.1pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[112]</span></p>
<p style="top:460.9pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:460.9pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:460.9pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Repeated administration of MSCs markedly</span></p>
<p style="top:470.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">promoted the expression of synaptic vesicle</span></p>
<p style="top:479.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">markers, including synaptophysin, which are</span></p>
<p style="top:489.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">usually downregulated in patients with AD.</span></p>
<p style="top:460.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim et al., [113]</span></p>
<p style="top:498.7pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:498.7pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:498.7pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Optimal time frame of cells injection was crucial to</span></p>
<p style="top:508.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">obtain maximal therapeutic effects that can restore</span></p>
<p style="top:517.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">functional de&#xfb01;cits or stop the progression of AD.</span></p>
<p style="top:498.7pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim et al., [41]</span></p>
<p style="top:527.1pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:527.1pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:527.1pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs transplantation resulted in signi&#xfb01;cant decrease</span></p>
<p style="top:536.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in activation of GFAP, Iba-1, TLR4 and TLR4</span></p>
<p style="top:546.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">pathway-related agents (MyD88, TRIF, P38</span></p>
<p style="top:555.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MAPK, and NF-</span><i><span style="font-family:MTMI,serif;font-size:8.0pt">&#x3ba;</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">B P65) with decreased</span></p>
<p style="top:565.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expression of pro-in&#xfb02;ammatory mediators (IL-1,</span></p>
<p style="top:574.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IL-6, TNF-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> and PGE2).</span></p>
<p style="top:527.1pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang et al., [39]</span></p>
<p style="top:583.9pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:583.9pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:583.9pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Number of mitochondria and expression of</span></p>
<p style="top:593.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mitochondria-related proteins, speci&#xfb01;cally the</span></p>
<p style="top:602.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mitochondrial &#xfb01;ssion factors [dynamin-related</span></p>
<p style="top:612.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">protein 1 (Drp1) and &#xfb01;ssion 1 (Fis1)] and the</span></p>
<p style="top:621.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mitochondrial fusion factor optic atrophy 1</span></p>
<p style="top:631.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(OPA1), were signi&#xfb01;cantly increased with NSCs</span></p>
<p style="top:640.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation.</span></p>
<p style="top:583.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang et al., [40]</span></p>
<p style="top:653.2pt;left:454.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1213</span></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 1</span></p>
<p style="top:84.3pt;left:252.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>
<p style="top:98.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell Type</span></p>
<p style="top:98.6pt;left:206.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell</span></p>
<p style="top:98.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Main &#xfb01;ndings</span></p>
<p style="top:98.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reference</span></p>
<p style="top:108.0pt;left:200.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Routing</span></p>
<p style="top:120.2pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:120.2pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:120.2pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs transplantation reduced tau phosphorylation</span></p>
<p style="top:129.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">via Trk-dependent Akt/GSK3</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> signaling,</span></p>
<p style="top:139.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">down-regulated A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> production through an</span></p>
<p style="top:148.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Akt/GSK3</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> signaling-mediated decrease in</span></p>
<p style="top:158.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">BACE1, and decreased expression of</span></p>
<p style="top:167.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in&#xfb02;ammatory mediators through deactivation of</span></p>
<p style="top:176.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">microglia that was mediated by cell-to-cell</span></p>
<p style="top:186.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">contact, secretion of anti-in&#xfb02;ammatory factors. It</span></p>
<p style="top:195.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">also facilitated synaptic plasticity and</span></p>
<p style="top:205.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">anti-apoptotic function via trophic supplies.</span></p>
<p style="top:120.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee et al., [114]</span></p>
<p style="top:214.8pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:214.8pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:214.8pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human NSCs cells can migrate and differentiate</span></p>
<p style="top:224.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">into immature neurons and glia and signi&#xfb01;cantly</span></p>
<p style="top:233.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">increase synaptic and growth-associated markers.</span></p>
<p style="top:243.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Transplantation ameliorated context and spatial</span></p>
<p style="top:252.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">learning and memory impairments in transgenic</span></p>
<p style="top:262.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">models of AD.</span></p>
<p style="top:214.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ager et al., [42]</span></p>
<p style="top:271.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:271.6pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:271.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">After NSCs transplantation, the number of basal</span></p>
<p style="top:281.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">forebrain cholinergic neurons, hippocampal</span></p>
<p style="top:290.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">synaptophysin, and AchE-positive &#xfb01;bers were all</span></p>
<p style="top:300.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">signi&#xfb01;cantly larger than the control group.</span></p>
<p style="top:271.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chen et al., [115]</span></p>
<p style="top:309.4pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:309.4pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:309.4pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Stereological analysis of engrafted Olfactory Bulb</span></p>
<p style="top:318.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs eight weeks post transplantation revealed a</span></p>
<p style="top:328.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1.89 fold increase with respect to the initial cell</span></p>
<p style="top:337.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">population, indicating a marked ability for</span></p>
<p style="top:347.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">survival and proliferation. In addition, 54.71</span><span style="font-family:MTSY,serif;font-size:8.0pt"> &#xb1;</span></p>
<p style="top:356.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">11.38%, 30.18</span><span style="font-family:MTSY,serif;font-size:8.0pt"> &#xb1;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 6.00%, and 15.09</span><span style="font-family:MTSY,serif;font-size:8.0pt"> &#xb1;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 5.38% of</span></p>
<p style="top:366.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">engrafted cells were identi&#xfb01;ed by morphological</span></p>
<p style="top:375.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">criteria suggestive of mature neurons,</span></p>
<p style="top:385.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">oligodendrocytes and astrocytes, respectively.</span></p>
<p style="top:309.4pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Marei et al., [18]</span></p>
<p style="top:394.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:394.6pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:394.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSC-VEGF treatment favored the</span></p>
<p style="top:404.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neovascularization and diminished senile plaques</span></p>
<p style="top:413.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in hippocampal speci&#xfb01;c layers. Consequently, the</span></p>
<p style="top:423.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">treatment was able to provide behavioral bene&#xfb01;ts</span></p>
<p style="top:432.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and reduce cognitive de&#xfb01;cits by recovering the</span></p>
<p style="top:441.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">innate interest to novelty and counteracting</span></p>
<p style="top:451.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">memory de&#xfb01;cits in AD transgenic animals.</span></p>
<p style="top:394.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Garcia et al., [26]</span></p>
<p style="top:460.9pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:460.9pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IN</span></p>
<p style="top:460.9pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Transplanted cells showed predominant distribution</span></p>
<p style="top:470.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">within the olfactory bulb and brainstem.</span></p>
<p style="top:460.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Danielyan et al.,</span></p>
<p style="top:470.3pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[72]</span></p>
<p style="top:479.8pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:479.8pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:479.8pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Placenta derived cells attenuated the expression of</span></p>
<p style="top:489.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP, BACE1, and A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">, as well as the activity of</span></p>
<p style="top:498.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">-secretase and</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">-secretase. In addition, they</span></p>
<p style="top:508.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">inhibited the activation of glia cells and the</span></p>
<p style="top:517.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">increased expression of inducible nitric oxide</span></p>
<p style="top:527.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">synthase and cyclooxygenase-2.</span></p>
<p style="top:479.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yun et al., [19]</span></p>
<p style="top:536.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:536.6pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:536.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Bone Marrow MSCs were able to home at the</span></p>
<p style="top:546.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">injured brains and produced signi&#xfb01;cant increase in</span></p>
<p style="top:555.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the number of positive cells for ChAT, as well as</span></p>
<p style="top:565.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">selective AD indicator-1 (seladin-1), and nestin</span></p>
<p style="top:574.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">gene expression. Histopathological examination</span></p>
<p style="top:583.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">indicated that they could also remove</span></p>
<p style="top:593.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">beta-amyloid plaques from hippocampus.</span></p>
<p style="top:536.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Salem et al., [116]</span></p>
<p style="top:602.8pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs</span></p>
<p style="top:602.8pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:602.8pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs labeled with LEO-LIVE-Magnoxide were</span></p>
<p style="top:612.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">still detected</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 12 days after injection.</span></p>
<p style="top:602.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ha et al., [117]</span></p>
<p style="top:621.8pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:621.8pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:621.8pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaque loads were reduced not only in the</span></p>
<p style="top:631.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hippocampus and subiculum adjacent to engrafted</span></p>
<p style="top:640.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs, but also within the amygdala and medial</span></p>
<p style="top:650.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">septum, areas that receive afferent projections</span></p>
<p style="top:659.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">from the engrafted region.</span></p>
<p style="top:621.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Blurton-Jones</span></p>
<p style="top:631.2pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">et al., [76]</span></p>
<p style="top:672.2pt;left:454.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 1</span></p>
<p style="top:84.3pt;left:252.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>
<p style="top:98.6pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell Type</span></p>
<p style="top:98.6pt;left:206.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell</span></p>
<p style="top:98.6pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Main &#xfb01;ndings</span></p>
<p style="top:98.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reference</span></p>
<p style="top:108.0pt;left:200.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Routing</span></p>
<p style="top:120.2pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:120.2pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:120.2pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Nissl staining revealed that the number of neurons in</span></p>
<p style="top:129.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the hippocampus of a transgenic model of AD</span></p>
<p style="top:139.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(3</span><span style="font-family:MTSY,serif;font-size:8.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">Tg mice) receiving NSCs was signi&#xfb01;cantly</span></p>
<p style="top:148.5pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">greater than the control group, indicating that new</span></p>
<p style="top:158.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neurons were generated. NSC transplantation can</span></p>
<p style="top:167.5pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">improve spatial learning and memory via neuronal</span></p>
<p style="top:176.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">regeneration.</span></p>
<p style="top:120.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chen et al., [118]</span></p>
<p style="top:186.4pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs</span></p>
<p style="top:186.4pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:186.4pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs transplantation enhanced neurogenic</span></p>
<p style="top:195.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">activity in the SVZ with reduced oxidative stress</span></p>
<p style="top:205.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and alleviated cognitive impairment in the mice.</span></p>
<p style="top:214.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Based on these &#xfb01;ndings, it was proposed that</span></p>
<p style="top:224.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs enhances endogenous neurogenesis in</span></p>
<p style="top:233.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">both the subgranular and subventricular zones.</span></p>
<p style="top:186.4pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yan et al., [119]</span></p>
<p style="top:243.2pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:243.2pt;left:209.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:243.2pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Combined MSCs and erythropoietin markedly</span></p>
<p style="top:252.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">reduced lipopolysaccharide mediated cell damage</span></p>
<p style="top:262.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in AD model, leading to effective relief of AD</span></p>
<p style="top:271.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">pathology.</span></p>
<p style="top:243.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Khairallah et al.,</span></p>
<p style="top:252.7pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[120]</span></p>
<p style="top:281.0pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs</span></p>
<p style="top:281.0pt;left:200.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV &amp; IC</span></p>
<p style="top:281.0pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV or IC transplanted human ADSCs greatly</span></p>
<p style="top:290.5pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">improved the memory impairment and the</span></p>
<p style="top:300.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neuropathology.</span></p>
<p style="top:281.0pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chang et al., [14]</span></p>
<p style="top:309.4pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:309.4pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:309.4pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSC-induced neurons highly expressed SYN and</span></p>
<p style="top:318.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">growth associated protein-43 (GAP-43) in</span></p>
<p style="top:328.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hippocampal areas.</span></p>
<p style="top:309.4pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Gu et al., [121]</span></p>
<p style="top:337.8pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:337.8pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:337.8pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">The improvement in cognitive function was</span></p>
<p style="top:347.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">correlated with enhanced long-term potentiation</span></p>
<p style="top:356.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(LTP) and an increase in the neuron expression of</span></p>
<p style="top:366.2pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">proteins related to cognitive function:</span></p>
<p style="top:375.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">N-methyl-D-aspartate (NMDA) 2B unit, SYP,</span></p>
<p style="top:385.2pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">protein kinase C</span><i><span style="font-family:MTMI,serif;font-size:8.0pt"> &#x3b6;</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> subtypes (PKC</span><i><span style="font-family:MTMI,serif;font-size:8.0pt">&#x3b6;</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">), tyrosine</span></p>
<p style="top:394.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">receptor kinase B (TrkB) and BDNF.</span></p>
<p style="top:337.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang et al., [122]</span></p>
<p style="top:404.1pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:404.1pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:404.1pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">The expression of SYN and growth-associated</span></p>
<p style="top:413.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">protein-43 (GAP-43) in Tg-NSC mice, 8 weeks</span></p>
<p style="top:423.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">after transplantation, were signi&#xfb01;cantly improved.</span></p>
<p style="top:432.5pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">This was con&#xfb01;rmed by the increase in the number</span></p>
<p style="top:441.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of synapses in Tg-NSC mice as observed via</span></p>
<p style="top:451.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">electron microscopy.</span></p>
<p style="top:404.1pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang et al., [123]</span></p>
<p style="top:460.9pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:460.9pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:460.9pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Transplantation of transgenic IL-1 receptor</span></p>
<p style="top:470.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">antagonist (IL-1ra TG) NSCs one month before</span></p>
<p style="top:479.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the neurobehavioral disturbances completely</span></p>
<p style="top:489.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">rescued the brain and signi&#xfb01;cantly increased the</span></p>
<p style="top:498.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">number of endogenous hippocampal cells</span></p>
<p style="top:508.2pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expressing the plasticity-related molecule BDNF.</span></p>
<p style="top:460.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ben-Menachem-</span></p>
<p style="top:470.3pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zidon et al.,</span></p>
<p style="top:479.8pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[124]</span></p>
<p style="top:517.7pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:517.7pt;left:200.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV &amp; IC</span></p>
<p style="top:517.7pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs transplantation improved spatial memory in</span></p>
<p style="top:527.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">bulbectomized mice with AD-type</span></p>
<p style="top:536.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neurodegeneration and no cases of malignant</span></p>
<p style="top:546.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transformation were noted.</span></p>
<p style="top:517.7pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Bobkova et al.,</span></p>
<p style="top:527.1pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[125]</span></p>
<p style="top:555.5pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:555.5pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:555.5pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">In transplanted models, M2-like microglial</span></p>
<p style="top:565.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">activation was signi&#xfb01;cantly increased, and the</span></p>
<p style="top:574.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expression of anti-in&#xfb02;ammatory cytokine</span></p>
<p style="top:583.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">associated with M2-like microglia, IL-4, was also</span></p>
<p style="top:593.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">increased, whereas the expression of</span></p>
<p style="top:602.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">pro-in&#xfb02;ammatory cytokines associated with</span></p>
<p style="top:612.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">classic microglia (M1-like microglia), including</span></p>
<p style="top:621.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IL-1</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> and TNF-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> was signi&#xfb01;cantly reduced.</span></p>
<p style="top:555.5pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yang et al., [20]</span></p>
<p style="top:634.3pt;left:454.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1215</span></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 1</span></p>
<p style="top:84.3pt;left:252.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>
<p style="top:98.6pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell Type</span></p>
<p style="top:98.6pt;left:205.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell</span></p>
<p style="top:98.6pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Main &#xfb01;ndings</span></p>
<p style="top:98.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reference</span></p>
<p style="top:108.0pt;left:199.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Routing</span></p>
<p style="top:120.2pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:120.2pt;left:208.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:120.2pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">No difference was detected in total number of A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:129.6pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">plaques between NSC and control groups after</span></p>
<p style="top:139.1pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation. Also, there was no difference in</span></p>
<p style="top:148.5pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the number of thio&#xfb02;avin-S-positive (TS+) plaques</span></p>
<p style="top:158.0pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">between both groups after eight weeks of NSCs</span></p>
<p style="top:167.5pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation. However, engrafted NSCs showed</span></p>
<p style="top:176.9pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">partial chemotaxis toward A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaques.</span></p>
<p style="top:120.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang et al, [126]</span></p>
<p style="top:186.4pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">UCBCs</span></p>
<p style="top:186.4pt;left:208.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:186.4pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">UCBC therapy correlated with decreased cognitive</span></p>
<p style="top:195.9pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">impairment, A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> levels/A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaques,</span></p>
<p style="top:205.3pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">amyloidogenic A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP processing, and reactive</span></p>
<p style="top:214.8pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">microgliosis after a treatment of 6 or 10 months.</span></p>
<p style="top:186.4pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Darlington et al.,</span></p>
<p style="top:195.9pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[48]</span></p>
<p style="top:224.3pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:224.3pt;left:208.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:224.3pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Single IC injection of bone marrow-MSCs resulted</span></p>
<p style="top:233.7pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in signi&#xfb01;cant decrease in the cerebral A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:243.2pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">deposition sustained up to 2 months. Expression</span></p>
<p style="top:252.7pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of dynamin 1 and Synapsin 1, key pre-synaptic</span></p>
<p style="top:262.1pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">proteins associated with synaptic transmission,</span></p>
<p style="top:271.6pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">were considerably enhanced in the brains of AD</span></p>
<p style="top:281.0pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mice sustained beyond 2 months.</span></p>
<p style="top:224.3pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Bae et al., [27]</span></p>
<p style="top:290.5pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs</span></p>
<p style="top:290.5pt;left:208.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:290.5pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSC transplantation dramatically reduced A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:300.0pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">deposition and signi&#xfb01;cantly restored the</span></p>
<p style="top:309.4pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">learning/memory function in A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP/PS1</span></p>
<p style="top:318.9pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transgenic mice with more activated microglia.</span></p>
<p style="top:290.5pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ma et al., [52]</span></p>
<p style="top:328.4pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:328.4pt;left:193.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Intracardiac</span></p>
<p style="top:328.4pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Systemic transplantation of autologous T regulatory</span></p>
<p style="top:337.8pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells (Tregs) signi&#xfb01;cantly ameliorate the cognition</span></p>
<p style="top:347.3pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and reduced the A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaque deposition and the</span></p>
<p style="top:356.8pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">levels of soluble A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">, accompanied with</span></p>
<p style="top:366.2pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">signi&#xfb01;cantly decreased levels of activated</span></p>
<p style="top:375.7pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">microglia and systemic in&#xfb02;ammatory factors.</span></p>
<p style="top:328.4pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yang et al., [20]</span></p>
<p style="top:385.2pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:385.2pt;left:208.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:385.2pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Six weeks after the IV injection of MSCs, mice</span></p>
<p style="top:394.6pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">models showed evidence of improved spatial</span></p>
<p style="top:404.1pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">learning, which signi&#xfb01;cantly correlated with the</span></p>
<p style="top:413.6pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">observation of fewer A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaques in brain.</span></p>
<p style="top:423.0pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Furthermore, the level of pro-in&#xfb02;ammatory</span></p>
<p style="top:432.5pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cytokines, IL-1 and TNF-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">, was lower while the</span></p>
<p style="top:441.9pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">anti-in&#xfb02;ammatory cytokines, IL-10 and</span></p>
<p style="top:451.4pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transforming growth factor-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">, was higher in</span></p>
<p style="top:460.9pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSC-injected mice the controls. These effects</span></p>
<p style="top:470.3pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">lasted until 12 weeks after injection.</span></p>
<p style="top:385.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim et al., [21]</span></p>
<p style="top:479.8pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:479.8pt;left:208.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:479.8pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">At 13 and 14 days, MSC transplantation group</span></p>
<p style="top:489.3pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">showed signi&#xfb01;cantly improved spatial learning</span></p>
<p style="top:498.7pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and memory ability than controls. 14 days after</span></p>
<p style="top:508.2pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation in rat hippocampus,</span></p>
<p style="top:517.7pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">PKH26-positive cells could be found consistent</span></p>
<p style="top:527.1pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">with DAPI staining. PKH26-positive cells in</span></p>
<p style="top:536.6pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">animal models of AD were signi&#xfb01;cantly more</span></p>
<p style="top:546.1pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">than those in the normal control group.</span></p>
<p style="top:479.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Li et al., [127]</span></p>
<p style="top:555.5pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:555.5pt;left:208.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:555.5pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">When MSCs were transplanted into the</span></p>
<p style="top:565.0pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hippocampus of a 10-month-old transgenic mouse</span></p>
<p style="top:574.4pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">model of AD for 10, 20, or 40 days, NEP</span></p>
<p style="top:583.9pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expression was increased in the mice brains.</span></p>
<p style="top:593.4pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Moreover, A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:6.0pt">42</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaques in the hippocampus and</span></p>
<p style="top:602.8pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">other regions were decreased by active migration</span></p>
<p style="top:612.3pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of MSCs toward A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposits. This suggests that</span></p>
<p style="top:621.8pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSC-derived sICAM-1 decreases A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaques by</span></p>
<p style="top:631.2pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">inducing neprilysin expression in microglia</span></p>
<p style="top:640.7pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">through the sICAM-1/LFA-1 signaling pathway.</span></p>
<p style="top:555.5pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim et al., [128]</span></p>
<p style="top:650.2pt;left:128.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:650.2pt;left:208.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:650.2pt;left:248.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(1)H-MRS displayed IC metabolite changes before</span></p>
<p style="top:659.6pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and after NSC transplantation in AD mice models</span></p>
<p style="top:669.1pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and had an applicable value in evaluating the</span></p>
<p style="top:678.6pt;left:255.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">therapeutic effect of NSCs on AD.</span></p>
<p style="top:650.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chen et al., [129]</span></p>
<p style="top:691.1pt;left:454.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 1</span></p>
<p style="top:84.3pt;left:252.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>
<p style="top:98.6pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell Type</span></p>
<p style="top:98.6pt;left:206.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell</span></p>
<p style="top:98.6pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Main &#xfb01;ndings</span></p>
<p style="top:98.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reference</span></p>
<p style="top:108.0pt;left:200.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Routing</span></p>
<p style="top:120.2pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ADSCs</span></p>
<p style="top:120.2pt;left:200.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV &amp; IC</span></p>
<p style="top:120.2pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Intravenously transplanted ADSCs passed through</span></p>
<p style="top:129.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the BBB and migrated into the brain. The</span></p>
<p style="top:139.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">learning, memory and pathology in an AD mouse</span></p>
<p style="top:148.5pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">model (Tg2576 mice) greatly improved for at</span></p>
<p style="top:158.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">least 4 months after IV injection of the cells.</span></p>
<p style="top:120.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim et al., [53]</span></p>
<p style="top:167.5pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:167.5pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:167.5pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Authors showed that transplanted epidermal-NSCs</span></p>
<p style="top:176.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">survived and produced many neurons and a few</span></p>
<p style="top:186.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">glial cells, presenting glial &#xfb01;brillary acidic</span></p>
<p style="top:195.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">protein. In addition, the total number of granule</span></p>
<p style="top:205.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells in hippocampus was higher in the AD model</span></p>
<p style="top:214.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">with transplanted cells as compared to the control</span></p>
<p style="top:224.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">group.</span></p>
<p style="top:167.5pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Esmaeilzade et al.,</span></p>
<p style="top:176.9pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[54]</span></p>
<p style="top:233.7pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Amniotic stem</span></p>
<p style="top:243.2pt;left:139.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells</span></p>
<p style="top:233.7pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:233.7pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Amniotic stem cells transplantation signi&#xfb01;cantly</span></p>
<p style="top:243.2pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ameliorated spatial memory de&#xfb01;cits in AD</span></p>
<p style="top:252.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transgenic mice, as well as increased</span></p>
<p style="top:262.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">acetylcholine levels and the number of</span></p>
<p style="top:271.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hippocampal cholinergic neurites.</span></p>
<p style="top:233.7pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Xue et al., [130]</span></p>
<p style="top:281.0pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:281.0pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:281.0pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Transplantation of F3. ChAT human NSCs fully</span></p>
<p style="top:290.5pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">recovered the learning and memory function of</span></p>
<p style="top:300.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">AF64A animals, and induced elevated levels of</span></p>
<p style="top:309.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">acetylcholine in cerebrospinal &#xfb02;uid. Transplanted</span></p>
<p style="top:318.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">F3.ChAT human NSCs were found to migrate to</span></p>
<p style="top:328.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">various brain regions including cerebral cortex,</span></p>
<p style="top:337.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hippocampus, striatum and septum, and</span></p>
<p style="top:347.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">differentiated into neurons and astrocytes</span></p>
<p style="top:281.0pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Park et al., [131]</span></p>
<p style="top:356.8pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:356.8pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:356.8pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposition, BACE1 levels, and tau</span></p>
<p style="top:366.2pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hyperphosphorylation were dramatically reduced</span></p>
<p style="top:375.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in MSC transplanted A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP/PS1 mice. These</span></p>
<p style="top:385.2pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">effects were associated with reversal of</span></p>
<p style="top:394.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease-associated microglial neuroin&#xfb02;ammation,</span></p>
<p style="top:404.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">as evidenced by decreased microglia-induced</span></p>
<p style="top:413.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">pro-in&#xfb02;ammatory cytokines, elevated alternatively</span></p>
<p style="top:423.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">activated microglia, and increased</span></p>
<p style="top:432.5pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">anti-in&#xfb02;ammatory cytokines.</span></p>
<p style="top:356.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee et al., [24]</span></p>
<p style="top:441.9pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:441.9pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:441.9pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Intraventricular transplantation of native and</span></p>
<p style="top:451.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">glucagon-like peptide-1 transfected MSC was</span></p>
<p style="top:460.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">shown to be effective. Decreased amyloid</span></p>
<p style="top:470.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">deposition or suppression of glial and microglial</span></p>
<p style="top:479.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">responses were observed.</span></p>
<p style="top:441.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Klinge et al., [132]</span></p>
<p style="top:489.3pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Amniotic</span></p>
<p style="top:498.7pt;left:139.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">epithelial</span></p>
<p style="top:508.2pt;left:139.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells</span></p>
<p style="top:489.3pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:489.3pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Transplanted amniotic cells can survive for at least 8</span></p>
<p style="top:498.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">weeks and migrate to the third ventricle without</span></p>
<p style="top:508.2pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">immune rejection. Not only they signi&#xfb01;cantly</span></p>
<p style="top:517.7pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">improved the spatial memory of the AD</span></p>
<p style="top:527.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transgenic mice, but they also increased</span></p>
<p style="top:536.6pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">acetylcholine concentration and the number of</span></p>
<p style="top:546.1pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hippocampal cholinergic neurites.</span></p>
<p style="top:489.3pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Xue et al., [133]</span></p>
<p style="top:555.5pt;left:132.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:555.5pt;left:209.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:555.5pt;left:246.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Immunohistochemistry showed that GFP-MSCs</span></p>
<p style="top:565.0pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">distributed uniformly and the number of</span></p>
<p style="top:574.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s senile plaques reduced after</span></p>
<p style="top:583.9pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation, leading to retard AD-like</span></p>
<p style="top:593.4pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">pathology and upregulation of DeltaNp73</span></p>
<p style="top:602.8pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expression in hippocampus of A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP/PS1</span></p>
<p style="top:612.3pt;left:253.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transgenic mice.</span></p>
<p style="top:555.5pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wen et al., [134]</span></p>
<p style="top:624.8pt;left:454.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1217</span></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 1</span></p>
<p style="top:84.3pt;left:252.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>
<p style="top:98.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell Type</span></p>
<p style="top:98.6pt;left:206.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell</span></p>
<p style="top:98.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Main &#xfb01;ndings</span></p>
<p style="top:98.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reference</span></p>
<p style="top:108.0pt;left:200.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Routing</span></p>
<p style="top:120.2pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:120.2pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:120.2pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Immortalized MSCs possessed better ability of</span></p>
<p style="top:129.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">proliferation and anti-senescence compared with</span></p>
<p style="top:139.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">primary MSCs, while maintained multilineage</span></p>
<p style="top:148.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">differentiation capacity. Neural-like cells derived</span></p>
<p style="top:158.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">from immortalized MSCs had similar expressions</span></p>
<p style="top:167.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of neural-speci&#xfb01;c genes, protein expression</span></p>
<p style="top:176.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">patterns and resting membrane potential (RMP)</span></p>
<p style="top:186.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">compared with their counterparts derived from</span></p>
<p style="top:195.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">primary MSCs; they play same role as primary</span></p>
<p style="top:205.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs in improving learning ability and spatial</span></p>
<p style="top:214.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">memory in AD models.</span></p>
<p style="top:120.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Gong et al., [135]</span></p>
<p style="top:224.3pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:224.3pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:224.3pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs reduced the hippocampal apoptosis.</span></p>
<p style="top:233.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Moreover, acute markers of glial activation,</span></p>
<p style="top:243.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">oxidative stress and apoptosis levels were</span></p>
<p style="top:252.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">decreased in AD mouse brain. MSCs treated AD</span></p>
<p style="top:262.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mice demonstrated cognitive rescue with</span></p>
<p style="top:271.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">restoration of learning/memory function.</span></p>
<p style="top:224.3pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee et al., [136]</span></p>
<p style="top:281.0pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:281.0pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:281.0pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Histological examinations showed that there was no</span></p>
<p style="top:290.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">obvious changes in A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposition between tested</span></p>
<p style="top:300.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">groups; in addition, the NSCs differentiated and</span></p>
<p style="top:309.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expressed neuronal nuclei-positive cells, and</span></p>
<p style="top:318.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">continuously expressed</span></p>
<p style="top:328.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">5-bromodeoxyuridine-positive cells for six weeks.</span></p>
<p style="top:281.0pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">He et al., [137]</span></p>
<p style="top:337.8pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:337.8pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:337.8pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs attenuated A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">-induced apoptotic cell death in</span></p>
<p style="top:347.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">primary cultured hippocampal neurons by</span></p>
<p style="top:356.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">activation of the cell survival signaling pathway.</span></p>
<p style="top:366.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">These anti-apoptotic effects of MSCs were also</span></p>
<p style="top:375.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">observed in an acutely-induced AD mice model</span></p>
<p style="top:385.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">produced by injecting A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> intrahippocampally. In</span></p>
<p style="top:394.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">addition, MSCs diminished A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> -induced</span></p>
<p style="top:404.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">oxidative stress and spatial memory impairment in</span></p>
<p style="top:413.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> model.</span></p>
<p style="top:337.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee et al., [74]</span></p>
<p style="top:423.0pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:423.0pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:423.0pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs into A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP/PS1 mice signi&#xfb01;cantly reduced</span></p>
<p style="top:432.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposition with decreased tau</span></p>
<p style="top:441.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hyperphosphorylation and improved cognitive</span></p>
<p style="top:451.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">function. These effects were associated with</span></p>
<p style="top:460.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">restoration of defective microglial function,</span></p>
<p style="top:470.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">evidenced by increased A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">-degrading factors,</span></p>
<p style="top:479.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">decreased in&#xfb02;ammatory responses, and elevation</span></p>
<p style="top:489.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of alternatively activated microglial markers.</span></p>
<p style="top:423.0pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee et al., [73]</span></p>
<p style="top:498.7pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NPCs</span></p>
<p style="top:498.7pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:498.7pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NPCs transplantation signi&#xfb01;cantly reduced</span></p>
<p style="top:508.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">microgliosis (by 38%), but not astrogliosis in</span></p>
<p style="top:517.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">peptide-injected hippocampus.</span></p>
<p style="top:498.7pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ryu et al., [138]</span></p>
<p style="top:527.1pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NPCs</span></p>
<p style="top:527.1pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:527.1pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Immunohistochemical analysis revealed that the</span></p>
<p style="top:536.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">majority (approximately 70%) of the NPCs</span></p>
<p style="top:546.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">retained neuronal phenotype and approximately</span></p>
<p style="top:555.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">40% of them had a cholinergic cell phenotype</span></p>
<p style="top:565.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">following transplantation with no tumor</span></p>
<p style="top:574.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">formation, indicating that NPCs may be safe for</span></p>
<p style="top:583.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation. Behavioral assessment revealed a</span></p>
<p style="top:593.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">signi&#xfb01;cant behavioral improvement in memory</span></p>
<p style="top:602.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">de&#xfb01;cits following transplantation with NPCs.</span></p>
<p style="top:527.1pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Moghadam et al.,</span></p>
<p style="top:536.6pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[37]</span></p>
<p style="top:612.3pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:612.3pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:612.3pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">The number of cholinergic neurons of the</span></p>
<p style="top:621.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs-transplanted group was signi&#xfb01;cant higher</span></p>
<p style="top:631.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">than that of the glia-transplanted group in medial</span></p>
<p style="top:640.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">septum and vertical diagonal branch. The results</span></p>
<p style="top:650.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">indicate that transplanted NSCs can differentiate</span></p>
<p style="top:659.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">into cholinergic neurons, which may play an</span></p>
<p style="top:669.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">important role in the therapeutic effects of</span></p>
<p style="top:678.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplanted NSCs.</span></p>
<p style="top:612.3pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Xuan et al., [139]</span></p>
<p style="top:691.1pt;left:454.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 1</span></p>
<p style="top:84.3pt;left:252.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Continued</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">)</span></p>
<p style="top:98.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell Type</span></p>
<p style="top:98.6pt;left:206.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cell</span></p>
<p style="top:98.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Main &#xfb01;ndings</span></p>
<p style="top:98.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reference</span></p>
<p style="top:108.0pt;left:200.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Routing</span></p>
<p style="top:120.2pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:120.2pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:120.2pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">BDNF can enhance the treatment effects of NSCs</span></p>
<p style="top:129.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplanted into brain lesion model as shown by</span></p>
<p style="top:139.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">immunohistochemical detection of p75(NGFR)</span></p>
<p style="top:148.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">indicating that the number of cholinergic neurons</span></p>
<p style="top:158.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of the had more signi&#xfb01;cant improvement</span></p>
<p style="top:120.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Xuan et al., [140]</span></p>
<p style="top:167.5pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:167.5pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:167.5pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs survived after transplantation, integrated into</span></p>
<p style="top:176.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the host brain and enhanced cognitive</span></p>
<p style="top:186.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">performance.</span></p>
<p style="top:167.5pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wu et al., [141]</span></p>
<p style="top:195.9pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NPCs</span></p>
<p style="top:195.9pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:195.9pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">The development of amyloidosis in the neurogenic</span></p>
<p style="top:205.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">regions attenuated the age-associated reduction of</span></p>
<p style="top:214.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">proliferation of NPCs, proving that their</span></p>
<p style="top:224.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">proliferation in culture did not depend on the age</span></p>
<p style="top:233.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">or presence of A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP-transgene.</span></p>
<p style="top:195.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kolecki et al.,</span></p>
<p style="top:205.3pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[142]</span></p>
<p style="top:243.2pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">UCBCs</span></p>
<p style="top:243.2pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:243.2pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">UCBC infusions reduced cerebral vascular A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:252.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">deposits in the Tg2576 AD mouse model. These</span></p>
<p style="top:262.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">effects were associated with suppression of the</span></p>
<p style="top:271.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">CD40-CD40L interaction, as evidenced by</span></p>
<p style="top:281.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">decreased circulating and brain soluble CD40L</span></p>
<p style="top:290.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(sCD40L), elevated systemic immunoglobulin M</span></p>
<p style="top:300.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(IgM) levels, attenuated CD40L-induced</span></p>
<p style="top:309.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in&#xfb02;ammatory responses, and reduced surface</span></p>
<p style="top:318.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expression of CD40 on microglia.</span></p>
<p style="top:243.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Nikolic et al.,</span></p>
<p style="top:252.7pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[143]</span></p>
<p style="top:328.4pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:328.4pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:328.4pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Results showed that MSCS survived, migrated and</span></p>
<p style="top:337.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">expressed NGF as well as differentiated into</span></p>
<p style="top:347.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ChAT-positive neurons with a signi&#xfb01;cant</span></p>
<p style="top:356.8pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">improvement in learning and memory in AD rats.</span></p>
<p style="top:328.4pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Li et al., [144]</span></p>
<p style="top:366.2pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:366.2pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:366.2pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs transplanted into the brain after neuronal</span></p>
<p style="top:375.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ablation survived, migrated, differentiated and,</span></p>
<p style="top:385.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">most signi&#xfb01;cantly, improved memory.</span></p>
<p style="top:366.2pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yamasaki et al.,</span></p>
<p style="top:375.7pt;left:440.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[145]</span></p>
<p style="top:394.6pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:394.6pt;left:209.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IV</span></p>
<p style="top:394.6pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">After transplantation at different time points, NSCs</span></p>
<p style="top:404.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">were diffusely distributed in the brain and around</span></p>
<p style="top:413.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the blood vessels in the &#xfb01;rst 48 h, then migrated</span></p>
<p style="top:423.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">gradually towards the hippocampus and cortex</span></p>
<p style="top:432.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">until 4 weeks later.</span></p>
<p style="top:394.6pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhan et al., [146]</span></p>
<p style="top:441.9pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:441.9pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:441.9pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not only NSCs survived well after transplantation</span></p>
<p style="top:451.4pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">into hippocampus of AD rats, but also they</span></p>
<p style="top:460.9pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">possessed the capacity of continuous proliferation</span></p>
<p style="top:470.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and migrated along the hippocampus.</span></p>
<p style="top:441.9pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yang et al., [147]</span></p>
<p style="top:479.8pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:479.8pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:479.8pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Neurospheres transplanted into the mouse cortex</span></p>
<p style="top:489.3pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">survived and produced many ChAT-positive</span></p>
<p style="top:498.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neurons and a few serotonin-positive neurons in</span></p>
<p style="top:508.2pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and around the grafts, thus decreasing signi&#xfb01;cantly</span></p>
<p style="top:517.7pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the working memory error in the mice.</span></p>
<p style="top:479.8pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wang et al., [148]</span></p>
<p style="top:527.1pt;left:133.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs</span></p>
<p style="top:527.1pt;left:209.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">IC</span></p>
<p style="top:527.1pt;left:246.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">The behavioral amelioration of AD model rat was</span></p>
<p style="top:536.6pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">obtained by transplanting single NSCs and</span></p>
<p style="top:546.1pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">BDNF-gene-modi&#xfb01;ed NSCs. The effect of the</span></p>
<p style="top:555.5pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NSCs group modi&#xfb01;ed with BDNF gene proved to</span></p>
<p style="top:565.0pt;left:253.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">be better than NSCs alone.</span></p>
<p style="top:527.1pt;left:433.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhao et al., [149]</span></p>
<p style="top:577.5pt;left:125.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">; A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP amyloid-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> protein precursor; AchE, acetylcholinesterase; ADSCs, adipose tissue derived stem cells; AD,</span></p>
<p style="top:587.4pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ACE1, beta-secretase 1; BBB, blood-brain barrier; BDNF, brain-derived neurotrophic factor; BMMNCs, bone marrow</span></p>
<p style="top:597.4pt;left:121.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">AT, choline acetyltransferase; DAPI, 4&#x2019;,6-diamidino-2-phenylindole; GFAP, glial &#xfb01;brillary acidic protein; Iba1, ionized</span></p>
<p style="top:607.4pt;left:125.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">r molecule 1; IC, intracerebral; IL, interleukin; IN,intranasal; iPSCs, induced pluripotent stem cells; IV, intravenous;</span></p>
<p style="top:617.3pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">nction-associated antigen-1; MRS, magnetic resonance spectroscopy; MSCs, mesenchymal stem cells; NGF, nerve</span></p>
<p style="top:627.3pt;left:123.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neuronal progenitor cells; NSCs, neuronal stem cells; sICAM-1, soluble intracellular adhesion molecule-1; SVZ,</span></p>
<p style="top:637.3pt;left:121.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">GE2, Prostaglandin E2; PS1, presenilin 1; SYN, synaptophysin; TLR, Toll-like receptor; TNF, tumor necrosis factor;</span></p>
<p style="top:647.2pt;left:122.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">d blood cells; VEGF, vascular endothelial growth factor.</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1219</span></p>
<p style="top:74.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Table 2</span></p>
<p style="top:84.3pt;left:148.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Clinical trials performed for testing stem cells therapy in Alzheimer&#x2019;s disease</span></p>
<p style="top:98.6pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Type of cell / Drug</span></p>
<p style="top:98.6pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Design/type</span></p>
<p style="top:98.6pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Classi&#xfb01;cation</span></p>
<p style="top:98.6pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Estimated enrollment/</span></p>
<p style="top:98.6pt;left:421.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Outcomes</span></p>
<p style="top:108.0pt;left:349.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Follow-up period</span></p>
<p style="top:120.2pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Longeveron</span></p>
<p style="top:129.6pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mesenchymal</span></p>
<p style="top:139.1pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">stem cells</span></p>
<p style="top:120.2pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Randomized/</span></p>
<p style="top:129.6pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional</span></p>
<p style="top:139.1pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Double blind</span></p>
<p style="top:120.2pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety</span></p>
<p style="top:129.6pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">demonstration</span></p>
<p style="top:139.1pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Phase I)</span></p>
<p style="top:120.2pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">30 subjects Follow up:</span></p>
<p style="top:129.6pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">primary outcome:</span></p>
<p style="top:139.1pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#xfb01;rst 30 days.</span></p>
<p style="top:148.5pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Secondary</span></p>
<p style="top:158.0pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">outcome: 2, 6, 13,</span></p>
<p style="top:167.5pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">26, 39 &amp; 52 post</span></p>
<p style="top:176.9pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">infusion</span></p>
<p style="top:120.2pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not yet recruiting</span></p>
<p style="top:186.4pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human umbilical</span></p>
<p style="top:195.9pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cord blood</span></p>
<p style="top:205.3pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">derived</span></p>
<p style="top:214.8pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mesenchymal</span></p>
<p style="top:224.3pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Stem cells</span></p>
<p style="top:186.4pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Randomized/</span></p>
<p style="top:195.9pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional</span></p>
<p style="top:205.3pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Double blind</span></p>
<p style="top:186.4pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:195.9pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:205.3pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy Versus</span></p>
<p style="top:214.8pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Placebo (Phase</span></p>
<p style="top:224.3pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">I and II)</span></p>
<p style="top:186.4pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">42 subjects Follow up:</span></p>
<p style="top:195.9pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">24 weeks after the</span></p>
<p style="top:205.3pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#xfb01;rst dose</span></p>
<p style="top:186.4pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Recruiting</span></p>
<p style="top:233.7pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Adult neuronal</span></p>
<p style="top:243.2pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Progenitor stem</span></p>
<p style="top:252.7pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cell culture</span></p>
<p style="top:233.7pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional/</span></p>
<p style="top:243.2pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Open label</span></p>
<p style="top:233.7pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:243.2pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy (Phase</span></p>
<p style="top:252.7pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">II)</span></p>
<p style="top:233.7pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">10 subjects Follow up:</span></p>
<p style="top:243.2pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">not provided</span></p>
<p style="top:233.7pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not yet recruiting</span></p>
<p style="top:262.1pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human Umbilical</span></p>
<p style="top:271.6pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cord derived</span></p>
<p style="top:281.0pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:262.1pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional/</span></p>
<p style="top:271.6pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Open label</span></p>
<p style="top:262.1pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:271.6pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;ciency</span></p>
<p style="top:281.0pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Phase I and II)</span></p>
<p style="top:262.1pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">30 subjects Follow up:</span></p>
<p style="top:271.6pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">10 weeks</span></p>
<p style="top:281.0pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">post-administration</span></p>
<p style="top:290.5pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and year</span></p>
<p style="top:262.1pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not yet recruiting</span></p>
<p style="top:300.0pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human Umbilical</span></p>
<p style="top:309.4pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cord derived</span></p>
<p style="top:318.9pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:300.0pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional/</span></p>
<p style="top:309.4pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Open label</span></p>
<p style="top:300.0pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:309.4pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;ciency</span></p>
<p style="top:318.9pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Phase I)</span></p>
<p style="top:300.0pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">9 subjects Follow up:</span></p>
<p style="top:309.4pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">12 weeks</span></p>
<p style="top:318.9pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">post-administration</span></p>
<p style="top:300.0pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Completed with no</span></p>
<p style="top:309.4pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">published results</span></p>
<p style="top:318.9pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">yet</span></p>
<p style="top:328.4pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human Umbilical</span></p>
<p style="top:337.8pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cord derived</span></p>
<p style="top:347.3pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:328.4pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional/</span></p>
<p style="top:337.8pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Double Blind</span></p>
<p style="top:328.4pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:337.8pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:347.3pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy (Phase</span></p>
<p style="top:356.8pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">I and II)</span></p>
<p style="top:328.4pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">40 subjects Follow up:</span></p>
<p style="top:337.8pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">10 weeks</span></p>
<p style="top:347.3pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">post-administration</span></p>
<p style="top:328.4pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not yet recruiting</span></p>
<p style="top:366.2pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human Umbilical</span></p>
<p style="top:375.7pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cord derived</span></p>
<p style="top:385.2pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:366.2pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Observational/</span></p>
<p style="top:375.7pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Case Control/</span></p>
<p style="top:385.2pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Prospective</span></p>
<p style="top:366.2pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:375.7pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:385.2pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy (Phase</span></p>
<p style="top:394.6pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">I and II)</span></p>
<p style="top:366.2pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">14 subjects Follow up:</span></p>
<p style="top:375.7pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">24 months postop</span></p>
<p style="top:366.2pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Recruitment status is</span></p>
<p style="top:375.7pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">unknown</span></p>
<p style="top:404.1pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human Umbilical</span></p>
<p style="top:413.6pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cord derived</span></p>
<p style="top:423.0pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MSCs</span></p>
<p style="top:404.1pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Randomized/</span></p>
<p style="top:413.6pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional</span></p>
<p style="top:423.0pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Double blind</span></p>
<p style="top:404.1pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:413.6pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:423.0pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy (Phase</span></p>
<p style="top:432.5pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">I and II)</span></p>
<p style="top:404.1pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">40 subjects Follow up:</span></p>
<p style="top:413.6pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">10 weeks</span></p>
<p style="top:423.0pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">post-administration</span></p>
<p style="top:404.1pt;left:421.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not yet recruiting</span></p>
<p style="top:441.9pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Panax Ginseng</span></p>
<p style="top:441.9pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Non-Randomized/</span></p>
<p style="top:451.4pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional</span></p>
<p style="top:460.9pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Open label</span></p>
<p style="top:441.9pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:451.4pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:460.9pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy (Phase</span></p>
<p style="top:470.3pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">I and II)</span></p>
<p style="top:441.9pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not provided</span></p>
<p style="top:441.9pt;left:421.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Completed with no</span></p>
<p style="top:451.4pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">published results</span></p>
<p style="top:460.9pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">yet</span></p>
<p style="top:479.8pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Mellaril</span></p>
<p style="top:479.8pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional/</span></p>
<p style="top:489.3pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Open label</span></p>
<p style="top:479.8pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Feasibility Study</span></p>
<p style="top:489.3pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Phase 0)</span></p>
<p style="top:479.8pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">6 subjects Follow up:</span></p>
<p style="top:489.3pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">24 hours after</span></p>
<p style="top:498.7pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">treatment</span></p>
<p style="top:479.8pt;left:421.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Terminated with no</span></p>
<p style="top:489.3pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">published results</span></p>
<p style="top:498.7pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">yet</span></p>
<p style="top:508.2pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Induced</span></p>
<p style="top:517.7pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">pluripotent stem</span></p>
<p style="top:527.1pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells develop-</span></p>
<p style="top:536.6pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ment from</span></p>
<p style="top:546.1pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">donated somatic</span></p>
<p style="top:555.5pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells</span></p>
<p style="top:508.2pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Observational/</span></p>
<p style="top:517.7pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Case Control/</span></p>
<p style="top:527.1pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Prospective</span></p>
<p style="top:508.2pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">120 subjects Follow</span></p>
<p style="top:517.7pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">up: not provided</span></p>
<p style="top:508.2pt;left:421.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not yet recruiting</span></p>
<p style="top:565.0pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Candesartan</span></p>
<p style="top:565.0pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Randomized/</span></p>
<p style="top:574.4pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional</span></p>
<p style="top:583.9pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Double blind</span></p>
<p style="top:565.0pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:574.4pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy (Phase</span></p>
<p style="top:583.9pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">II)</span></p>
<p style="top:565.0pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">72 subjects Follow up:</span></p>
<p style="top:574.4pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">12 months</span></p>
<p style="top:565.0pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Not yet recruiting</span></p>
<p style="top:593.4pt;left:136.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Filgrastim</span></p>
<p style="top:602.8pt;left:143.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(G-CSF)</span></p>
<p style="top:593.4pt;left:204.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Randomized/</span></p>
<p style="top:602.8pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Interventional</span></p>
<p style="top:612.3pt;left:211.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Double blind</span></p>
<p style="top:593.4pt;left:272.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Safety and</span></p>
<p style="top:602.8pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exploratory</span></p>
<p style="top:612.3pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ef&#xfb01;cacy (Phase</span></p>
<p style="top:621.8pt;left:279.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">I and II)</span></p>
<p style="top:593.4pt;left:341.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">8 subjects Follow up:</span></p>
<p style="top:602.8pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">2 weeks and 4</span></p>
<p style="top:612.3pt;left:348.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">weeks</span></p>
<p style="top:593.4pt;left:421.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Results: Granulocyte</span></p>
<p style="top:602.8pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">colony stimulating</span></p>
<p style="top:612.3pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">factor decreased</span></p>
<p style="top:621.8pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">brain amyloid</span></p>
<p style="top:631.2pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">burden and reverses</span></p>
<p style="top:640.7pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cognitive</span></p>
<p style="top:650.2pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">impairment in</span></p>
<p style="top:659.6pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s mice</span></p>
<p style="top:669.1pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Sanchez-Ramos</span></p>
<p style="top:678.6pt;left:428.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">et al., 2009) [150].</span></p>
<p style="top:689.1pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tem cells, G-CSF, granulocyte colony stimulating factor.</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<img style="position:absolute;transform:matrix(.48014129,0,-0,.48020429,-90.783969,-20.199967)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAA4oAAAHWCAIAAAC+POAKAAAACXBIWXMAAA7EAAAO
xAGVKw4bAADjl0lEQVR4nOy9h3Pcxrbue//3V6/q1atbp25455x9j/f2trVty7Jy
srIoSiRFMedhEoOoQEnMChSV/D5gzSz2NMIAGGDQGH6/Wh6DIwzQ6LD664j/9hch
JCVfv3799OnTly9fyg4IIaRzfP/+HZ/fvn37/Pmz/kkIKYL/VnYACKkeh4eH0zNz
C0vL5peoq1BvlRUkQkgRBDXo9s7uy1ebolAJIQVBeUpIavb29y9fvQ7b3duTb9iP
QshJ4MuXL09XVheXnn769KnssBDSzVCeEpKa7Z3dC5eu/O2//jE4NILjvyhPCTkB
HLx79+LlKxk5seb2fPcpK2CEdB+Up4Sk5u3W1p83b//H33747fezQyNjqlDNwX3W
VYR0E/sHB8tPV+ZqC548XVwSecpiTkhBUJ4SkprNzdcXLl394R//PH3m3OWr14eG
R/f291lREdKt7OzuQZvO1uaXllcmp2dmZmtHR0f6ryz7hOQO5Skhqdl4/uK338/+
8I+frly7AZ165dqf4xNTW1vb8q9cIEVI14DivH9wsLK2PjNXW1x6uv5sA4V9Ymra
nHtKeUpI7lCeEpKOr1+/rq0/O3fh0g//+OfFy9f+vHn76vWbsMnpmZ3dPT2NIpWQ
LmB3b+/pymptfhGfK6trS8srkKeww8ND60yKVEJyhPKUkHR8/vwZVdSZs+d/+MdP
l65cu3Hr7s3bd2/duYeD8cnpg3fvyg4gISQftnd2oUoXFpfwKbaytj4yNjE8Ov7+
/fuyQ0dIN0N5Skg6QuXp7bv379x7cPf+g8npGVGoMb2n7FglxCm0SOoCfHyzt78P
MTq/sLiwtAxhilIPwzdj45OUp4QUDeUpIekIlafQpg8e9olCnZ6Z2z84KDuYhJDs
7Ozurayu1eYXpesUx5ConjxdXRufmKI8JaRoKE8JSUeoPL3X09vT++hR/2N84nhm
rhZae3F2GiFu8u3bNy2e2zu7kKFztQWUdKhSHMvIPo7xyd5TQjoA5Skh6QiVp3fv
P4AqffCwDwoVn7CZ2Rr7UAmpFlCoMt+0Nr8oYlQ6TWE6/ZTylJAOQHlKSDqiBvd7
eh+JPO0fGBSpCoW6u7f39etX+aH2zbAPlRAHQVF9u7Ul2tTrOPU7TVWbyvg+DsYn
pylPCSkaylNC0hElT3sf9UOYQp7i4GHfAAwHqOdev3krCy9Q+eG3+MSfX0lH+BJB
2eFyhaj4cS3e8gpPaNH75vPp0ycUVVmnD22qw/ryubK2roP7nHtKSAegPCUkHTFL
o8T6Bgb7Hz/xPgcG8TkzW9t8/UaE6eHh4YcPHw4JIWUADRr65cePHzc3X6NcQ5vK
aL63IGptXXtMZcdTkaoc3CekA1CeEpKOo6OjZnl6R+ae9vQ+6n3U/6j/MUwU6uMn
w1Co+JyemXv+4uXBu3eoC/G5t7+Pz/2DAzEcq+mXNBotd9vd25OChjIIg8TE8fbO
LoonNOi8J05XIEChTc3Bfe1GVXk6MjbBHY4JKRTKU0LSkUqewgYGh4aGR2dmaxvP
X2yjJtzb29raxgE+xXCsf8px0PRky6LOz+s6ed037fVdu2/R8V/08xadT1zLb3HX
2dmtn7azi9L45u0WCqaoT6hS2XhfOlBlIVSUPGXvKSGFQnlKSDpSydMnwyODQyNy
PDU9u/5s4/Wbt6gRN1+/8WzztWdyrH+mMv1tQkt7HdfCk5dliOpCn7foeEh7tbzC
WfT52a7jH6AkvtrcXFt/5vWV+mP6MohvjulHydPRccpTQoqF8pSQdKSSp9CmQyNj
MDmYma2trq2jUnz5qm4vXr6C6QEtmz1/8TLUOnNfd8LTrfGcY/hf+MUNtvH8BQqj
zDet95sa+5tSnhJSLpSnhKQj7eD+0PDoyNgEDAeiUFHDPdt4jtoRhoP1Zxvyp34Z
NPyTU1aVcBZtSDux0kOSLeSZn9ey0h8nuUlGRZhljilM5puqNtW9TilPCSkRylNC
0pFKnkKSev2mqlBHxlC3QaF69dza+ura+opvq43jVcdsJcJKD1hBz5XWqhvP8dfP
Kzxpr9OB++rYvSzPh+l7oXQPKcpTQkqH8pSQdKSVp0+GPXk6PDqOKg0V2/jEFGy2
Ni/T3cxhRP0zaNqv02GLCVIlwpnXcyW/frb4qXp8Fp0ued1XTITpwtKydJ1K7+nT
xramssUp5Skh5UJ5Skg6UslTWbYPbTo0MoZPCNOJqWkRqTOzNdkA/NisP5MYfpLK
0l6nrPDkFc6O3bfN6+cVn2mjvSrpkl8+F0kq/aamPDUH91WqUp4SUhaUp4SkI1Se
yktN5X1RIk8hTGVplNd76q+OGhmb8LpOJ6dhEKmT0zNQqHO1BalQ5xcWSzcrGI6E
Sqw271npwaCpSYpULl0W/E5TU5vqO0tFj+rQv3a1ml/imPKUkA5AeUpIOnKRp9Cm
U9Oz0zNzs7V5s3Y3q/yTYGm1BdR8qEVdP+r8JJLLBUv+vG6G3zVLK091lN/sPUUp
pjwlpGgoTwlJR77ydGa2NjNXE8FRorwwFU9LzVeKqshXflVFntJyMc3SMu7fljxd
W0f5pTwlpGgoTwlJR17yFNpUTRVqifV3sC53JDy00PhxJIqqJestearzUClPCXEN
ylNC0pGjPJ2ZrdXl6WxttjYfY1GDvPG/SnWd0D/TXqdoKyt+XL5+WWkhZsrl4tK3
zXhWGU15SkhVoDwlJB15LY1qkqdznjzFZ7nmQhg0JEErPVQO2WzZAfCtEkkjajW0
95SD+4Q4C+UpIenoTnk623ycu/qZTWlla5qk4S8rHvKKq6Ljv9z0bdxIFSqXRhFS
FShPCUlHnoP7czVzZL8DFXbUYGhe18nr+rnpmKrI35ySNW16tZm+7Qe4oA5y82pm
7yk3liKkKlCeEpKOGHkq2tTclr8uT4dHRZ7qW6N07mlXqiV3ZEqkldVr2HyjTg6O
FyQ03beE8vT4rVGGEtVt+fVNVNyWn5DOQHlKSDrSylPRpsOj46FLo064PD1xFkju
rleHpRvlKSFVhPKUkHSkkqfadQp5iiqN8pTmlp2AyQ+Up4RUEcpTQtLB3tM87QTI
IxftJEU75SkhVYTylJB0ZJl72lgaxbmnJ93C0roDg/snef4A5SkhVYTylJB0cGlU
F1iZS7LCAtPJ501yWukJlO+zU54SUjkoTwlJR7bB/WN5OjlNeVq6ncAF7Cf22SlP
CakilKeEpINzT2ktLd0WTh3PACdHm85QnhJSTShPCUnH58+fRZ7+/cefIU//vHk7
ybb8VV253+E1NB2LkNy3/U8YgYETukwdOqh6Z81XRjVeaopPOVD1aW7Lry+LUnlq
vjWK8pSQDkB5Skg6TpY87bwxQoKxkWCHf7fCWXp4DDPlqdV7qh2olKeEuAblKSHp
oDwt3IqPkOI69oK9hifibVhFP1d7KaLyFJ/BwX0cUJ4S4hqUp4Skg/K0C6yTQ8/t
TPRM8uJ7R8bQnbVQeSqqlPKUEGehPCUkHZSn3WnFJ4SL8vQEvGSVg/uEVBHKU0LS
cbLkaQcGi0t/xnwDU2qCptavKeVpFbtvo+SpdqNSnhLiIJSnhKTjZMnTou2EP37C
+HF/aVTDHJStlKeEVBHKU0LSQXmap7kRA5nlVPs6rDMyLsXcgGzJ4bZi5uA+IZWD
8pSQdCTflh8KtWvladqevCS9gDHXaXX93HrsIga743bUT5CC2cPmbI+pFQxnw5l4
W35Tnsq2/PKJ00SV1v91bR3ld2SM8pSQYqE8JSQdlKfZ1UxmeWpIjVKWsbeQp52P
N0cStPRgJLB25Km+PsrsPUUppjwlpGgoTwlJR9qXmlZbnuYkK3OUGqVssRQnT+Pj
rfQULMiq83TtyFMd5Vd5iuOx8UnKU0KKhvKUkHSEytO79+vyVKx75Gm8OnGwV68Y
S619uz1CKmQ5ylM5pjwlpANQnhKSDsrTbra0c09pzlu+vaeyNIrylJCioTwlJB0n
anC/ivtctmW5yFOHE7RNC40E70uHe9MpTwmpIpSnhKSDS6M8c1iOFGEp5GlXx0mk
PC07YPFhpjwlpHJQnhKSDsrTzkgKpzoskwam7KVjRd+X8pRzTwnpDJSnhKQjRp7K
tvyhc09hqNIoT03RkOecgeSyLN8Iz2VDgxw1ZU5PF5kWya/vTMYOylPZzTRmW35d
BRW1LT/lKSFFQ3lKSDril0ZFzT3tMnna/pzUfOezljZHNiIFU08GKCsp21DGVZmL
bL41Cp9JXmpKeUpI6VCeEpKOKHn64GGfKU+tl5oG5enU9CwUal2kll2F52aOzUnt
sH7KuCHrbODPTk0SSBpal9I0wzNCnnr9potL8glhKkZ5SoizUJ4Sko6EvaddLk8d
k6Ex0qSTCjWfe7kZnyVOqM2UENaf0nuqc09NbZpBng6Pjh+8e1e2KyKkm6E8JSQd
ec09rbQ8dW3DqZxfJWWprrx7KxOG38F4jgpz6YFpGc+iUKXrNOHSKMpTQkqE8pSQ
dOS4NEqtLoA6sGSnbN0QHsjO3zEmfkL/TH7BbEHKHOD48OcVwy2v5mDuCoQNCjV0
5T4O0spTFGfKU0IKhfKUkHTEbywl4/vJl0Ydy1MnzdTQSSyVfkrxq6zhzHy1mD/L
jeG0z5Xj9VOcnFle5xerVrAlVDIJVeVp5rmnlKeEFA3lKSHpyGVplIzszzTL02xK
IpV8SXsdhDPU2pELLYNRkF5JGG/BYLSMzzbjWad55PvsbaZjDmk0l2eWzhCl1oNI
kMzF+5SnhDgL5Skh6Ui4Lb/IU0+bDo/qtvyo2ESeZpBH5pctJUJaVZG84m8piVSa
aOdZKmERqggzyxSrA6/1E82F9+/ma0XEfHyyxstTlW4xvZ5tPm/a1I/5pp04kUc2
FarIU9Gmsuu+KFEZ8efcU0LKgvKUkHSkkqeDQ8fydGRsQl4cNTE1HSNDg+pzOr08
zaxjWlf/sYO2Oeq2XK5cULRkvn7oT4p7nNwjP8ONQi+S8OT2M3ZUEszVFmR/frOj
1JSnXBpFSLlQnhKSjnbkKSo2aFO71yqgXZLL01J0TMz1zXFqtdAv0145bQiTXzz3
C7aM59yfywpPcddJmzqh0rDl+cljOMNzTTcypKlQKU8JcQ3KU0LSkVaeytxTGdwP
rtlPbjIaGzzOxaIGf6Msr+tb/5pjCOPDbCmb9h8weTzk8mj5hkpjI+rKRUdL1B0T
npYh9upzGyBRF5dEdJryVFQp5SkhJUJ5Skg60spT6UCVdVGy3alZQYb+GWr4rf7c
PO6M5SIQE1qHH63lg3fy2Ut5uu5+RtNk7EIeFseT3iyb+QVPoHLfU0LcgvKUkHSk
kqf18f2RMR3Wn8oqv8qVpxkCmS2orj3ayZFuEvNi3f3I8nSSzaBPoVB1IRTlKSGO
QHlKSDrSytOh4VHUZzqmrxVkcCx1KjCaaX5j/TB4cnFjrEER0/L8zIPCcr45+N6x
h3XQMkRg5ltYAi73W5h/Fhr4eGEaegUIVN2cX+WpjPVTnhJSCpSnhKQj7eD+yNgE
6r/6WxbDVjUFF47EfJNtSUqOFn/94L+mDU/9/ObdnYp7nFShKi6eE6qxVOdnTtPQ
fJgk3UPDkCSfFx1vMdEoLS4c6yRUylNCXIDylJB0QJ4uLj1Vefrnzds3bh1vy9/7
qB/ytN9/axQUqmpTs1aO6T2aCSxbzlz1JqzUs8mvdmRBlNJKe5f4M3NRPDGhjXmo
JA8bk+5pHz9Jbmlf9sVknplmxRkaezFZLsnzRgUpYUZqeQvpQ52rLXgCdG09dHBf
10uNT0yNjk+8f/++bFdESDdDeUpIOqzeU0ue9g0MQp5CpEKhDo+Oex0z/su+61Xp
XAp5Glr3t6kXrfPblJtpLSbwUX+mepzkUixz/IfLo7mQ09LK0wyJklyeZkiR0HNi
whAlT6PkY/yzJwxV6INny89TjYX8KN2yXb+s5Vd5Kh2olKeEdAbKU0LS8fnzZ5Wn
Fy/r4H6PDO6L9fkdpzP+7t8wkaeiU73juVqBJnV5vlcLWjvXSXtOXmFIFdqoP8Pu
HpKms83nZ0u7+LiKDVLnYiZ499nmx08Y7MyPkMd16iXUXyY1v+C9U0qUaKg8HRuf
pDwlpGgoTwlJB+Qpailz7umtO/cgTx887Ot91A+R+qj/8cjYhGjT2vyiahfRpiJY
o8w8wTxfjoMW/HmSuyS3hPdNdZ3QBwyeE3XrVMHI9sNgwEIvlSQdrURMHkXxtwjN
Gx1IX+ufQn9lPUV8mBNakkcITbu0sSHlVPpQzcF9c99+yFPYhw8fynZFhHQzlKeE
pCOwNOou5Ond+97SKBhE6tDwKCo5EabBunPO16zx1SROMM9peX7Mb1v+a/z5+ZrG
g94xVEkkDI+EPN/wW9GeJKWswKRNr3aC2k4+afOmqaI9NJy5hD+YXpkjQX4rChUH
8kIplaSmPB2fmKI8JaRoKE8JSUfEyv0emX76ZHgE1dvC4pJUk6pH5xcWTSnTpiyI
qolb1tBp5WnC+2a2KHna8i4FBSkYOS3DEHocGrE59moHY6k4md5+tIfGamj40+a3
0CtkeF4kjRZSaU/qEH+oPOXgPiFFQ3lKSDrq8vTchb//+HNjaZQ3vt/T+8jTprM1
1GowrwNmcWmuoU2l5pPPDpjcMdRCT+5MqJLfNz7AxcVPhivUGmLL+nnwgi1FWHEp
0v7zVssyP6+VoCjI5o79nHtKSMegPCUkHZY8vX7jFhQq1OngkN9v6mtTU4ya2lT/
NcqgaM1j88+o85OcFnPNVD9v08zQ6rH1p3WmZWnjIcN1QmMmNNI8a6RmzKMlieTQ
Z+9kiqSNqIRXCH38qFhNda/c40HlqXnxmj/Kr688pTwlpGNQnhKSgu/fv3/9+hXy
9PSZcz/+dOri5Wv+8P69gcGh6Zk5fG+qz5a9OB3QH9kC0LIXquUPE/ZmVcXQ7pC+
cHwuLj2tzddFDJJ71n9pu/wpJ8SIpyTxk0SEVStWgw9SlfBLKsgQP9Jd5enQyBjl
KSGFQnlKSDqOjo68lfvnLvzwj3/+ce7i1es3e3ofQZvOG30wtWQz6oICpQODm6Ff
Rv2qiPDkdc1OGlJWphTDkNb6UPhO0h3fedq00XGei6XKP8njv8NpESpJo0JVYhLH
JMH8Qn2llCjU8Ymp4dFxylNCCoXylJB0QJ6urK799vvZf//P/7pw6crDvgFIE9kT
UXrRUIfJIL50piYx/CTeEl4n+QUTWl73RVRI7Z75yuWaF2B/KF960Z6urIpkkeRW
k3/NFj+pYj5tNBad7vH3DYa5M/dt//qyqxTSWhJdUmp0fILylJCioTwlJB2fP39G
LXXql9M//nRqaHh04/mLvf39ra3tN2+3Xr95K7b5+g0+324dfxNv+G28JbxO8gsm
tILum/ayLtj2zq4kKz6R3JK4eJbNzdfPX7yUh8Ixvo95wKgIkV8lj6i0MVl0usfc
1wpDaHhyT6wcnwu/evkKCftGUhwHk9MzQyNjB+/ele2KCOlmKE8JScenT5/magvn
L16+e//Bzu6efPnV55sPDr40+JoG+W0plHjrqnB0dISWiUw+BjhAuiPe5FO+wTn4
TJvuSvIfak6rFvFhzhxvxYEU/9oImKS4tE4hT/cPDkr0QoR0PZSnhKTjw4cPy09X
BgaH5hcWP378iD+3trbFtrd39ADm9bc0/imJ6c+Ls9BbSGiLvnWlTaJoe2f39Zu3
0CUbz1+MT07L+xeebTzf29/ffP0GJ7z1Tm03Juv3Onkp4hWXssMQnhY7u/hEWxSF
HUV+bf3Z5PQM5SkhhUJ5Skg6UD9BnUCXoIoaGZt41P/47v0HsDv3HujBvZ7e+w8e
6jdBwz+JWd/jh6EWdR1ax+zOvR6k6YOHfTdu3fmPv/1w9frNpyurvY/6z56/9PjJ
sKZRTKLHmJnESRI9213KiLR6UDXDx1vpAQ57hB45QNIjoVHqp2fm0ECFPJW+c0JI
EVCeEpKODx8+vHy1CWkyOj6BCvX6jVtXrt24fPX6pSvX8Hnl2p8XL1+D4U/5TG5y
kVwMlwq10H+K+VVB4UkSzkIt6r7x4cEBkvvX02f+/uPPW1vbyAyHh4e//Hbm9t37
yAMXLl2NieT45wr9J+Sf5Ndpef1S4tkqAjElIkn8l2JIVhRq2J83b9+8fbd/YLA2
v/ji5auDd+++fPlStjcipGuhPCUkHUdHR5Amq2vrM7O14dFxVFcP+wYePOyjdbf1
9D7qGxhEcqNN8m//43/P1uaRGQYGhyBPJ6am5YTeR/04kE9ad5imJpJ+cGgEab20
vPJqc5NLowgpFMpTQtLx5cuXvf39l682l5+uQKHKC7ihU0NtZGwi1NKeT4u3oZGx
UMvrOkPDo0jlsfHJ8cnp/sdP/vP//DC/sPj169c793pO/fLbyuoafosT5AoQMaVH
iOMWlf/zSse06RtTHrV0o6RPTc8uLC1vPH+xvb1zeHhYtisipJuhPCUkNVCo+wcH
m5uv159t6NsOQ032+wxa2vNp8aZvRbcsr+tI0kCaPNt4PjNX+8c/T83VFpAT7tx7
cPHytQ8fPsg5i0v4/9rK2nrpEeK4ReX/tOmYthzFpG/UdSRZZd/T1bX15y9ebm1t
Q5uicVK2HyKkm6E8JSQLqJw+fvwIkbqzuwfz1vaGmfxr0NKen9aKvr5rpqvdLcvr
OnIpJPenT5/QJvnj3EUZ3Ic87el9hMwgP9cV36VHiOMWlT/TpmNe58eXFzne3dvb
299///790dFR2e6HkO6H8pSQtvjuE/Wv3yJIe35avkeQ1/VdI6/njbrOX43NTb/5
afdqc/PDhw84EEUl/yqn6ckkA2nTMW05ypBP9F/jSzohJF8oTwkhpAU6khsqiaha
CCEkXyhPCSEkKfFKlDqVEEJygfKUEEISEao+zS8pTwkhJBcoTwkhhBBCiENQnhJC
CCGEEIegPCWEEEIIIQ5BeUoIIYQQQhyC8pQQQgghhDgE5SkhhBBCCHEIylNCCCGE
EOIQlKeEEEIIIcQhKE8JIYQQQohDUJ4SQgghhBCHoDwlhBBCCCEOQXlKCCGEEEIc
gvKUEEIIIYQ4BOUpIYQQQghxCMpTQgghhBDiEJSnhBBCCCHEIShPCSGEEEKIQ1Ce
EkIIIYQQh6A8JYQQQgghDkF5SgghhBBCHILylBBCCCGEOATlKSGEEEIIcQjKU0II
IYQQ4hCUp4QQQgghxCEoTwkhhBBCiENQnhJCCCGEEIegPCWEEEIIIQ5BeUoIIYQQ
QhyC8pQQQgghhDgE5SkhhBBCCHEIylNCCCGEEOIQlKeEEEIIIcQhKE8JIYQQQohD
UJ4SQgghhBCHoDwlhBBCCCEOQXlKCCGEEEIcgvKUEEIIIYQ4BOUpIYQQQghxCMpT
QgghhBDiEJSnhBBCCCHEIShPCSGEEEKIQ1CeEkIIIYQQh6A8JYQQQgghDkF5Sggh
hBBCHILylBBCCCGEOATlKSGEEEIIcQjKU0IIIYQQ4hCUp4QQQgghxCEoTwkhhBBC
iENQnhJCCCGEEIegPCWEEEIIIQ5BeUoIIYQQQhyC8pQQQgghhDgE5SkhhBBCCHEI
ylNCCCGEEOIQlKeEEEIIIcQhUsjT79+/FxcOQggpju8+ZYciCxUNNiGEmJiu7Nu3
by3Pj5Oneq3gASHt892g7LCQEwFyWhK36CaVDjwh5MRiVvHJq/ukvacUEIQQUhb0
wISQ7iChN+PcU1ImrHQJSQWLDCGkinz69OnDhw9/JZ5q1WJw/5vPX/SJpACQtT5+
/Pj+/Xt8lh0W0uV8+fLlr2r6MRST3b2912/eHrx7V3ZYCCEkIy9fbc4vLKLGT3h+
i97Tzc3XT1dWP3/+3HbACLGBVkBzCtoUn2WHhXQnqkdfvHy1tbVdxbmbCHNtfvHa
nzcf9T+GTsU3X79+LTtQhBCSAnitmdla/8Dg9s5uwp+0kKcTU9PXb9xaWV2TvgdC
CKkcHz58gCtbWVuXPyvUhypBna3N//yvX2Fj45PJ+x4IIaR00MD+/Pnz1tb20PBo
H+Tp9k67c0/l9wuLS7//cf7KtT/nagtsshNCKsfh4eGrzc0nwyNr68/KDksWEP6Z
2drZ85d+/OnUuQuXoLNl/hYhhDgOtOmXL19evHy1urYOefr4yfDbrS2Rly1Faove
04Wl5TNnz//2+9nrN26hBR9UqLh3hboiCCEniu2d3Y3nL1bgGUfGVhu9p9Xi6Oho
fHIafviX3/Bx6cq1G1SohBA3sfYhResaHnh+YXFt/dno+ET/wCD+THipFvK0Nr94
/uJlNNnhF2/evru0vFLFyVuEkK4n6Jr29vdXVtdg8IzDo+MVlacH7949GR45febc
73+cv3z1+sXL1+CKZ2ZrolD1qdlNQAhxik+fPr18tbmwtAzp+Gzj+cjYxMO+Afjh
hEPxLeTpbG3+j3MX4RBFpN66c2/56YrMQ+VsVEKIg4hQg6p7urI6V1tYgTjdeD44
NALfVXbQsgCR3f/4CeQp7Mq1G1ev34RIhSteWFxiHyohxE2gTZ+/eDm/sAhPtbK6
tvH8BeTpg4d98MMJF0O3kKdoo8MnQptev3Hr2p83oVPv3Huw0ix+2WonhDgFJB3a
6LX5RTTc4RZh/QODOC47XFnYPziAPP39j/O/nj4jwhR249ad+w8ewvUfHh6WHUBC
CGlCx/Rh0KMiT0fHJ3of9S8tryT0WnHy9Nu3b5PTMyJPr1z788+bt2/cuotPuEVd
A8uxfkKIUxy8ewdvODNXe7qyurj0VOUp3GLZQcsC5GnfwCD88G+/n710xRvZhzy9
c+8BPuGKFxaXtCuC3pgQUiLSWfn58+fnL17W5hfhfqEV8QlXLPL0Yd9APvIUjI1P
oskOnwh5evX6zTv3euAW0XCXCQQc3yeEOAXEHLTpXG1hYQmN9lXpPX228bzP7z2t
4lDP3v7+o/7HOvf0z5u3oVDv9fT29D6CN+591I9qgLtNEUJcwBzThweGQY+avaf4
OuGLeFrL03/9+jvk6fUbt2Bwi3fvP4BbvH33PhTq+rMN7thPCHEBSM+Dd+/W1p/N
1uahROEQ4Qdh0KbwVFB4kHFV7F/c3dvrr/ee/gF5euPWHbhfyFM4epjoVFQGfPUa
IaRE4F0PDw9fvHwFTwuPJMLU16hrsgBA5Cmccw7y9OvXr+MTUzK4D4WKVrsMJz14
2AeDToXTxD3Zh0oIKR1Zpw+3iE8Z1pdxJfgo+EbIU/yTnFmtPtSd3T1ZGvXr6TNw
w5CnN27dvXMPPngAvh7/gzzFcXKnTwgh+QJtenR0BA3q9ZtClvq+V7Sp9J6KPIWn
yrP3FE32C5euytxT6T2FQ+wbGMQnGvFQqHD9Vh+qLpyqVjVACKko0HDwgGi1Lz9d
kVY7DmDSewofBZc1V1uookfa3dtD4H/7/SxcschTOF7xw9DcIlLve2J1cGFxCRq9
7PASQk4c+wcHqk3hgUWVwv3i05SncFQ4Ibe5p5Y8hR9EY109472e3sEh73UswT7U
KtYEhJBqgbbx9s6u9JvKDibiGYPyFOK17MBmwRjcP6vyVPwwhCn8cP/jJ/iET8YB
YgBKXXyvvEsQfPH52uBLg6/RfIkg5vzQ63+OIO1904Yn7X2z3b26WI+cVwzER2+O
6ZsXbT6vUnQ+jyKv60ddJ+a55FfSabq9vQM3C68L6SkLocQJix/unDyVVjvcItx9
v9+HCnv8ZHh1bV2n539vYB5byMN/axB1Wr58iybhT3K5V7YLZqP77psqvYp73uD1
c7lpi+yShlQXt8pjhou381zBM6OuI6pLgoo/5VXOK409pLwdTNbWpfdUfKLOPe3v
Fnkqk6zu9fRKH4HI04HBoYd9AzKuBZn+dmsLdQbqjw/NfPSx/gzlQyasH2a+TudJ
G9R84y3+mnldP3iv+G9OAlFxW3T8l0v7TwSxh89Pnz7hCvDAkH8iTMXxijwVYSrd
BB2Vp3CCMqgEtwhtKgoVQUGIv/nTYxFuOEc5COWwQdQJbXLUoKDrp6Xo53WWUp76
0KDDt3YNqxQcJsCFcMag7gXeZvP1G+jRhcUl8YCyUBQmnlFX7nvy9PETnXtaLYK9
p5Cnph+GwQ8PDo3ACXtj/EMjs7X512/eIn4O3r3b29/HFWipbGe3bqWHhEYrwuAW
2vQM4lvggdfWn6kqFTGqTlisc72nPb2P7j94KL2n8gmfCNePA7hF3BhFGoIa4nr/
4ADPgE9aqEn+KD0YXfaYoffKMQAok7DSY7UzMelg/kSQEP9wL/AtL19twvdBm4pn
lOVQ0oEqw/revzY2lqq0PA3OPZXeU3hg6FHpQIX7xefQyJhIVTws4mdra3t7Z/ft
FthOZfjJibK0D/7mbbilvW+Gn2R7rpap3E66Vzf/tJN27cS/Iw+e+efwKviAh4Hu
hAeWAX1VpbqfVKcH99Utej5xYFCG+J8Mj8Anes5xeBT3RrhRi+ABPNveKcXMrFDE
xTP8U6qwpa1OyornjqVjqvPjvykonAm/tJ6roHRsPx46mbuS3wsnQK7hE6JTpjp5
vs8f0FdJKuNKsmi06+Up/HCf74fhgWGQp3DCcjBbm19/tvH6zdvN12/qtvma5pZp
0iS00gOc8HFKD0mbaVF6YAq2V5ubsHbiCn5VhqdkTN8a0C9HnspG0DKoJK32x0+G
0Vj3HOLwKA7gFqGmIatFm0cVMzhN02/Kn02elFYF04SzzDoh9zuW+7w5xo8jAS4r
VkNv2jIk8IzwiTqmD3kqI/vmcJL4RLjC+tzTKsvT/rCV+9p1KgY//GTYG9+HB8YB
XPHI2MTMXG1t/dmLl6/Enr94qSYv04oy88wkv7L+Sf9Me50cw5P5/CTXycs0aRJa
2uvHP2/7T5okM7Rzl7T5JK98VRUrOp6jzodHtUauPHnqD1vpNyXIUxncF7coc/N1
UAnyFAbPCLeIcOPZIFITmmr55D+hVcIkZfO9Wo4XzDFgCb+sRPxrPEulWPpTqCEw
9SWiDc9otdRVpMo3x/LUXzOUg1rsOLsRS6Nk01PpLNDeU7jf4dFxeGN8wuCKZ2vz
q2vrUtkgKsQQIbIdrBwEDf8UalHnW6a3yMvaDE+SAJsx0/K+eYUn9wdJGP7QBMqQ
ammfveh0zCt+8gqn5ivL8gpnhusk/DLeZNMo7Tc1Z/ybPalqnZCnumJU5uPDxC16
naa+NhW3iAO4xbnagv+mgLoMl6SyvGRyi1L3GS6V4/WTn5+2VZfXc7UfnmzxU9Bz
Jb9sh9Ml6gTLSRURnoQplc06nL7m9a17ybEO3NeH9f1tpHTiqU6B0kY8vtmo/uC+
JU91cF+6CUSeykAW5Kn4YXhgVAb4HJ+YmpmtyRSIVX8WBAwH+FMjkGabHz/SK1/s
9aMs4Q9Lj6iy0iVtvBUUgNIjJG1EpbxOvVtUr9kYvhf3a4pRdcLBgX75Bk4Y7kjk
6ccituWPkaeiUKW9Lp+T0zO1+UU8kmhzfK76/lEPusOs1kzp4Wn/ceRAcrP1ZekW
2oJM8pPSQ26Fv9BruvO8eT2gHIiiEudY30bK8KGmr9TjrpGnOrifXJ7Ce0Oh4nNq
enautiAxJt0euilsXqZ1lWU53sIpi3reEuMheK8M983ruaqSH6oSznLjZ7E5d4n7
DZWnoRtLuSVP4RPFLaLhDoW62Nim1dp3INTMDuHKWTvh19HJYBR1/kE057X/XEVE
ckx4Qv/VjNhOBtKpeOsCs6qN5YY8XTbG98XPdJk87UspT+GHxQPL5+T0DGxmriZv
LqCFmF/jJj0tyZnZrt/+I5h3yfGOenHLHEmXThlK0AksRE2PLMnRSp6Gzj0tX56K
Z4QwHZ+cxica7rOeV1ySGkWzdZRajywGFbG0zxX81wxxEnValvhcXLKCUXqUZoh/
+4kWo91rJ0NCS2uB3Gi245eN1ojlGeXM7pCnO7t70KDwwypPTT8c03sK9wsHDpuY
moaJK67Ne/WrfGp1G7Rs1Xby6+R1fl4Wda+8wpP2twnva31vnZNNiBSaH9q5fo7x
VlDOcSeei0iv+skN55xcni435p5CHJYnT435+NCmaK/DJ+JzemYODXfvtS5GXBQd
3XlZfHgKDOHScstgFPe8x7mwpGhPEc5kyVduODvg7GL+dMEyPG/TOYZCDcpTcyxJ
d5haarw1qgvkqdV7mkSewg/L+BUMThjaFAZXLAo1d4tK3yLuVYTN1Ra65vo4znw7
+W3Q8rpO2usXHW9lWV7x3AGzJIF2u7QjTzu9NCrYeypNdhlXUreoDiuvtkvRFp9m
7bvj4K8SXrZjj1x6EkQFMibwpQcvGI2Fxqojj5whNlr+ZN73jCpMTYW6bOwqZc43
7V55ar/UNF6e6iiWylPYzGwNrljqQj2gISqSx0aGeEt1/WxmSZ94GZT54gllVinp
0gHrzFM7ZbV5o7sqkzxd8tdlijzt6X1UgjwNdYviGcU5mm4xJoFLbyskLH55FdTQ
H7r21KWHJyaGQ88pPagJQ5vvvcw/S3/8JLGRJJzzzb2nZjfqcvOmp0HP2B2D+6mX
Ro2MqR/2OlCb5ak3ljVbm5nzvDE+0/orkQvtW9rrF1f75vtcRVtUgENrE/yZV7pU
Jf6Lvm9eoc03PO0/b8xPTCesCrWlPLWWRpUsT+sbS/kdqOITYdp7KvIU3lDcYlll
IMdiE3Vm0eGJqu+jgtT+XfJ9rnaKWTvls8PuLHi+Fb355orgTfO9flnpXveMxlRU
a2mUuf5Me0xNz9hl8vTy1evmW6Oi5KmOYsn4/vEkq9kaPmW2lcS/+OQCbTbCir5v
ESFP8KuofJ4iZuIt6gpFp1fadCwu3cvNP9XKw23bnPaeJhvcX4zYWErkKVxTnvJ0
ZGzCl6dXrly7kbb3VAf3j5vsJyZRaTRaOzbbmAtk9p6qT9QhfnODi6jeU9kwFQoP
18lBLXac0LdGmfJU3i8NPxzc91RGsWRdVF2Y0g+HmrMyus3wRDxXnG7udmvReHAk
3cs27T447j1tVqjqhxOu3N94/iLnbfkpT2k0WuctSp5aW/FFrdynPO1KeWopCRfV
lbMyNxCTJ1ae0pIY5SmNRqOFWEt5Gr+xFOVpVeVprLyrgDyluW+xjQeqdjMenJan
uBzcIuUpLbVVpBeB5qZRnionS55W3FLMPU1oXeY/S6oXkg/lU56a8VAJeXqV8pQW
apHumPKU1obFzz21Bvc597T75els87Grj9C18jQvf16qPC0t9ipoVZKnV6/fpDyl
0WidMS6NUk6UPI1r7uppbj+CW8ZuAiseSg9JRawa8vT0mXOUpzS6OVonLdXSKMrT
rpGnVbHKjxo5GzA+rxtGeUqrjkW53aq4Y1qljHNPFcpTzRLmEG3Ow7Up/Vj+g/gJ
A5b7ZVNGfuHPS3PDKiBPG9vyX4E8vX7j1s3bd0PlaejL9ChPT4R1xK0fn5B7/snb
9dN95xWN7D0VDHl6VuXp3fsPIuWp74QhT+G9ZVt+dcLHClUzf9kJXZSVVdck9IfW
99Y5nQl5fBhoJ97ECVtvjTJfjGJuwh/16j5TnsId9T7qz1menr94WeRpVO8p5Smt
KAvLMIX0mpT+pDTDKE+VUHka13tKeVqicTSJ1i2WuzyFMsxTnsK1wSdSntJKs0Ce
cbRXklVRrkZ5qmSQpzK4T3lqZidH/QaN5qrlK0/hhHMe3Fd5euXaDcpTWtAKn5NE
eXoijfJUSShP+x8/gSumPI3PVJH/2tlez1BX2WnPxsF9WqxRntJoNJptlKdKO/LU
Wxp1MuVp2kejPO1I7RzVncGlVw5a7vIUTsmTp4tLHNyndYk1+anqZCG61zZjj/JU
aGdw/0TL0+r4ChrNQXNdnnJpFK10K1aeFpYtKU/bjD3KUyGVPBUnLPJUtOkJlac0
Gq09y1Oerq2b8vTjx49JXB83lqK5bh2Sp8XkTA5aZY43ylMh1cZSlKcxOcqhctdy
Y6kOTDYoZe5pzKNxxwPHzHV5isv5LzW9cuXaDXNb/t5H/eIWRZ5Cmw4OefJUNjTR
7aBhJ06edr6Qp8xwubnpfJ80YgkU5d3JtJby1PSDLeUpXGP/4yfVl6f1bfnNUayY
bfnhhGV839yWv0meVsiKli+UR23GW1n3ZXoVaVHb8uv7pVWettyWP/+lUVHyVN2i
vjUqVJ6exN7Tjj1jGzeyOyNdSJcIeVpyqGglGeWpklme6sp9ylNa4elSekhoBVjF
5On9Bw8teQq/HypPT+jgfrWeMbmjLzr5cpKn7G3tDqM8VShPaTRaKUZ52l3Wrc9Y
kYeiPO0OozxV2penkXNPaTQaLdq6TZ6e9KVRbs89zT8YpUc4rRuN8lShPKXRaKVY
l8hTcYuUpxWTp5mvc0JSk1aSUZ4q2eQp/DDlaQrj3FYaLWAVk6dRS6NMeSqLRilP
XbhRi3FtOmKak0Z5qqSWp/7GUpSntA4YZ091t1VSngY3ljJb7ZSn5QejYbm5D8ee
i9bdRnmqnCx5WvFezJM29720B6x4PqmKOS1P4d1+PX3mwqWrkKdwizdv39XtoHVb
fvh9uMWWc0+PFWrZMZ6PhT5IVCHJ76ld83chgYnxFFE+pXhHE7K3f7a70Bt2xDLL
U3hDcYimPPW25Yc8XVpuXyx2nqA8td4aBSesftiSp7ItP1fum/mqLfnobMF3M1Rp
w99+LUDZmqs1bcvfrFCXjHejqDwV3yvf6Amdk6dRb406cfI0uXX1U4d79u593qZn
pPsrzChPFcrTcvOhaz0CNFrHLKr3NF6e4tNyyGXK0yQr97tVnrbwXB2QL90Rq1XU
eZSnhRnlqUJ5Wm4+PCHD9LRCrOK9wk3ytPmlpqHyVJ0w5WlF7GQ+ddrHN84pog4I
uWZe6XLC07cYozxVKE9pLY3SmVaEiTxVbdpSnrL3lFYpS5bo2jmB8iBGh3uSjfJU
oTztAjtpS6ZcM8Z/NgvK0+rNPT3R8jTBQxVaDFjMEllzGmV3T92XgZ00ylOF8tQp
O5n+lvLuZJp0GJmD+9WTp1waZSbniSq0uS2NKnpiTV7ylNYRozxVKE9pra0qK9ar
Mhcz6vpVief8TFxxwrmnofK0c4P73FhK0yz0y8JHpR0rD3ltLGVdRwf6S39AWilG
eap0pzwtq5pPed+mHburKKfyuo5r1097nbKuX3R4Cs4/Xv73h/jVCZvCtOS5p/62
/H+EvjXKGtw33/Us8nR8chrWtC2/GRd5RWvpljWX1AXZbPOfYddMMphi/2sg+9oX
sYKtebGNTN90i6KLU0nJGqnFq/ukbpofgfVxJaPJbpp6RnGO5h7R4hNh5rb8uFT7
YrHzxGzLL69H8bSpKU8bfli0qW7Lb3cTGDWQ9b1+k9aCF0z+w9CwxQQpPqhpnyWt
jMhw2cyx6oKljYc2462iluSpKxcP4jdQ8UGhiuOVblSrj0AkqW7CrwpVPvHNxvMX
OctTXC7qpaZJ5Kn0noa8OKpjNhf7p1MWI3dClVOq50qgqOILWLqncDmei7F8Yo9m
WaPhbqlSc9hIPaMlT+VfKU8teRrMscHKNVsFHPx5fOKG3rflyQkvHv/bfAWHC9ev
+nVa5o0OpHX7z5UkVGn/Nd/4z3z9oCsODmGp462kPJ1O057OMTOZfyY8M/Sbljkg
r5OTZK9sudD6YXHR3slUThuHRf82SQyX5V5diNsk1zEzqsx8suY8ae9pUJ6aY0wn
WZ7qS01lcD+VPM3gVYJ5IIN3Sp6vsv02bb7NfH7mbJ9X/FTLP6R9oqKjK9sF28mB
ztpxyP2XSJn9ptbgfsXkadSgUocLiflnzJkJv4zKapmze8uTY54oScGOKkgZnrdy
liS220zZ+IuUHgMVtVC3GDW4H/W6Z5172q3ytOXcU5GnIQsAHOg9TegMLbMm0SYJ
Z8L8li08bV4nr/sWbRmSsk3LOTxzKS7eZvqm/dckRabo9Iq/zvGfhkI1p/hXT55K
12lZ+Xs6zBEnPD/+y1TZLm3yH18nMD7e4vzoeyUMUuZ4dsrNtZkcoT+PCX/mxywr
fnKP50LdotpsbR7i0hxRojxtKU+1m8CUdIVakpKV2aSnw+zviM9vaUPe/kVyvE5Z
9y36Onn5k3bCU3RaWPdN+KWzZkWajPKbrlhn/5clT68mlKfwiaY8jZqM3wEzb5ok
DFGZOFWJynxykou0k93bDHzyOE+Y1wtN94QxmfycpvObZ9ZmftKy4qeIeG4n/HHX
aUS1/BlUqDr3tOXK/e6Wp/Xx/dCV+5NNe6eEKrxUZl7BMuu0lucHz2l5fjvhz3a1
5OEp95p53auIMBfxjO3HT3HxEPPDzBFbYrpPGwJDz9QJVw7J05ht+ePlaedtKsJd
do1ly7V5/ZzG+Oxk3MrBzGzT5CdRoqHyVPtWRZ6urT87IfLU2+CvIU/NRVEdExYx
f7Z/frBClbUNQTNLJS25RcUnw5PNQjOhVWtU0RB4WSlVYXla6QRInk7ZHjPfYhbM
8db1o/7J+mHax6l6MSvuSU9OzBRnVh7GsShUc9m+OEftMbXkKT5PjjzVt/fJJKuW
Hrj0at4qI2nLS4XKV+V0VYet6ootbfpW6GFDH20cf/t7TcHTOrRy//6Dhz29j0zP
CNcpPlFEqrehyeQ0i2LuFnTlbubvhAHL9zTXnq5yz5Uh/Am/zNcVyKXQcPdc3tq6
tNpl22dz7qmOOh1vyz8wiN98//69TbHYeULlqb4eRZ2wvr1PnLBElHYlxsdnki+j
fp4tfaveK5bkueKft+jrdyZd3EmytB416knZW5wqzmUeqrX5tO73p1Ot4KvhhIdH
x+G1cH4nlkb1PurHpw4qybjS2Pik7mNCK92iHFmJ4Un4pQvxVhU34azlHm9yKW/u
E7yiMa4UujSqi+Xp/QcPZWOp+qv7/N5TGcgSbWpO7Z1qNbcsyZcdm8gRalUJT9S/
WjOtMz9XwuuUXvDbj/n4uenZ0iV52KL8f4ezn8smkSl9qNJBoL2nurtfp+WptNrR
XjcH9yFPYaJNJyNm4tPSFu/cL5jkmqHnFJGU2XJIS/fUMUvoLiv3XO7bdKP2glv0
RpQafagxK/e7WJ4er9z3FSqc8ATiyH+32XSjjg9m1/Yt4RK3Ni+b+xK9TtbfScLQ
sTWLbcZPjrfOMQO0f69O5od24r/QaMxWjtQhz/gTrkSD6noA890o5fSeeoNKfpMd
NjQ8Cm0qYS3LHXSTFVfmU/2k9HgoNFrcCY9rz+Va/FhWd4v+GL/uLRXclr+L5an6
YQjT+vj+4ydPhkdkThjkqcSSF/lzRWWqQqrViJfcFhHmNqvnXEJS9LMULVOKE47Z
LMkFi8gnJ82mGiv6cSBz3KFQtbu0THna0/tI5zx5g/v+3NO6NjVcSb7FoKxsVFY2
zfF2oYEPvaZ+mfzWeRX7jjm+3NM9r3yeV3g6Ew/Bu5vfFFoem/6cOx5aMhfy63F3
y1NxwtKHOgTfD23arOdO5huGHbSEBaq1Bd4a3ZTQidO6UD+TY4wVF585BvWEWiO/
1aXq3PGi1dLkqQ7uo9UOt4hjtNpxmrbUHUn4QktOKeEJ/WE7niKm7k8S8mzuzDoh
r2hsPzzl5qvS82ebIW//wdPm2xnfLdb7UBeXzIa79KR2tzyVwX1dADA4NAIXjJiA
zdbmxfRPRJF+mbtJLZXv1ZJbXtfP6/yo3yb5vp1nKSL8GeKz8xkgaTqqAyk+3U+C
Bf2MaD+4YrhZ7S8oc3AfnhF+c2RsArWFnaKz9bRsM7edXAsUpOPvZ1t901ycgqfZ
X8ZeocAH7PxNad1kjSzk7cDnv/LUlKfiGbtbnlradH5hUaoKsdr8oipU8/tQM2ua
LraY6jaX84uO2BlDIYWGM+F1kDdCrf3z46/TThpli3+Nt5kwcZlXupw0kySWCJQU
n/XbADiwhrM6Kk9lVykxOEbcD2FCgOrh86uKuS5ydnkVj/bvG/9P8eGMCnnM91qe
4+MhQ1SkCn+SJyqimkl+fo6R0GVWULqoN5wzPKNs1y9u8STI07v3H4hCxT+NT0zB
A+Pp5owKQ6MxiVxoJx+2L0e63oLR21IOprrmbHMHuTuP2f7Vig5qwugtPW5ds9kw
QTLX8M+69Wmx8hSODz7x3IVLV6/fDO57OjQyNuPP/ZpL3xory6oSzphskaHYxPjH
NuMhmE3jr6+St3Ix3xkrrlcj33QvqxxF3Xe28cpT9Yk6uA+/6MnTx08qLE8fPzl9
5hxcMfzwzdt34Yfv3PPk6cDg0OT0DB5cnHCG6rboajiv65cV/uShyvy8Ca+Q7/Om
vU62UFVX3lWlXBR9/Wzpq688NVdKwQmPjk9AN8IPf/z4MYnri5OncOUjYxPwidJ7
eu3Pm+IWYZCn0KYypj+bsver3OKUVzK49rxFZ7vi4r8z6ZJv8SvO3EmXzoQ/x+vP
+aPb+iZo9Ywbz19I7yn+9du3bzmJxs6xtbWNwJ85d+HX02cuXYEbvn3j1t0793rw
5cTUtNQEMn4lOrUSFtXMKOv6UeentXaCan5TegI5nr5Vt6rHT8tSIJNQj9/tt7Zu
vjXq06dPSVxfi97TsfFJtNovXLqKVvv1G97YPszTpsOjqA9QDSAQnSnGZbmbvCxt
NZzXdYJXi79+m8+V+/WLtrT5J6/0Kjrf5lWO0j5vXuFMe199tPlGH6psE900uL+4
lINa7DgyuO/3np6VSVbwxL2P+uGcpQKY7wpBU0VLkpNptJNmWiLMzgI4YbgsOC7t
PW3ZWZBkcN+be4o2Owye8e79B6JNcY+6+Qq19BhJFXHJq0laaLwF/zXmz5bx3354
MssgWjZzMJ6lMVAzxpXQaoeDWn+2AXvU/xj/VLne0+/fv+8fHECe/nr6DFzx5avX
r9+4da+nd3zS6zeF38cDak1QoXzuda6EWVnXjzo/xkIv0n6wS08aGi2zBYuGLFpd
WV3beP6iLk8Xlz58+JDE+8XJU7jykbEJuMXzFy9Dn169fvPGrbuDQyMzszVxizqa
ViG3SMtmCcVHS/daUG3krBVdDXdr+DPf12y1y6x8tNpVnlZ37im06alffjt7/tKd
ez3QpmbXgBbMvLq0O2AxyVfK9bPl0uAVMoQzGIbSU4dGy2bB0iHe2Ht7ytr68Oj4
w74B+OQc5p6CianpM2fPwydeuHTlz5u34SUhSWVWgeUZXauu8qpWM7SqQy1tMud1
nSg3mqMFrxxzl2BCxIfKNXmUpFiGRk7C812Lh7LCn+G+1jVFocJTyeB+nz/3VORp
tUTqzu4etPWpX07/8+dfbt6+C58sg2V4tJbRSyvUkuTwFubXpJF/0ipuaf1ht5rM
thocGunpfQT3dXR0lMT1RcrT7z5j45P/+vX302fOXbpy7cHDvumZORlLmm1eZphh
KUP7izDytaLDmVZW5jXHMe35GeLBumyq62cOZ17xX1Y60nK30AhHHvMmoa6t9z7q
x7/mphk7yNutLQT+wqUr+Hz5ahOe/fPnzx/DODw8DP2eFMQHg2xXsJKMKUi6EmRs
lJGZuRpkJNzy+/fvk7i+Fr2nw6PjaLVfvX4TOnVt/dnW1vbm6zebm69hrzY3vYPG
n7R4Q3SlsqLvW/SDtLyCd/z6zes3b1H7Il+lvU7a+MwrHspKR1oL8x2RFeGSBJ7X
2nzd//hJrZqD+2/ebvUNDD7qf4yn+CvBegJCCHGQ1bX1gcEh+OEc5p6CwaGRcxcu
rT/bgFunWyTtExxd/fz5c3nBISeCo6Mj2aS57IBkAU24qWlvo5Q3Xktu+8XLV882
nm88f1EJk5kVQSvospmvn/ZquTyFg4a6Hq0gfMoxMtvzFy9zj+3qWrkxYN3I5Zg3
owVZ6OUrr5sAB/MLixCpOfSeQo/CKULtbm/vfPnyBYJ3b39/d28PhgPT9g8O5ODg
3Ts5B9/A3kcjJ4gFryaGq6lFXUf+NepSQdPLWheJCWrMfdOa/FDCaT6j9byhMSDf
h/5r8MyWFh/bQdO41ZODTxH6LFZsSy7CweHh4avNzTv3es6cPX/z9t219Wf4Ff5V
Mk9UTuu8RT1g8F+TfK//FHU7eWp9cL1O2vyZ1+OnLQg5RruV96zMn7DI4yeHPnO1
hZXVNfi0anWgfv36Fe4XDt3bhWBxaXxyemh49PGTYbjlUMM/hVrU+Wmvk/b6eV0n
r+sXHZ6ywp8hP+ivzIOx8cmr12/+j//17//93/7n33/8+c69B30Dg0+GR3K8b6Hx
5lr852v9j584ng+DeWxwaAT5Z3R8wptn5e9+ilZ2u2+Ngh+HVoD+hU/EFReXnk7P
zI1PTME/mjYxdWzev4pNTqO5j2/wOTk9E2rHv5JLGb+1rhx1hfDrmJcKtUCwk9yl
fTNvoaENBsN6HP1V8F812PHhj7++GduJzvcj8Pibxp/WHUOzh4YTuWLWf8fP2fOX
/tf/959DI2P+quTTw6PjtflFyTbyW+8gPjXT2mTifBLILaEPaEVd8Puo2E519wz5
zbpjuqc2LCaLRuaQPCwY4TG5N/zp/G/wc/gueLCl5RW03RNuB+0OR0dHW1vbnh9e
Wh4Zm+h91N/T+8jff/qBYT0J7EFKS3LNJNfP9zrH39y971n66+cVnrys6HC2Pt+P
xgfyHjIIoP/8r79fufYn9MSPP5366dSvt+/ex/dF3LeYeHMt/qtiBZYgZDA4LuhU
VPqvNjd3dvfa3Zb/y5cvu3t7L16+Wlldm6stQAWjFSXOUQxZVl5wKu84hcmB/imv
hNbzLZNzTIs/p+V1ok7I/YdR4U9uSS4Sf0KbAQg+darY0DMliVte3/wGOVW+QWb9
j7/9AG8oLyf7f//7v+Gf8Ocd/51kVgbLy5LkqLR5teX3oRdMm6/yjYd84zNbHCYs
16HlJeZ8689H/Y9R0cItrq0/e/N262OyDU2cYv/gAMIa8hQPAj/cPzDYZtnvGkN9
VHoYusA0GlHFD4+OQ5Lu7e8j4w0MDkGq4ntmOVpmQ+562DeAml26nzaev9je2YW8
TOL64gb3379///LV5uLS0/HJ6T4/g97r6YViwKe2t6QJi2/QxsKB2cySb/JrdRXX
yin6jrYhZsSyhrzD8RN509hHMH/VdCnJPMhR//l/fkCmRU5D1vq//u//58atOxAT
ON/INkU8bPY4TJ9k4T9JEG9l5s800RhM5eTPlfTp4stL459CA+O1hZDH4MFW19Yh
TxNOyXeKw8PDra3t9WcbC4tLM3O1endyo5N4bHxSDfpVDsxeZPOEvCz59aN6x3MP
RtEWdevg9y3PaSd+8j0fGUb+lJyDrLW0vHL2/KWDd+/+8l/K8+vpM1AVM7O1zPFT
ynN1Pgvlkp/jw2mFueg7th9vx6f5o1gy63Tz9ZuEI/t/xcvTz58/b2/vrK0/m6st
4AbIwUMjY0PDo0+GRwaH6pNRcCCG72E4QJMLZyJDT03PTs/M4TPUZJA33szBynbO
SXKXbL9Ne5egJfyV/In4DEZp8vgJvW87sZcwEfUYgcefyLWoZeEH/zh3Ufb6wT/9
8tsZ5C7kNDlfMnRM/sklqBmeOuo6Md9b/9Qyvczoaud5M+S35GaGrYjikyT8SZ4L
OW1haXn56Qrc4t7+fsJWu2vAFe/u7b3d2sJTyDoDy168fFWuBYMUHzA8RagluX5Z
z5X2+3bCnDZ+2nxGOdjcfC2vKIOA+Pr1K0oNWnf4Gu26otMlr3jL6zqu3de8VBEP
FZXf0uZD85/MM+G4ICbhgVWbJlkD0GLf00+fPuGiuMfK2rpsrPp0ZVXexSJbQ+ux
2OLSU5ywvbObPATl8r1B2QFxhe8RtHmd4Alwf+b3qhvMDSK6YLOIrs9dbeaTtPcq
9Pou0wVlgbiPZjPdYgWOutQQkZNLi42lkDvRcJfV1ltb25Cq+FTDn/INmvUwqFL8
WdEJXqSThGpQU3ycZCFCCkIyFXUeIUlQJ0xvTHIkeb5qIU/NK6IV9SUaqFh84pzK
bd1CCCGEEELcIak8JYQQQgghpANQnhJCCCGEEIegPCWEEEIIIQ5BeUoIIYQQQhyC
8pQQQgghhDgE5SkhhBBCCHEIylNCCCGEEOIQlKeEEEIIIcQhKE8JIYQQQohDUJ4S
QgghhBCHoDwlhBBCCCEOQXlKCCGEEEIcgvKUEEIIIYQ4BOUpIYQQQghxCMpTQggh
hBDiEJSnhBBCCCHEIShPCSGEEEKIQ1CeEkIIIYQQh6A8JYQQQgghDkF5SgghhBBC
HILylBBCCCGEOATlKSGEEEIIcQjKU0IIIYQQ4hCUp4QQQgghxCEoTwkhhBBCiENQ
nhJCCCGEEIegPCWEEEIIIQ5BeUoIIYQQQhyC8pQQQgghhDgE5SkhhBBCCHEIylNC
CCGEEOIQlKeEEEIIIcQhKE8JIYQQQohDUJ4SQgghhBCHoDwlhBBCCCEOQXlKCCGE
EEIcgvKUEEIIIYQ4BOUpIYQQQghxCMpTQgghhBDiEJSnhBBCCCHEIShPCSGEEEKI
Q1CeEkIIIYQQh6A8JYQQQgghDkF5SgghhBBCHILylBBCCCGEOATlKSGEEEIIcQjK
U0IIIYQQ4hCUp4QQQgghxCEoTwkhhBBCiENQnhJCCCGEEIegPCWEEEIIIQ5BeUoI
IYQQQhyC8pQQQgghhDgE5SkhhBBCCHEIylNCCCGEEOIQlKeEEEIIIcQhKE8JIYQQ
QohDUJ4SQgghhBCHoDwlhBBCCCEOQXlKCCGEEEIcgvKUEEIIIYQ4BOUpIYQQQghx
CMpTQgghhBDiEJSnhBBCCCHEIShPCSGEEEKIQ1CeEkIIIYQQh6A8JYQQQgghDkF5
SgghhBBCHILylBBCCCGEOATlKSGEEEIIcQjKU0IIIYQQ4hCUp53j+/fvZQeBEFIN
6C6K5uvXr38xnglxFcpTQhyCleUJhxmgaBjDJF+knUPyBeWU8pQQh9C689u3b+WG
hBBCCCkLT56yNdkBQiOZMU8ICULPUDTS/GM8E+IsTb2n333KCsoJhLFNgjBXdACz
c9rZCHc2YIQQUjR1efrly5dyw3FC4CQVkgoKFEIKhbNoCHETT54eHR0923i+ufma
dWGhfPjwYXt7p+xQEKfRMsjCWDTffMoORQj7BwfwxvgsOyDdzKdPnzZfv/ny5QsL
GkkI3AU7mDqAumVPnu7t7w8MDg2NjO3s7rnpr7sDeMOVtXW4xbIDQlwHRRK5Be2Z
sgPStcDRvX//HjHsmsdDeFbX1vsHBmfmah8/fiw7OF3Lm7dbk9MzB+/elR0QUg1Q
MI+OjtBuPDw8LDss3YzEs8gkT57CCT5+Mnzx8rXbd+8/23hunc3GZWY06hDDyNZL
yytPV1bNeRS5xy1uVOj1TzISmfgU91RQ3MplkVXu3n+APBNzI9d0leMEo/HV5uaL
l6+0snEnPjeev/jz5u1zFy4NDY9CQ8uXLMttohEIDwlVurj0dHxyuuguaslUqGsL
dRrkL2OCYhGRLNdEwewbGMSndSMma0uSR9HXr19R8W2+fvOXyFOUHET673+c/+33
s/d6etefbRQYzJMHXOHq2vrK6trMXG356UpBtSCSf3dvb7Y2r8kXNQzBstQO29s7
cE+fP3+WPwuKzJnZ2q+nz6BU7uzuFXeXE0JoQXj95i0KC0qlgz2Ua+vPLl+9/uNP
p85fvDwxNc0evhxByUXl92zjObwx5KnEbaHlC7IJOW1haZl7BRQH6r7nL14WXZbh
+a9ev9nT+wiVrFYBJC9QQNCQQw37dGUV8tTb9xT/IVH7BwbhCs+cPY8me++jfm0f
kAyYGyDs7e+jspmrLUChwkktLa9IZVmESEWK3rh19/6Dh7hp7hcnf/mphhScnpkr
etgddzn1y29QqI/6H7/a3Cz0XicHKZVIRIh+FMn+x0/w6Zo8RSBX1tav/Xnzp1NI
/3M4mJqepUJNi6kC9Vi06TJqv7X12vxiB3pP//KXHNy6cw+yRgZD/mKvWwFAL6KY
vHm7VehdoIsuXr722+9/3Lx9F7lI+muZiHmBwgixNL+wqEnpydP3798/eNgHYXrh
0lXYlWt/PuwbgNYpTkidEFCpoKZBFYisjJyN9jqivri5p3B/f5y7+ONPp54Mj2zv
7BZ0lxML6jbEKqq00fEJ0TTFOSbkEzhBT55cuNQ3MPj6zduCbnRyUG26tbUNdQIP
iIhFS8M15Yc6D6l/5doNZIDzFy9fwtGtO5yHmhZTAsrx0dERyhFU6cLi0ouXr/A5
PDregbWqqF6Rgv/19x9RybLfJ3ektYnijFrv5atiW/LSe/rb72fhmNHkQOXOPtR2
MN9BAz+M6EXxnK3Nw91JW84b3IdovdfTC2d44dIVOEPI0+s3bg0MDmm3DRVqcnQk
cXdvD026haVl+EHI02cbz1GEEPXFyVOk19nzl/73v/8NIrUznrfr0Zwvs4cha6BN
xyemip4dPzk9869ff0dqorF++ep1CKm3W1sSGBbGzMAbIhqfrqyiPKLRODg0MjE1
7VpDDvJ0ZrZ24dJVNE7gkFEdwu7ef6AtW/bWJEe1KWJVZv+j/kMGgDxFFdiZZjzq
3Tv3HkCeooaFQoWE0pZS0bfuelDbopqDW0ZSQrEgWQu9HSpxOGS4ZfhkNB3v3OtZ
W3/GvvD2kX5T+GToJRRSVH+I6vpLTdH4gPs7c+4Cov7Pm7ehTdHau3HrLty3jkeQ
VCC6UWZEmMIbLi49DZWn+WZoqGGUnB/+8U8kJZoZI2MTHOXPBSQZGnYoOWguj09O
j41PmhGbu1dCvQXZdOqX02fOnkc6whWiWA4NjxY9dNXdIFYRgSiMSEeUSsgURCka
G9oz7UjtAiE1PTMHYerL06viiuGW7z94CDdydHRUdgCrx+fPn9F0156CldW15y9e
Qp4OjYwV14bX7AQFfPP23Z9O/Srjkw/7BnB36xySAcQeSjQSFI4ZBRnyFDVgoRs/
QUIhEVHJwiFLx0Hvo35U9EzHdkBl6nXkLS7BJyMpUU6HR8cRq39J7ymK6K0796T3
FPEOh3j77n20DPAlzoP7ZuynAnJ/xdemqE5QeEShIgGgOWZmawUt4UTtO7+wePrM
uR9/OoVkROFBMwNCandvL98bnTSgTV++2kTcothApCIRUSjebhWoFHFHNC1O/fIb
5CkKI6QJPpGa4xNT2of6F+u2NKDSQk3m+b5GixGu8MnwCASKa1N7kfrIY6gC//Xr
7+cvXoaygTyFQ8bBg4d9CPz79++Z9C3RKEJ8etp0cUkmWcEnIxtAIM7W5geHRoqr
3fSym6/foFqFW0ZTE54ZBiHF6TptgibH1ta2dIejtkWL7vGTYSRuoaPtaNigSP5x
7iISFKkJtwy9JGt1tN3Ispkc1GXSkSdjGiv+CnLUs9AtOKgvjULz7s49r/cUbbur
12+iOsSfd+8/QHsdn/Dg7LZJDiqPZxvPvRlOfmcbIl32k8KXk9MzkKcFDe5/+fIF
/hdtjB/+8ZPf6XIXJQcNDJRbKtTMSN0GbQpDKUIijk9ODw2PFlq7IClHxyd+/tev
Ik+lxYikhKHcujYY7T6ei/NXg0KjSNcpEhIJCnWCpHRNnqKeg6NALai9pxCmcMX3
enrhlh/2DeAROOMtId5Gla/fIMakY0ZaJvhEg1PWxhXRzrRWZeFe3j4MP//L7/zx
BifxP29k0t86h2QDCYcERSKKrEHTHaIfqVzotuK4F9qNUEpIRH+Q+S58MkonSiVS
mSMbSTDnm378+BEyVLp+cCAlFMdwy3V5+pc/+oAoFnkqbQL8CYcIXyhucWRsIrQs
mUvUTxqhM04O3r2ToXyUE3zKflIiT9HAQq0DsVhQJsZloX1/+/0PyFN4Q5Qcv9/F
kzX4nqP8GTg8PHz+4qVoGiQikhKJCHmKqqVQTQPxMTw67vWe+n4QVRrKIxSKuEJP
obYakeS0NhMZAZz3Ok7r6kTa60jHDiynSAsK8tT0LOQp0l/amf5Y1oOe3kewO/d6
+gYG8Si6UurEeuCW1PtNfW0qA1mS+rAXL19B2Tx+Mlx0zwuammjTQpj++NMpuGWU
ZXHL+EQdTIWaBKuqhXNDvKE4I01hSNNVf84VygXStNA9VZBz/jh3UXpP4ZllkBll
E58Qx0hoa2oBy2YQjROZbyrVKzyylE0cIk1R/eE4Tp7CFUKe9j7qxydsdHxC53Qz
0kOBBEQGle4ZxLIIGuk9xYH0nqLiKah5By0F7Svy1F/tW2/YibJxcAMddwhtZSE+
keG9+WreaPCqtNE9eToxhVoN1V5xpcCSpzAkpYxmwFAw4Yu57i0JshbKmwXeSEcZ
P1p/tqHytOjlFGmx5CkEjaQ+nPCj/seSB/ofP4ETN2ti+mQL752lm68RS6j/pPzK
sH5Z8vQf/zwlE64gTGUk5F5Pryxg5ZLHJGgsoURLH5tUsipPUTo6IE+l91TWAyAR
oU3FJ+MT2QkVBNe9RWF15CGupN/Ukqde7+nIWAt5Cm+ISIc8RaMEByhLY+OTKNV8
52wQxMnu3h7ckLf0zPeGiG5trKs8nZiaLk6eQn2qPIUflEREMiLhJDURNu1DZWUW
ikaL9JtKL7iko5eIhjzVploRhMpTGc1AeUSCwuCOC53/2gVAGWxtbXs1WaP/Wwqm
33n6rCryVAZAUAuKPIXJoNbDvgGZh1p2eJ0DygDlF8mKFJ/1BvW9USwRNKX0nqIt
5PWe/vwvlad37vX4UzV6YKiJOQ+1Jar5kF5IUBkJkbq1Lk8npjojT89duPTHuYuQ
p1ev3/ST0iuYKIwy9wYuBXVES410MuvfkH7TxSXpLrXl6fBoC3kq1SEM8rR/YBAJ
gOTHz1CwdX8TJIP0POHgWwRffaL+1UQuleTMdoi6y9cGCS8iz/6XLyZQZqBdvJZ6
YxRYVakcy8ZShcpTs/dUdmDQThekIAoP2hjw1a7t8uggEPo6pq/aVCo5fF+6PBWB
4inUiSnteiFWciBaEDlSJCUdpUjKAZJS5p6KPHWqtggO7mvfOVIfrrj/8RPkARRn
HOApdGa56ZCj/F6QdnxpO+QVALmCemN8ohHubWvqp7uM6csMKxkILkue/vPnX2Tu
qczWkLrVn63xAAVZg+FUVnSEb423baFBLtpUFxzLp8jTzgzuo2Ce85eQIy1NeYqC
iQMkLFwKqgnz1eJEQVLCX4n7lU5TVUpaNhPJU9R/cICId4n6gcGhPl+kjoxNoH2A
TPDJ58jnUxiHPkcBPvvon6G/Nc8PPaHl+aE/tEIS80/WOYcG5vn4E2UGkSvTm2Qt
lAga6W/TuacdkKe4+K+nzzQG96XTpUf8IJISrhDJNzNX40qpGGQPmvrKNr/MSK3m
tTQ63nuKZrrKU/GD4gr7fFeIg9HxCVRsoW9YjZIjUTdteUKHSRv+v4wBNW9g9/Ub
LZXi/lSgyOB+deSpN09R2pma+n2+Q/bWSQ0OIaNCiCMPoEZU73SYmCiPmvwK5aIu
WuoUODfZA07SXRok2k3Q+cF9hAqZ7eLleu+prnGUkUmpXmV1x+s3b7+xqRmB7Lxh
TtWQWtXsPUVhQHnvQO+pL09vNORpjyQlNJLOhIRjQZC0opdG1F/Ns8gy+LdUFH39
5GHQP+GgZJNa1aYiScUti6WWp9JhAz+IwgzD8fjkNKpqFCf8EAaPcPDunWnvDZBd
PjajnuVjNKYDijkt5nw9+OATf2srkB8M5CnwUPsHB2LyjDhtZ3cPUmbV7zfVKDYn
4JuNgw7I08npGVRpujRKNI3MIRY/KAVpZrbGXrcgKAxIbhnTr8/QWFvXZoYkbmd7
T0+b8hTlUdNRWowy6waFEXWtNNaRpjiQ5t+XgvkcQdH3jUKHPlAwUSolEVWOaEkU
eSqvzquIPL2r8lSSXob44ZD7Hz+BITdCaaGRLI5LfNTe/j4MnlkOMpi6u0LNuikC
nPBM0+CN5cFRJSFltfyaKa7H5cpTGdQyi7M0NWFwLJubrzl3Loj3Klp/+wUd09eW
hjn3tDPy9Oz5S7I0SntPpVYVmSRuGcnqrT1fW5fAwL0EPWdZfrJo5NGQjc1jALd2
vAzA98w6sGxqJ/mz9dxTWSiqRUj8IBy6iFSUJdwAkgvlHFlna2tbpCoUG1yMuEXT
uQTF64dWBJWiqRcTnm8J5Zh/1eAFvSEex3u67R08pvek2zv4Ewd4eJ1xLw10cyKF
lBxdGiX7nkJBFiRP8ey4+K+nz/z9x599eXpHxgS9QcBGw04GIKQY46GQe1Cd41Pq
deSkb8YkB4uowbW05+dF1H1jwiNlRtFAyvdIem9M33eC2pjTYiPJitw+Nj4JZVC0
PPX3PT0NV4j6TKo0qc/gAfsaM208dTIwiAPkK4QceRguANkAB8jA71MSVS7yIqqY
53gLPDsevN7AaAzoS/KZAkXqswrJU+07l3QXb4xP+GGEHwf4lBd1ihP2HFTDWeVu
cvGgpT0/6rdprw99KSfIS92kp0CSXjPA8XBWo0bspDyF6xd5eunKNdmNSOfOSYJK
pw8cNUo9HIsMhsikBctTZfB7OdK+E85wu8PDQ6SsuGUVppKg1tzTzgzuR8lT7TJA
2YRjwTE0FvIb9IP07hfqXdsnL/8sbUX9oUgyRMKrzU2ZACklsT7rxp8Ubg3up5Cn
sjRKmgUiTNEsQMzjc2a2JlMqUaJEpKLxitIOjSxqFVJV1apq1iRtdKsvViSj2X9p
ntnyfPNGlgYNbb7DEOy6o/dlKJ4Ij4ZCgijGpzwplLm5GtTsmm4aFG4kAOQpWnhQ
kIfFvA8T+QC12m+//yHy1Jx7qpNjZNYayo28NAyPiajA80o2wudh9GBf1OSHqiDj
lWZvujwsnhrpjqhAsqIi8eZj+C08SUSt25a9iRtec0xeT4IM/62w7mdUSEF5qoP7
MpAkpRJJKa4Q3hlhk84neZwo04xtmRbS+NPU0l4/JkipLOr6eGqUU0SCrIUSSSpO
UFWplNPKDe7LGkdzOFhmW0lFiEfwNnAdGYNDhjSHB/ac1es3nqcSw3F6g68LtePL
Nlva8xFIseObRpzZwnxvjPpntTHWYa5MNWd0aEEuR576b0uRjaVkRNisXiU1ZWQS
kQbvdOTPHJNq3hoezIvgpLiYk/U0a25evkEKjosifZFqok0lKRGfIb2nHVwaBbeM
lGwsjeqRXrw+vw9IklJMSiV+AgmBelblkH7m4veK9s9p7ytViffD7Z0dr0Lax4Fo
U31tm74dw1w7nk6e6lIMq/cU3hA2jFp6alrWNct25fCMKPOmgFOpqj2O8dGh+tVS
tOafQaUbFMFRZ5pfBmP/WJU2Guumo8ej6QPiwHsHl78KymqjmyOJ6hblX4veWMqU
p8bc0weSiDJfTdIRSTczV5MgyRMhmSQGRMdLD7c1T+ODMUHCnFOhrjM4d82StpZf
szxjPMEzo/zaoTH9TsWohB+PYzWK8MhSs0oTC/Gx2mhOBMcE5V2Inek91aVRqNB0
cF9mD8vYrvSeSpGUUulNuVldk6QMqfsbJrk6aPhezfxeyrJloV+2NA1DaPDSXkp/
LkVVWhfaXLSmG6o0kXIqg/veW6OGRwtNygwg66IgGy81vavtTB3cl7mnkvp4BDwI
jlGuUT0jDyMnS35GdhWvFWNypmXyQxiu1o4lv4IGVW9tmXk1PROBR+GFH5N+AWuU
UJ2wmQEseVr09hfHg/uNfU+t3lNZeSypiaREHYGKHJlZaiJ4JzwvnhFeS3oQgt00
6tOsfp+oziBz1od22QT/KbQXyeoDCt7UuqB1jlWnW3c0+4bkUxqcSER5G7s2M8xp
xB3uPTX3PTWnz6lSEmEqjUZRSgiqNxNye0cdbDb/WRWTpxPt99royNOxLLNTz1q5
n6c8na3NSz+TdCypZxSRqnVek0gVa6jAJmto1qCEDcrZoNAMteBpodrUHEJCaC1h
KsJFDM+56s9ENOWpVWysiW4uyFOp0iQdR8YmpmfmpLRLwvl9315+klQwPVRwJnHU
bAqr1RsvNIPfx7eqY86Jmkb8vnnChrRkzIFCcRNmfYy4WHFVnkr/mcpTLZJSHkWm
IIMhqJKaZg+WFEk9zmzWNVue09Iy3FFKpf6T941fSJGRZVMS1aDW4EZQnkqkVU6e
BmdbSc8NssHMbE1dMQyHMPwdNPkn+Vc9Nv+0vm9puK9akvOD94Wpj9Vj/UYPcLJ5
jldm/Rchyj7tljzVieMy8yrYe1q6PJW+A0+bjozBt8Azy1CbSHBR3lKoZbBLZFxk
/5ZWr6E1rFHNBeti8YpaWYfPuAjcK/xMf9Qx5CfyvRlOIzDWpRASFG3pddPELV2e
6uC+JU+1YKo8ldbvkC+VFhaXkKKmokjlJ6tl6r2lSlU/rFWqOQMnSp7iz4zyFDGO
OPeK0mxN1saKxxfHIeWqLlIb/SKqU63cb5eWYKGyilxsp3SLbuewomsWBu06kmwk
Ea0+UUZ+NXJ1J8X6su4weapdOC7IU+1yQ9r5STevM5S1G1VSSnu7pXNeW8DasRoz
YcXsxYwSmgmHdaKInx+jITQXiGi/eD19/cQNdu0glTWJnZWn2hGufhCFGefjEw0P
pKvMkQ3toIrqUTP7pax/tbqvknTIWX1goV+27JwL/a00gFWvaKhQNj1t6u8FpgJF
HF8SeVpQOmYjIE+PV+7LCoz6zGNf0+ARkA1krzH8iXJdrwb8OSqy3YTYajJDzFjf
rBiW8CJyHbHgP60EzPqJpXH1InKw0nwXqfzktcOmPNX6T17d56w81b5wlF+vy2dm
TgayJe0Q4Jm5Gnw1ngK+y1sF0ehDscwc94gaIQkOWYRY7ISQ8OuEzbgwx1GtX2lQ
tbaVngLrglL5yoiwOZW8dHnqD+7fsOSpTNIwlZKnTUfGYDiGZ0ayphpPqKipozYr
U93fTatU7UwtTJ5OTMGNmioHuUTawVZPquhULTmqU4MNtSTz6EP0a2xL0VKiwSJt
FRWdSqXVtidMG9Gq2+lp/Ko8NVWpm/LU9IPQMfISAb/7e13SSxxKU4e30QCwVrwF
d2lQwZpca4bKzZa8DyxlsyYZ67CRpU3F60myBvuHJKGtGWyWPO3wvqemPDX3FTJ7
T6XfRWY2ozLzBjT8mtvqDDPdR6jyM1WsOTocPCFeoQa1qcZ5Wjdn3l276ESamH2B
lh9MIk9lW/4qylNdh6Hj+9KHimwAeSOF2nzwundKJjFjZGXCH1oWJUy1h1vDZulj
/bmcbA7Nq7/VdNctvs0uGdUu1sRTp+Rpvz+4j7KMgowErI9J+ikog9r4AoUaj4CM
elxJRelI/bJ5TnDUXGFzgCL+/KgLam9Z1NQRuYU5JGJdTU8wfUV9LEteyG6krOmW
S5GnjbmnTfJU5xCbc65EnkrHgXTn4VlWGo4r1dBE5Uxr0qAj0nWK8fIU37QrT73q
0O9A1TG1VaNe3LB6UhtlyWzemTPerJkA+VqoJA22ArXQml1KuuW+alMzfq0O1ErI
09Fxb3wfXk9fcyVjgvXZw9Yqt+bZF+aM3qhlbTErAYP9nUkI/spSpcE5x8e96ds7
srhNekzVNWgnjVmVauFxTZ6aO9HU/aCkpu8EUbHB/SFNj5uLzaLBVKjJpaFkiSgh
G/9bs37SKidbixyBF5Fx7Ob8lrAkmTTTddhI6y0d4qi0PJXFNKHyVDaWkhUYyDBo
okj7RAq1+eyWm7IEa4xyjZebqcy+XSAY1pl6LGVQ9koM3cJPnbOmvvQjyPGqsRe1
g/L02C0Pj3ql2O/0QSLieZFFUZylH0FqkA1/IpY1+yVKO1oCNOFStqBF/Ur7OE1t
GjpsYplZyW40z9zQIi+T6Jaf1vuDzB3i3JSnSEfdUMVSSqhtYeKiEcKm9lXXmTl8
Yaad+h9Tnq40b3ZUiDzV9roOSYhfMztsmnpSjTaf1fOvHZlBzRplCU+2zglqU7MB
p/UoHkHGj3SIwRzZr6o89f2gbMIKQYPkE48vfaiy4EDHZUShHutUY0JF6G4MMZsw
6OB76E4LURZ/sjWn3pSk2iapjxz5k36kL1zrXXPo0OynqYo8lU4XlafmaIbKONUZ
683TEDP3Yqb6Vai0jbmUGTyzIbHSqKvUydS3WfAHbbTo6foY7VSr+uC+JU9194b6
zmKNHnSRp6JsUKKlz0ndlFmXN4nUgBYMitSEwjTqnITS1tasxniU+Ft9Pbe+bF1c
cX1Ey+89NRWqPvuK2/JUJyxa7UxNR0lK0dkyfc4qX8HuyeA3SeYLWl2eCX9uytOo
ZW1WE1eFaX1ksrnvXMq7tEifNq+kcUqewjMnkadIUJRNfFoDXJJ7u8/MsqnfSMKp
WEoiT7MP7qs3RFxLh434DqtStLpRzQ4VqzP1tbEWOEq2RunLbCvLgpNmrB5THUxU
yWIO64fK0+Dc06cOLI0KTlisN9Mnp0WhSmmRYEujQpfEmvu/hHambhsbEoVu0ZVk
o++WO4QHLbjYU4WpuSGiLpPU2RrmGLE5eriSRp6iFOBqJcrT+uC+n5paGJGax4Wx
MbxrlUed0pdQp3ZyplTUkh0JtjnCa5U4+adjpdKYphbfe1qVpVFR8tTrQH38RMb3
TYc8M+tNVUSZrs0vmj2OqsxihvtXmstCLpNNUwz6G70varY89WWo2V1aPxZ52sj2
Feo97TM2y9SJOk0Va2Pm5Urz3DmzkIYOqQf1Zfz3UZ2dSRZHxsvT4OwgbXxq6kjq
a36QA1OemlVtifK0Mfe06aWmMfIUqSnyVHY9l06E+vhGV1qjVEoxNNsV5rxhTdMC
5anUiDqcpNN9rD5Ua96bKVLNkQhrK7tgr2qK+d2BCd1BSRpaxkLlqdZ/pvtbDMw9
VQ+ojX6X5amUlnp/W6NpEVzfZu5TGFzcZurUlpsnmJuJhCrOJBa+MVtg4aduvyBJ
b84kro8Ua1dNYwWJ4/JUBIruwCBFUqZq1JvmMprhF0ZzeNec3rcSsQAluKbbWkad
qsPVVJxRPaP6jTljybxXUMFo0mjpM1uDUjBVkqpnjJGnldhYKji4b8pT1aaj4964
sA6JyHoab9pVoMII6UZtVodW32romHui4ft4syYYNA8OmvJUgi1Crd6baMyzshVq
owNVu21WjaVRDspTXU+jsxUlKUWhat1qre4IFsYYeRraRRqcfqOVYKiKNSeSmorW
Uqiho/xmYbcGRlbXmrvMjXnJK8ZbhZYaW2OauaIseWpty69bN4YujZJhfUlTaNN6
B6o/yNWVJj5Hy+Bx72ljjCuhPF0+3lhqe0fl6dXrN0XZxA/uS7yrPA3ts7FGFaPG
/kLLUvz6wZC54Qm2idZ52cGyahYqs2EnRUUKkgzxaydNTO+p2Y2qZUxeaoroOix+
W37Z/1k1je7mLZsGy9wMETTeUtHZJg8YnDpsJkdw+kTIrgsR+yokFKDh26YEt24I
bLwQXMRq7sAg+Q1/4jNkJLHxjZmItjxdW/fk6eQ0CgKuWUQiCiJPf/7XryiS0KZm
Uh7XZ77JXon11PQdn1mlBfc+M4f7zc6tmEnuMfI0dMeimH8K7moUnFBvruhabSyU
EUEpSyWsUSQtg9pnJl1NemzJU0lilwf3j46OUCrPXbjky9Mr4o2l79zUplaXm0xb
1Dan+GTpQ43q0tCaPuo4dCZAUhmabI5a0/Wb9fFyYK0bkkzGuxebVwKY8tTqPdW5
H6aggSHRcSk4w4691PSfP/8ibhkJCk1j7XsqTU3JkJKU1sjkcdePnwRmwbRqVUun
Rq1cjO9tDVrUHHTzalGTdqwZOxuNWXNSwK2Wg6lBVcqYO3JYbvlpZ7flhzbVwX19
a5R0HFjyVPdUqctTf7hSiqdXQmdr4qhllEOEnVqOYtH6Rrs5g2eaJ0edFnNl/eFx
kWzkW021p40t3hYbM8iXGq9z05oXv8pHnkpPtRnRUaOKUW2+qIGJlusH45VozNTv
mPEIs5F3POzrK7Y1/00V6hPNOW2hg/tLy3bv6br/1ihEV4flqc6M0XWF2vkt9Zk6
wcXGe8ZWjVEkswmhq6bMGRehvaqhm94leStG+O5gYfswhO6o0rQDg6FNdarTS3+z
krbkaWPuaRGJKKSVp1oYdbaGOSy4aKydDA7sBldQWTVfkq7TeDEapU2DnbjW4K+p
VFaMXYSCClX72LpAnn769MmQp1ej5KkOI2otqE2UYOVnKtTgtDCVBZEdq9H9psn1
aJQ8tRSqhsfqfVn2XwZ2/DhGT2ol5Km81DQoT1XTmPJUphGLZ9ZaVWv31cBU8mC/
j6rGqEH2lmuYYkb821nmqE5An2LVn1ZuWlCeLhrr4aoiT3XlvvaemvLU60cw5uG0
NEtHJjk/82/TmozXadkMdp0G5anWsEXJU23kaUHSKflmjRg17y20M9UsKvGzs6Pa
dqHzuM0z49d5BLWpSk9r+mmUPF02JvyGylPoyCJKTlp5igIj9Zkup5CE03ZF6NRh
aw6GOX3CWpqW7b3bVp9o6HbNifZhMISp9ojLs5gTNuzRzGTyVF5qWvTgfkJ5KurE
dH8iTczyaIrUpp7UiDmIwS7Vlj2gqilbdseuN+8PFbqwZqUx80xb2HWBou3D5pKo
1q3y1Jx7am19ai4QbupANbKBqerMWWKhcRgiUhMLzZa/Cp5s2VJgaYWY1cdjzXXr
DnkqrU2Rp+ZIiCjU4yq1oVBjqtSgxSxXMivc0MVM8XNJY2b1hPoNrV5lSETlaTAT
mgr12F0bb05xXJ6iVMbLU7OQJjScnOr80J+3eZHQ8KgONhcvWmM1WsYXjX1PC5Sn
wdlO2qLV+mDFGOg3q66oQhXTpEtoMYMaMX0/1h5DK4ZfEw8YNbDovjw1d2VTeSpl
Rmoyc33bsrE4er15y8zgpGGdK2xtnhCcAxAchbdG5INfhv6k5Q4M5tQoTXEVRqq/
zflMyeUpag7EoWvy1FwZWnd8EQo16CysTrJQqRq1tCX5ahircK0G7mX1w5lrJrQA
zhvzDq3Zh+0sjSooHbMBeYp0jJenmgcseSp5wOpDVc8cJexClzIEh1nN46C11J0x
Pzd1SVCbSkep1c90/CDGiJaZyZvkaUPQlC5PkZot5Wm9pdE8V0d2bwyu7lhtXu0e
nJmTtnqNX9KUXKGa3T3BRmnTjP9GF5qZ9GZiLTWmJ6o8leLsmjy1lJIkJTyzrg2w
B/cb8jTGVEoenz/b9E/xP09o1nVMCRv5q9mmMy15GhyiMWXSkjE1vFPydDa8OqwH
q3nziCTNvvhlgDENwdAhjPiBhqjyo2LfqhSTzD3VEiVlrNzBfVlMY8pTbdKpEwzO
zQhOHbbH+hMsZbNka+iX8RuEhb4IPji1I7jKzZqwse5vkKn6e6l5NaiZgjHyFJHm
sjytj+83vFhweDeqhyxmyUuoBUVq1NrtFsPB0StjzEHnbPLUdI7dIU/FdFsxsyI0
5anplqU6sftQm2MvtOs0qClD9WVL9RmqQYOKRP1qkzb1E106aaxhUK0LqyZP78YP
7gflaUy/T+jknNARj4SD7/G6M16eBvtKgy1Sq3pdfhrSILFK7rKxkMMFeeovjbrR
cuW+yqR6wYySp9E61ezjrCvC2PNt+Thbs3/V8vzgaY0vkRWPe3wbZoawqd0YUEqh
7dtie0+DHTbBDU3MIYl4kZq2ICUpMBvNm+OEDlCG1qxW+QkdUoyXp1qi5MyylkaZ
8rSveadMHXGw1tNEzXOyGt9BkRo67h/5KrzmF4mFbgHWNJG0eVVc1GTiYDd50yrR
xkCS5eDM+jVenjrde9rwgHVXEhzbbc69GhWmLrRG/KN6VUO/t3tGQ6+TbMzXEjTS
iyZ9SKGF0ZQ4VZen1uC+rty3RvaDa4St3lOzHz186YOx4D1myoQ5Tmd1cVnjsElk
aNCi2hsSPJncZnbShHegNsvTxcZyb1fk6U+n8BkjT62Whi7xDi3CVq2afGQySX2a
6vyYCeWrYU5DvcSKsfrNSvSW8nS51MH9FvK08To33ffUXLmPNDXH9481X1jPZeig
vK0m2+w6DV4nqJsb2rRJoTYavVbwjtuNxl5vy0+bHIg5XFmgPDVnVFhTfVuuzIia
5RY11y1evIauHQ7912BBiura0W4b04dqXRgjT1eMzWa19xTBkFgqZeW+KU91Ar7U
Z9rfZu1EE6NQzZ7UqPm+IYvbgnssWPswRLzEueWG0pY2DY4uqa9UtxhsxiWXp07N
PQ12nkmCmlNurKnrVreZpSpC+8/iBWVLxdly0mFo8/pp84TvujyN2GPvRMlTa7m3
2eC0+mmsmR6WvItagRvUrPafASmZ2YLXPL6jP6yvyy/M+k87QYJdNZY81YnmZvZ2
Sp6a76eN6j01N2EwRybNTp/gWsPMnT7BKtW6SPxKx3h5aqbIYmAThta9p6UujYJP
VnlqvfjGTE0tmDpQKQVT1++HTkK15GnQchnKTydeo/tWVUObYVMno+VXC/WSscpN
+ymKladmjRjTYdNSoQaLVpRFzbbW32pxsoqNtTgjbuTRmEhqDS+2HNxfjph7KvIU
qduZfU8tear7ZYbKU3OSk5lqZgM9Zq2ouY7NUo1BqRolXq0tF15GbyUd2lcaNdIU
3IRBGt/BJK66PA3OcDKlScgSmcAbemPGZEOlfKgqDZ6WRJgG5ancVFTpgrnaKWxx
T0t5qoMY7svT4MZSofJU38tgbWFj9hqYHQdRmSFkyZT2qkbr0WC3aDviNfhbU5iq
RxKRKmGWWjB0JNGUp08b88qclaeajrY8bZ44d+ycjTy/bAzxh26tEDX9Zq2xH3lQ
ZcYIUNP/W9+sBzbiCMpTHU4x3az2kSeRp08dWLmfRJ6a78swF++bClW0qdmHqkNe
ccPuyTo7m06L+rNVN2qULDa/CR6bbci6PG1sNaU+2erOSy1PW77UVCJdu6zFFWon
nCVPWyrUlusqTHEZNdEteHLUpULXZ5hdPsFKetWfsyg1n7YDYnpPzQbfsrEtP/Jf
cfIUF0eV9sM/frp89bq5Lb81iiRlJnR6hpmxmjxg8zR8c959yw1KrM3Coro/Wy4p
jdr8OWawKThhQ76xktj0g6psQuRpB19qiqSJkaf9RueZWR4lQc3WeVCRhPahar2+
HBicjZKbln4N/kqLeWiBCv35YvMCRBnK98pdY1PexcZCmaZuVGOJjzarqtt7CnmK
hDt/8fIvv4XPPQ0O7od2oGo/TXAMMThdrEXXqbUBvtG7GS5tw863vwmq4caxyFDt
5ZXUX/QX7wc7gE05u9D82pRjeRpYuf+isS1/GfL0zp17PfoSOGvuadPCgMlpc5Ji
8GVgZlkze1JD+1NjKtPQfoeNwMKmqC04Qi8eNTvInF6lB8HcEu9/zNR86sa2/Lo3
TrC9YRdM37T1GKJQw9RkiFJsKUzj56RGyVBjP4FQbaq9pNYPvcmBS8u6AOl4iCNs
vE6TUjvyND948nR4NB95GrpWNLSrxhxJjOyASSZV45drJDw5VJha/TciSevVYUOV
aodBReWpV2YMNaPNdHOamnpA1RmhM4aTzAmO32MhyUK30DOjxqFCF7qtNnpQ5KFW
GstFu0+ehu4uFDXE37LHK9iranaYWX1p8Ro0VIya/XBBNaPHujgGgVeFavoWKaeU
p6HyVOu/0LZKlIWKzlBVGiNqrQ7RKLO2+7ZEs7cuxA/5QmMJvw732xdvDGp1gTw1
d7E1+w5Cl3YsG8Nc5qLDmGoxvk/UGmOMGdgMVrLyjVmnmxN+rEaszLbSx9Ge1JbN
3YrK0/+/vTP/kqO48v38/z+/8857b7wBxgv72DMDNsLCtoQxm1qtXqTulsQusQmM
GSQhMO923spb37hbRGZtWS3VCelUV2dlVWdk3PjE9y4hhBrhaZicVI0ZLVvhc3dz
mw58BtUE3BADwPaEF4fWsCgFYe142sf8qkAK7T+CBZ87mdn1n5uKcTM4IAPQOD/D
dTLiNEzfnK4+3UnXTrnmJs6FW4GnvnO/pBkb56QEVKWhooxaDW9qLEQytLqea1jf
TQoYdTzKfyC/KF7grcTTv/0ds32tC0m7+E0AogxMRzkzGljkio3wVM0u4zy8rJvy
F6O/gu5S+v6yYlSGReEp4u/W4Sl13DPPvZDjqdhk3KKGbwDcQdElVBs3Zosg2oBU
tyXQ6QKoFWttiW+MLqVG35n/EGaXva7GCH9JreZCmvC246lAjKwzo6g5h1CN3GMl
m8gnaedQ1zlpj1czrFKgxLoqeVspPqofIzy9DrWQN46nUlmcexODiWXbFNe/PwxP
G7G1UVs1TvxMZ00iCgBP+SS2Vj+DhOtFXy2eivymEqQQTyN/oiVUX0+1LefOWo6w
K5TaCRXnVPr+9Bdd6/ZVU7PgtuJpH62IeIpGUAVmoIyqQp3ybLah8fiNofp2oV+x
mP3CnRUIfoX+wAhPj93Y06niqQo9FDyNqkAjp0qrZHbH3l6rpFa505FIVQp2n/J5
rU+Hoi9Mf8JMPe0dGmcST8k+CJ4y0IR4CiKNVD/NUzGSWVBxaqSqNmJrLs3iMe59
iK/Td+Mvz+/Cb3gm8VTldWBhHJ7+3ag5l+GUrVYr9ptlebgRLZltcU5Hh+R1KHtJ
fwVrIjf6zYpb8FSM+abwtKt76uOpynVTeKqMs82RcnP5W7325ZHRirRyKglS7+WM
KJhVxCx5I92r9AfaREbEUwtOa8JTtyS4xVMcVK6Ab4FVtTq/1mrWRFqpq/ScQLCp
DKrj7Yk91XgKO2EinvrbK8CKoligB6HDuMJ2I+gbay9YDM2RtMViSu9wf/GAka7f
UjxlC+gMyVp+KOpneRhi5LrV3Ok6gmte3VxsK55DfKENbMKvJHgqEuyZxFP077ub
KFqdRm6GYuoynj61GYwFRyV2trSIU93D5PlBWe5UHanvt1JQLPC0T8eZOJ5inbgE
T92oOatLFdOlyf21ag4a8Lorspxb1WyrplecZE9gv4wZnu5vE57SwByEp3bdyHga
DUxtrqtBpS2HVZXUvik+Zjx1gmKRX/uPoL+F/joXT9XEsSY8RSPo4qkOd4uDk1Qg
mguvduy5w6DlGFcuTbyQNCBZy+FBxWNsK/G0V09VclvBMSaFX/uPwORFkGoD5y2n
tmSw4XsryW0ekuJtwFxC7biv2h0tjc4MnhbGLpbKEoxQemqLWqZ8vnO+PD7BV1rU
uGt9IhTfhEKlGIR3xvB0gHM/L6jSqwYVkaYhFs1ia5TPa+8rC6PujYdNHDji6+du
lQlPXrxqoqgVngqHTRlPba63OPfFOCuHJA5JATtlqCuajoenUWJGJPrYObc6ycpc
n6x1URKemnPf4Ol5xlNmUxUXHuGpBN4keOoTYTN3qhBSlX2VtAhYXTxVvji7uJ3j
Kaym1oun3bUu8DQn1FhoSULTEFITvqwe0Mij6Jo86msiIEafSTxVdbwjQlVefjeh
LXEJNeauqbeoWKjEgEbrE/H0YSdiV8phOZ7SBbx1e2J42vVm4dAwXl278lZIYVtV
/RrnAs69vS6eMomqg69CUT01WrcaT1tSo7RH2EinbpSbOwVmc2HuTDQxcO7Ng9yJ
eb7ur9x7T1BVmtwbGN1hnfvTx1MsYZvgKfWOiruYE6rZO03Ng5ZWZcKK4DWyn1VX
ZHWqRbmXueSUSLw1RoKnJ5tLjXLxlLtS4SkW52fjrOQDl00jZKyyY2OrflBy5rk1
KAXUeUBgl7mPQ1hTX7mZ6MrxNIrzVV8d8bTQY5JMT49Wc7IcB6A5m4pietTvmnjS
JwVvNZ4WTsBA+cZes7ZP/up8Ue5Im8aX5IbkR7lxM9XW/bjAsIo5k/thRjBlnEYT
nl6+shE8tXJLMSS7KU3KXirxTMeFu/Dhsch+WdNO8UESZWj11Jx07fHovb0KdS7x
cy2eFp17pvFUFBo0yCjSKEjliRAbzlKKXP1NF1NarS51EoUVtdh5mkWvF3L4KX1J
iT115UMxUIKnPGZvbiee2qyAJGQumQet29DaRnlFbJ0lzghSceLDj1bfRObTE8iO
khEqPn30/yKDqs/dMjzt140oH6hhqMbdCNxsbPi5BZL2ImtYkBWHP1iDgz4piiNP
cBQ7ouRoPH3qmefH7RrlexLxLwE1rtqUsOojYwPRthwmDkdf2fXi7Uarp2SkuI4d
ceQqRg6X5Sc8/cnPHuvw9FyHp+clMgbxlPNDsVKm3WdIzQFRAIY1f1pktYTqap/q
ec+ariDq+pjst3LXJ+qVYwjbQpRx8HSNZfkZT2lIkhHM1VMlnc6GJEgvKoNbRiga
nchxk5OECyWuJKaeq/ik5AwHJlfGsRVmRLfjKV29lXbliAfHngKenpN1phAqb+3t
Fq9B9RTrLCqXorRoGqsKq2rSsjCqb61UfMW1saVeDLt07oE+N0C6W5Q5Zhe2FQI9
m8JTMss0lqlDRf2xWW4FnhqnFqrOGN8id76a/hJgtWZQBoglwsjI43nUma+VRb6E
S4qhCvMsTtkonV6H/RSm4NyPUqOoK6W81AXYOMpNRLaxp27sDQJojqf0dky3iobz
Xpcy5aYiKNK1n97qS+kLa1hCPQIXh8LTG2VtB6cs/1A8tXVPczeimmwSx5+DqsvI
t3DOA/KMjavbUjwt1dMmPMXYU4lcQQFVLRuOAhdSwqmRI0lZQGtArRyulvWJRl6N
GHHxVJB00nhq6p7ikFSOXcfLj3hxMF89D3DpNrh6rQ/IFdUSEc5y6sOJp7hrlOCp
sslO2r5ZokSxbtF85nDqQYGn0WH16a0a3PZQ4Wkpttkt2vGCqEFhBwJOWJErMlrA
yyuuaOqiLXrk5e2hNoRTajmnIJ5KEzy9Po3Y06F4aiPCEUm52eWiFUet9wNNOh4j
Z8jHtauqWhROVq3RTMHjtPBydH29EJ4O3dRUpUa5dRbtrFONZrPzkA0Gb8/SWCQq
rirlTgpP7969K3hKowfL8rfgqSrkjngaxWC4YqoYNfd1l2jtMTlQWnXc/61ZkJw1
PO2MIOKprXxpV+eRufFVseGtKYSgGX/RaNghrHT9M4qn9bL8eA/Y6A5sSrBJmnUF
JnNeVX/NpVnb3OnDV9D7Xj4zeOpGzVmzrOYpN1juiPcEDkQWZQOrxFkYXq9sglol
XlXlNboicb6j0gjAqOZuBZ5i3dMCTyEiHDeBd42zlTAHjbUIOrHxYczECMfVVas6
YE4LZj2Jy0hXQUBwWi2euvWf3Ukoipd3mwJWK5+oX9lA+/bzq89y42UXx9P3P/iQ
8ZQ4chUjZ3E8namnhgmQAKI1cQtQ5qyJRtCeM1TNvS9wTQVspF8V8RSJeQvwFNRT
pZzZukLtspk1fDlYJLBrn+ORIad6Js9OySiePWx4imn7Sj63+9NYTuX7wfX1491i
X3EnPKsA2ZnMni2SWl2NQ80dKvgYrROP1jOAp5hAs9tXpMaB0ORjbAt+U8bQPz7x
Rqryc+CNxDn0EPZcyNlUplcJNtgWPKXvUMfTbjBWja113ze2aDhHQzU5wK5X5Ys5
+QzlMlKSB6yL4wRi/xrw9M6XI/C0XmHRfG83Lq0af7ZfZnoeQoES6w0cKslYrpXT
FmNpGXjKhmYieKrqEF0uq+upSMFMr2oJovC0zIg4i7mnM2qJCu6cNlDWo07cVjzt
y/Kr7YIk6NC6d8WguMvryKLlKlqLrYyUOdel66hoQVLIIzwV76EsTiQ3TlYpckuo
zp3TKiIstOIYAFmRXrK3x68n4XF4txRTSZ9+EeEpdv0xFH7fajzNnfuRR9Ffw8er
dH/Bj1RhfJXqhNZdqYL0hFMP+n2JHQHVfCucXgVDp4yn9Ok+nnbDU4eDX/bFgite
pGluaf1BbVpxjOdXkVO5o9V+W3ejUHcZqfAUe3YwnhLYNGbuRxUWq3jayJH7ZeEu
m2MxPjbOg1p72v2+MoKdBUfjKV2cFeEpx57+6jdPLYSnHr4flpUmXe+Mj4Px6xGP
oi6OArnlkihm48Ak03BLVHCLp0fupqYbxVNOjolSo5yIwwAOGi2au4BuXKlHJ4+W
45EXCf28yq2p3LsPNZ6W8ow8Ua2YkPpbAhczqmnELKexhGvV+Z3fBqot5jDgPSBz
gTVH1yBtX7p+q/FUaAanf1ejssPBWlQ3pE3ZXnUGa1pzP6QSlVSQnnwTOSaKz7H0
rPBUpStsDZ4KKZW5icokuuqpWrklXg7XgLsLSKRkec73m/qtSuGyQ3UHM6rLO1PY
CcepOEi5NwfgKVnADk9/twie+gGzRpBrwcdI8hxPpbXzF0xcCjbbhac/+dljg/G0
E0u471yZyoJmYyxv45E5erpvz+M6ZLHesswQ0WXKeJpsamozQx0jhT8iKHgr6cTn
ixYqsZjWSdQCu64jSRkQf7o9y6lRGk8lusP2vrSEOxtbjp7FMZFmY3+L2Brccnir
qBsA8VTWnNuOp7KZn+pNkQyKSNx9LaxY+SBiygQ6cUy5FlWrRRiEYyZoxNbIU+p4
+Us8xdGK0ulk8dTGnqJ2IDe8dR0oUxn9quLl8GJ41GgVEsXnrrlwJoh4jkB1P8ov
kvWGDMx14KnaElNZk5AOh+dGDKXSMRSrypr0P24LntKwHIenss3arkQ6w0yQYGWk
jya/dY+P3PeJVc1jMyyeFgKDF6u6fXhaTmlKC1d+GbvaVr9K/PsKQ3OQdZk111zd
ACxqlk4ET5077azjKZfJdPEUx3IiojvxHonQbo9va0lsiZ41zc3DPa5+RL0DDcKZ
xdO+K8Umo2qAdk9xnhs7lxOqpVirg7pwWXU87qlKIN6Ee+DuTOvhqcywWOlla/BU
5HDwX1mJ1DqUxFSGy79afI47Hi2eKiVVjEPErGoi2NnVrle83/h/4aVReDoqNQrJ
xvXHbXtTUT6KUDGdUMYM4ukRFJu9Dpn7a1ZPpSy/eJGcsvylKdwz/qOqROriaTuJ
Ji13Lanpyi7W9zwVXAU5iXMfO1HwdB4o8+57H3z4EXUiDYRbt1dYy52mNOqdxwlP
urL81Kq7RjnR96UpiQgyEUFzm1hVTPPT7pReLdsEXtGYHPQhTdfK3aRUUh3i6VFf
BVpchIin21CW/5yvnnp1v3l9InMhTjZhS7WWcaoqujKjz7X6+uU+9YpvEtEOhc/U
SKcePCqzzlXs6WwUe2X5qdPpDHQB14enjz1B/xOeEtMgnsr0qtRTXmfORR+zxw3K
pdYSuspCYiqjVyyM4lrRVY7wRTwPkuuBDUsweCpzKxtnLIyNqoHgKY2L9eDpU888
z3gqAhB1JeOpqqpxSkodLM28573pu9LXYsP8UUwNjLxPjjktYRTHox2wSkbV80V/
TPQrtNsKtW0Ultyr1/q9byQ16nq/fSPjKSOTzLx0wCM8Pct46u4atSI8jbDSdesv
F0yj1oinyKkJnir1lK4VDYSVMs0gPLXuXYWniiYzp39Dq9JnQqVVVVUprJeDpBC8
nap4mqun24CngXMfdzQt92VQisglNwbUm7Eif1+7bupQb4DC0XIlwtM9qHs6t8nQ
9VuKp6o3izjyy05sXy6CNhrVRA11DamFzpxND7qNvuT5/EgvTsPi6bzveoLB2NMp
46lsshBtHq5czUkVFJsO5S/1q76LQA19Bwu8eL+NxqyM0AhPDyENzuLpTD3tt915
hKeL4qnrFN4SPD2/LDwdIXyqucQ9iSVXZR8HwWjke7LLDJUrOghP1+Dcb8dT8R8p
364N7/MZ1Kpcw4NQW45XCOLGp6rw0zmeBnOz9ObDg6cO0JiqUqy94fQzNPB0KJ46
oqm9wcy94d45KvZUtMO9UnJz8VSwRqbDG/12dCflDplTw9P5BmCApzteyJwyie14
mhvMxLRaJLW/xQMy2bWcXARfUC9QeVHiwrJ4KsZZ8JROu4ZNTSM8nU+yJuwqKsGp
UvWjVFFXQI28ExFc5gyqX/Sc+K49V7foAdRWwkF6XBYkxhjiR3i6HDxVbDpBPLWb
mk4ET1ckmjaGQ+1DSs2CeEqXi67htPDUCz3UDtbGAKZmuXSovGoVslxMvaI2HIIY
YoWnuC4/k3hKQIN4esEsThbH00RSbZFO1f1W3B47Tphpy8Imx9Or13w8xdjTGdMA
ngqhTh9PxSaPwNNGm2mJ1j1YLr6lWDS2kU12J1b8dIunOFRdPJXhLAL5dPBUaeF2
O9MWPMUleiueqqFXjjuFp1Uvhx2kavXoDNIeTyXgRGZbXE48wtNHeNqEpypzXylV
Ck8bnUeIDovTZ4udVVZv1XhK9/wE8RQTtzMpy/OrKp5oF0ob5VVlzqLXbc6+i6da
PfW2b0A8lejhs42nKnl/nHPfn8CqbUhYSPttg3PKHjgN0SYfmR2PNJ52nv3p46l1
7qNkYPEUL0VkG9UrkR2uGmcrrx6aIAH1Ysvcug+xiTh4lTWeGp4mzn2Fp7Y8Di7R
c+d+1a3v2mT7esiy8bDNT17FU5z6ZapFI6yo6RGeLg1Pz5hzfxCeDhVB3bdUl/JD
2TRST/dMsJTtyrOjnr75tirLL859ZaeG0mTOpgueSoGpSpOSRIEk8G4onkpXbhee
Rs59pZ2rG6BQxNspcyyV7niKaZVW3SWKxdP9vmiDxVM0yIKnRYhbj6fo398uPHV9
4pGTyuVIa5arBrZRU1CmO2FTa5wPeoFNefaH4uk6nfsunvLAjMZmkravdiRBu5dE
5Lvw2m6fGw24ezZ3hKo1pMJTydlXc+sjPF0OniYC6uTxNEyNsnVPl4undoG+RAB1
I6Lsr6Qr1ay2IJ5OM/bU5lra6X8Eg7bjxdBm7aybGWBzQg8Cn0aEp2gHtx1PbWqU
DdSZhx33t0FjVxZ8OVorbTgyvyXU5Gd7/2pft05ZYykdJXhK4HKzT8KYcmqU69y/
XNY9VTe/TEzucysWuL+tgmmj1yu31dbLL72pDLKyxhJpegKF3AVPN5Ua1RWWepHM
cldY6nyOp5i2v9PXYPJ3LzJ75rlxqO6PmFMYjTKLsy3wmqQHtOMp2l6kpkeZ+w8j
nrYUlhqKp0NT79Xauh1Pq6FLqo/wqzpvKSsmjsDT+Tq+Kyw1WTwtal6CNXRtUx1M
PchoQdvkt8rMuW4sKxUoPE1Cbs4onmaFpeyuiYVw3ms2rauOJPC05vtrRNiWRYuL
pziKpVhmjqc0fqmjJ46n7o6miKdsk+3abJ7zbnYctcxqa0u5paZyoj3wHP1WNJVx
6lvyYMsbNMVTxtOnnnm+BU9FC6cm43EH5XDYasF/flAHVrWqz+MB0OS6eFoMZKgw
kFvpDE9BDrd42lxYqtvUlK673dQUd12TIot6Ouz+Kjfa1+5u6jSzbnAOhlfUva4i
x+WY4o1AXRHfRDBUjKJyY0w1ihSeHpdl+TeOp5JRaOPVZPwU63VzzV3btAdL4ejy
WvRUINsSruT2V/bGMuNbE6rZ4xQTe3kIceN57rQ3ezylsbDOwlJclp8Lsxe1S7pR
6UYfhhGE1vHqxSCq5E2LmGKb+AwqUdRdiNv3JtLpZSgshQYBb0K72DiC3bpbUqP4
0k2tLL/g6ZO/dvB0XikTRRoo3ZAlP0Gnq3hTtSHqXH/1+NJlWZ9NvXyL2Z1ThuIl
E6qVzwWe7PpExu+xVCMC57406nQ621rxNC7L7zv3LxdrM1SO3ZZs7BcpqQnFyq/E
bouhRnOtSDRSUudv2dfzwtwae859BaNCqC6erqcs/zPPzcvyq41v5oQKRd9ki1rH
oLlQ5CmpGA8gr+AaXkHkblc32pUAcNAVtr33tuFXrWoHaLTVlpMYHS7jcVTs6XA8
1SlpJrTC1a6LLonItdwnrY4sbfibnDBxQBRDKJbcpoynMnhkNwsXaHDBZAnVdaaj
MUoMkyuOhmJnwKAtVFp1JBVsWnblduGpDEnl01D5+1maS7lQdikkiXByBbnEZ+Ra
N/UrVxWwbBp1painR7A9CQ7SbUmNqm5qOmeacu9Eu7Wp2iHGpdWo0EyLmj400yJX
09VaRekUauZz8wG2EU/d2FO7a5S9/1t894ew2b2yyfbtPJoib756BVeJVUe/i6e5
QcbRyoOXuzLB0/Wop1U8xU0WZMMUFIDqdGREU+FRtMCu5bR6p1UKXO+HYtYETC3+
onpqHZXYoevCU09+Ux2gNkUIObXEi0YVzcfQZtWthYeKC212NLU+iCng6ZO//u2/
//QXCk8lr/BCuRGi7sFujsEFRiFLm8ubY2jVfd+IpNFJWqAWbboK0hiNp5y5v0E8
xSEpbkF3c8uKkmpkLdcwRWyR80eujCo76JpX6xXJAUXcu5IOpSpsCK/wYKSTbC+e
YvVvu7GtNLwH/J21Pe60XRziaYMT372RolsOpz01QVSBxs6CW4qnLtCoS6E8Qodx
CT+FmJFWWn2XiKnROdH7H6kY7kBOpB+MzLF4upHUqKF4KtlRaoa1AOr68V1CVZSV
e//VcM49FVYxdV/BcSqcsO86NyD8dB14iuGnLp5arHYc9wlKNoCsgpKEcVu0t3x9
mVSVGoSn7773/krxlE4reIqpUUo9nW81FOCpzBaaUIOOiDgywU1lqvZLD1GEp+0a
qjpe2eXIGg7A09de3xSeFu7dEk9lSCKjNG0C1FZMKvfDusv6xMahNVRBQW4Iu3Sl
CrNTnYixp2oNqdTTGZ6+9c5K96cd8aCBTNeQZkFbWIobxuoUW5vCDZCsUlwNVSNp
kA7lquYWSXEiyEV0u4Ap5CUY11Fkjkx+ZwRP+5oqKt07CbiyMie2+eUqmwoJcGNS
Fc6q52qtmAenKoOswhKu9ZXb1cQaqacnUEfzpEtapWtFF5Muy3TwFEflvLZUn6uT
rMl9S9igsCquxQGFz5WPIknDsswqb7HjVC8gzepRzPLG8FTxjQupde4cgqcuKkX0
WcVWuwKw1xqH0DA83dndPJ72DkGnB8uUGpRRG9cJEU22CNUtXdPSla5l1Hga+JLa
8ZSmt1V0Ij9a8RQWG2r3IFdFcxy4JaFW9TCXTfOoAPsudWtZE+lGn+d46sae5s79
M4anbJbFK2J1dBXyEaqhfUSpS6g7u3FSfy3tKfdFSku6Xqsyfe+LQd5SPL3gqeCq
kLu7ZouU1EQlRRJVjogoqhXVUxsD4GquiRbrLDMMnqJu2oKnNyeAp8qvJXgqdanR
8LqMlNCq9UJfgbp71SZvd88sZxuEy65rC73NCpmuwQ4aK8RTJdWg1XODUKN1QPFj
oH02NS99J2IXezUTmnFNoUKZ631ttnY8/fbbb1cxciLnPs5nOHKU2GalFEdDbSNU
tJiNiOme070Zoi7OwwkSPFU2cevwtHDuc9SNkVGVhKZjT/s1vcuaiUra7s9NfP2R
PbXT8EGZGlLFU1FSMzzdBuc+4ylH6RTVVGp4qm4AW3vfjze10ckqtS7GU7uAifo9
63qlU5TbaiR+QzTO24inbrHMSzYlINYFIsnTwmKEsOoVVFXRfsqPkbzqhg2ok7hr
DJdQW5z7p3i6v3k8vdiAp2oZjyMiGhrVyNRoQKnYgKra6n5obpn3XYez591aOZ4q
9dQh1DIItQlPFyTUBlqKJNJ83Rk5khBPsVZwFU/pmqwUT5PUKMFTXGBE/n01eBLN
OxJHczzVM1ADnkZnzsHUx1NgmqF4StdqI3jKgKJDDzst3CVUdPKqzYTGqV87JuQ0
0Vbt8whK9tyqHTX9zHXun8nUKC5FhHiqCzhAelyEpyqj3+ZOqYlz3t2RmOopr2Lz
o8DipN/9+a/EU+sRVg79LcXTixCoo6MVg4yOKpvKYLFzGf4YIayFS1dYVZprFEXg
UIsn+rQ797cUT1UBjdyb5HOhnShB/lTEidAZmV/0WhR3l3xWmimEljkxztKnK489
nV1xNzvKZATvQOms8Cq73BP79wtq2S/lNC80ZyjBqKscxZ5uC55yP6Jnv+AYs8Zw
8TTRUBOtGnvKAdPyXo9u/dwKiy3eL+PuIzkcRRcVSdyOpxcmiafYp1EMouIMq5wp
snQDE3PvbS6XOndRiqfKAlpAUV2JiqmbGoV4uhWFpRI89Qd1gKdKR3fWKjGbqkz/
6HgR+VSwmh+zEXW9F65j8SjB0yIqcVvw1OyEWXRQnLHqGkY/Pq1cllvffdQUaKLI
OjunEXHmz1VNVjzYK3caTazHXmGpKeOp2nNYWeCd3Ss4giyeKvOo+l1Ppl4VKtdZ
MXfKu4IoDEB3Xs7x1Fl+lHIeAtIQPG0uy69FGhPkFPmI3TCL0KFz4Px44GV8n/4Y
QL2S7lRMpLvclFc00MR5hWqRh3h6ZMvyrxJP7969S1eS8FSc+9SnwjRWa7ExavMy
YSaCcNcER+PgcfVvn0ejwIBYPY2WE9EKxL5FLTyS1Ci1dr/h7Rq1HvWUPuWxJ56M
nPtF6dM0PyZKlHF9/b5Q2iasyrui3Be0iWIBdHwzWFvkVFygu50ogU02iz9ST+mE
04w9vXfvHl2Q5174XV/39GVZnAib5niqut7Squvy2ukzmawHH49JVimukXfXIXgn
uBMkGoF8ZeL6hcU+z/C0U90UntJpacisE0/pf+pNai+/cl4KcYhZLtK9u22K7e6m
rhcLR4cK7nTANFZM1dznDDfDmqfXHyhEXBb0SqJ2zyE10E2xib4jTaZXhadr29RU
8LQry1+kRtmSGhKwYbcxUk6GbCVfsqNiU4unUdqTc8J9PdZUs4S63xfBVdEdWpsv
7bPg6VG/87DgKQtAMkKXiafKgagiUKMAC75kvm4c4GkE7xG+ROop/pg4NVzPfo6n
IryFeNpN3qvGU1FPqU+Vc/9i7Ny3BVCTwMEcT/NVV7ICizA0klQTis1CNUyNMJu5
n+DpemJPB+CpDT/tFx6uipbnx7gRqFpU81Yv1rxGa9HGNaoroSk2VT04CE8PJxx7
6uIpBp4im2rnvqegu+sTiUNVQx6XJVHeW9TLtnOTrs99MpHr0NrkhG+mj6fKuT+z
zB2eothm3bJq1CjxRdChuFylQz/y0Ucy2FG/KxuOPjUM8VPckyh5Nfdi4QQqehvi
6cn1Uj1db2qUwlMsjyN6gbPt8OVKDIyVPNVqRE+CnjMqHFzBCjBip32ozygfKhxl
pXo7PBWeWuf+avC0jFxsxFNnaKkssAhPGxz3rnM5ceVbJ4g/Pr250IZv53j6/gcf
XuoKS63Bue9m7juxp95uQ1FIme1BPwAj0kftWGooShUpsvsmZiBh09zJlRSWSvB0
1YWl2vEUR2WRHeXlSBUhUElCTKCQ4a+icb1b1pBCTMmx1XWDqG5Nlo4RnsogFS//
9cnXPbV4yr3v3ABQuoEb3waquIornFvffRTFEcWY2nYZajVgv9sbQC90a6vWJOvi
bOAppkah2HYprpSp5sQWPE0muGi+k4usMRRxszxDoZ/VptFEOrV4KvFyKJBvNnMf
tw23ZcLUlhkYPrdTliNtX7w1Nc+l6c6tdnmTiIDWod+OTOvA06i2lFu5xmbYYOiD
XMesDwyeugxq6cd14kc/2kAcO/+5g0qNIgmkcPGUF8Fr2DWqBU/d6mDRDkMSQ+zb
R+UsSAeSxZG8H90VXnUFEhFqC55i+Pb01VOFp9jcUu1RsrYbtu8oakF5B8QONynK
Tq7+aide1mcyD1QtOZPqaYSnIpzbpuLe3EJjNrQ0W5MEefoY/2N9/crTgr1vAUuk
Gjuio4lQDVvrGt4uPLU7MkYBclf6fXpclM+kULGBllA9XVNppWHzcp5sS/AU1QGE
GIunMpw3h6cvJniqQq1kJ7BcAAqnVw83VYuciu69EbnsXTaV8XhotmMIb61ScccE
gA3gabg/TQOe7nfBo014GgtpSbNaaRVPI3kmcgS3q6cbwVMcPAviqQWLJjw1rgf3
sGhVh2uSg4aEfTegKvfsq4CNYygdPH08ZVPoEqrFUydZO83fv9zt0azpxNSQssJY
NOotpkSuq33w6obWEAamdNyZxFOJPUXnvgrt4BvA4qmbIOXcAx6e2jhUd2WiVHM0
+5F9cGPW0WmoGjqm1bLkDOApJzhiWX7EUxtqhXgqK3ZhCOsPDEm0DBaUWFKLp1YK
RUk1w1bP5LrqAHYlImkjnq531ygHT7E37fbvBZ6Wi/z5ZHrgJwu6IKSgKFHx3GA5
VwIQKJI3qmMwN84POQ0I1XXuc87xOtRT6zTMnft6WRAERrgaWzuYNhIMXuVo8ReF
yDSmRjGe0h8+BTy1+OKWmFE6mXSfxtNA8lQvzvq93T1hHBOonkad6yafqm5dHE+n
49yXzH2n+qkXHe4TapwCldwPLTGIURDI3A54vbxfFhJyfBrGvSsdJ8NT4SmO1okX
lkI8xboNjoDa4akqfequT0RA9euLeWGmak2igjoab4D2ZYn149vxa1NtcNpTfb1d
eCoxVwpP7ahEWRpX9XgN62wapDpZddOlzyNIcJGhVyAsHGklUjmzegUnVqm6ICGn
Lp5iahT94Zty7qvMfVseXqmnKiVROjSKLbYg5E+Xnu6DzKPeqKXQ/q4QTrX3VSbD
B9lvdj5dC572ziNbdbaaGuWr1sPxNPqtUkwTQg09IA14KiPHFpZas3oapUZFeJrF
njZ0otOPblcaKPFd+fFIixYb0TrEYo2EYbmQilYSrW2Ep3SJ6BpOB09lVOq4cLOJ
FO4e5PZ1S2pUAqbRHeKa3Zb4OTVUff+GUU9lbObqKeMpXa6VCuEjHu3qqYunanFi
0wNcD6P15tvnbqJkwqlROIezaInFnjAxoM+Ikj5VP24vnqI7WEIVlTI94/7SCWsH
SxEDWvruq4GhiKdHJikKL7VPqKWNRZc9dpBMo2puPTW/7753s+s7IVSUUeWcMzy9
fIWGA/3hG0yNcreoxTHoFt+UIVZx7pdreFyTJJqOO6DEuY+/UrL6YblFrePCMhly
1yDCyi5OXC18Jc59V36LTF5kv4bi6UFDxKELoPkBkdhmB7ZdBSKb4uXeLJ6qwlJD
8dRm8iqzmOGpu4wrm+++Tz0XVW0VO9TtepvxrcKeZPyoMnsWT+nikOlZaTWiRfG0
61Obue8nx3ggYl35OYtgvKmLsDYzJhQJjAYg9lFiT5V7USa5Kp7K7Lh1eGpjT3Ei
TPAUlZsoAM4NNrVy3a5XTHG3TIdys+IsnvputNLg42Ss3Vy9eocawRnD07mAavJm
bOC+dTiEMaBBVKjrfHf9+8rXpNRQ+17pF1RMpSkIljNzx91kQgX1x+LpSTee14an
SWEpFXua46kdLDNXkomRUzIcCjSIp8r7pHz0+HwfEvDVsl98FOjlj8LkrHpq75aC
lPphKHOrGO0UT7uy/Iynqiy/WMOksJRbQk/RjBt/5nNJDVYavfkRwrppUlpds8J1
7Nw/KaNkEjzlC0LTzypGTnXXKBV7Gu18aIvX2snGuurCUO7S17DPdWoDYdUPFQhu
APdF1cuu/Jaop9iJyDQy1X3w4Ud0ccj6fHzr9upquUdl+XGlodAE82OsbhomLwbh
p+7ipNqq3t4kO8p2tBXIMQYR59ojqIAofXfcl+hX6il3Mc1ndCqyY3R9aKUxqbL8
Fk95FuTeVzuaKjydV+QAv1Y94Njrd9v7/NyNAFF42nID6EnBM+97pWvSDl5xMSu/
YWGZOzwVg7xmPH3w4MEMTx974hRqurL8NJxZC/c3Ne38+/MuK/2/EZ5azSWKUkuo
VEmniKeKO4/LRH7LJa4Wy/Dhvu4oPj2eijogT+R4dO7TZdyIcx/VU9TyohjIeeSM
V6ltb9/PHo4ktlyks0Fx1u18ANEgio4UXylGUlE3gqe2c7mP5j3YrzfYuX/cl+Vn
K013CF0rek4XfDCeVjP3legS4akfp9gsmLUQqkulbppUNJ5xTFoq3Qo8jVKjol2j
IhU8Igw/mCzp4sbDar2fsKmLpBGboteJhtC7773Poyhx7m8ETx31tKMTYRQloOZ4
mkQfKtpYnEoj13/CpqpP8/y2wgL29i5y7m8pnsrixBaWigrful0/iE0bu77xBnCt
hxsq506KKj5SrRt52CphZivwVFVgkBLuSucuNLYyWjeLUmtG0irFot7pqqRVQpVR
aYVVFNXmDZz7x7DVUBR7OgU8tbGnfmH4MmE/MYA54URUo+AyF+wU5lZJCfHUhpG4
TmbsTfkRnR4uno5RT8W5n21qagTUFjzFFbNtVTZN8DTqwkqYTo+nrjtj2/FU7THj
5hWqUeQ65vxgstWAKd4DVenU4qkbeIqdeOr0/eBD+s/iKc9zG8dTCcC3qVGqT23O
PgKKLbJhFdMqnkZh5Y2AEvV+BCg2HapglHffo86jHpTFxqml6wsPnSU8tYSq4Mbt
+hxM7Q3QgqSNVBqGc8RgimPZhnMopeBGN2zp33XIoSmkuFJvmzKeKtkb8VQt58LF
W4Cnlgtb2DR5V97c91rnPs6eEonBSMpAQ31LTVYa24KnGHuqUqNkq4VivWHCmYQa
Eza1WRZVPfVqvGEYepItKTlBI6rArVHxJM6YlxbclfNe7vtxyXiKIW7FbkMmZjFj
02ZNNG95Z0SrBBtC7ozwOPB0i5z7jZn7/n5CpiSb7dDW/q2yafT2BpaN8DQXyC2h
8hC6WcowVj2lC7hBPMWuTDbLsCGnUdWwKAvKxdN2LlEcowJC8pWJ8j3psempMjdY
+e6EFuHRFvV04pn7uGsUL04SNkWzjJVu58UZamCaOPHzrs9/O2JNEuGpo552KxNc
VRZ42ms208RTRzUo656qvBm+eplvoQFPXQXU6qP2RfvbHFLVpGnnUIz4n8ulXWM2
/eDDj6gJ3yDHTApPVeY+bgAmtYejbH20jXvGlW/7Gnscs2VcysToUgQeN4EYX8zu
LhPKrKyxZdPr3WYo1PjHmzU8pVcWij3N5j8Iqohy0CLCqIqmQ3nUitW2PzhV7aHC
08yzDxMYOpVaIk0rEajteupAhRXvH/ceSHJUxbsk+CJ9J1LcSR97SpdlI3gqgGLR
xN04Koq6iRTTlrhDVzZrlNOi/BjnZigHu/Xs24Ep1hD7S7n+0Q4KntIQmDyenlN4
6rIppgT40qmpEpWLo1Fu6zg/fnU4K/Nup+HIWTxn0M7qolaKgtx24amKU0QLvGfi
cbV3KM7EzznypCzw5NLkSZmhXwVQbApYcep01FOFp90rU8ZTf9cokxSlAqKUuUPv
cZVncuhsb8hF7m/nA1DF/YN6Kqsd17HMw1PjaT8ql4yn0XZ5bmrUIDyN2HQEntqO
tCsM2x/u/GcH1VbjqesEdKaxcixFeBoCaw8cLcGpLRPYnhd16v4WJzk3iVX5qhBP
hWyQaYRcT/H08hW6gCv1COd4imiilTPI2vbjDqXeXlDl1CXRltYCKC6hRv2eOZU8
PJVZc+7Zh/zu633lGsFTOuf24unFckfTovfLXWpEgYuCjKN7YGh0aQijZvmRO/et
WY7YVBlhmecKPO1ZZ8p4qgq5y043qqqULOdcPHW10kTdTOhTfnSxsrFFsOuwC+Ip
EOpNcO7zbzGLf8p4ivvTFnha1g/eLaNOrfcAKUWRTySR2lwLPZTMxnv2AOddgKRK
N1WrlOtQN0PhKXsm510JqQLLVk/jepmKTUPn777DFiPc+klkRtKs2zdST/PBvEV4
KpuaujvKaOdvmVe406dG2alIyauomyZ5VEmShJ668oVNfDv5hBroCqjEnJQpwFY9
3TieYl6UcutHxaSqnv2IUBePQbTDP0uRMXjqwIrx8qNCI/3FHS3dembwFJcoLp76
2RhBOEdj5lOj7766Fq1GoFbBSy1LTqBWA+LpUVet5ub24Cm6JaXXlHqtAk+LC1Xm
8ibSKY6UfF6z9F8o1h0p2gMEU2TRqBb5yu07p1LA05tSVUp0cYhJPZlk5r67qanG
034AYm9au2f1NRdpIjy1kR7FUPIiQI7KXRUEirQrv7e61/rCw0ilbsMlh4TJVZ37
C8Weht7DMp+mnhoVq2KKOyOKjbTVRB53QdaK27mXZNvxNEpuw6683G+l3S6SJTOW
Vc7seSzTVNY23uvuMsYZtzIsj45FdcvwtK97SkNg83gKqVG64GUee2pjEIfkbssA
d+MORzv9bQ/iMiPyeKDpRA31ROqeHh27eMp1T7cET+exp5gadcHtfa/r85z9FjbF
16OxP9TLnzjW/KAOM6eqhaXQj8JTdCPKYZPCU1VQhfsOs2fmkTD7jsbsELwXpa3w
MVJeUP1CwtDAAbVIXUKVweiGYRRU2r2iok5vYhxqv6ScpUZNEk/p0108xc1plSUU
LRwj7F08PQh2Q0ykUL2isxharvR8fdRGmgKeKq/ydQz4hkrwuPw46YPFq3h6MqIs
P40f69+3eOqmRlU8vGlk4dCogKRFsR12Pep3sykGjk6KHE95Ul9RWX4allf6svyy
qSlvNuM7972y/Jjiplo0/SjyUJ2eOwRbfIXJbBfeSEaC9TNsgvDiRD09xdPLVzj2
dBWdyA+Fp9RUahQTqlOSpg89REap525bXa0ZWK0OJ0tT9WPS0U4QyEEFWazXCV2Z
J315Z1ZPrTdwypua3r9/ny7Ls8//B/W/xdNCQAXJQEWTO8nCfbc6xePKe6AabWzX
HoOiPnTXm8LjttPD+Kuu31FDVc5f9ifiK/w/dTqdmcbOOsvys2ogeCpzKw5kiT11
o/+tC1jF5toopuPAv+964VFnwdkNm+JOeQU9GKjRqulSLScU+zpO4V5yw7JEKJlf
3/SmpgpPMWmVky9nvWnK4NhJKvIDXy1jTHMHvauezjVUGDu+ZFO+Pr+71LzpuZft
EkX1psykskpBPD3p61WP3DVqHoMf+YW9wNMWMHXjTVeBp0kMaxL2ZGN6Rqina8DT
J3/92wF4Wm5PMp/GjPsvmWbsrxYE00ZVJtRmTDzAPqRMWbhRYf6qTx08XXtqlMLT
uXraO/etHD60pJRNk5JX7P0QJfuL0qZUN6XBLwVPlTgknqaHAU+VSKMCrvJliVP1
NqjY0B7gscgYt35/a6W1Umh8WYPwlBvjKV26zz7fMJ5iWX5MjUI85Sum5krHmgWB
ENUoNRdV3ZkO2TQPFbB6qhs/4CqyheTWjKfTce7b3oyK4SgB5cCrTur69CtIWvro
E4+/6zEO76gypFUthKJ7wK5DIvV0CXiKERW24qn16YcqqRcULE58C6ARnkapUSMI
NQzgCDS2SeHpt99+24KnquCFYlOLpzmbJrpmdMBy8TSZ7VRHKzexO9U14uma655a
PMXMGAbTXDzL5VI3J0Z+zJHUworlUfmxZYHhensd/bsUhx4ePJ3PguVeDGKTI9Ug
ug0saLoi6HLZ1C5OhFAjE63w1CWhdjwV5/768LQhNUo59wVPUWaWseDTSUClbj4Z
Xjobw+2+ReGpi6qWei3Iooyahy3etM59wNMTce53m5puEE8xbTGLPVV4atbeEZlU
WVPxqKuwXjNbPUmrRK8mqqq509TAtCEiN1eLp0HGd1O8aaB6VpXRoRgaHX9gtuqy
6qmzKvWS1KaGp3RywNNzam0nLqTGPWltitsgslxw3kqanRerd5pVx6102oinXJaf
preN42le8NLdyK0lurSxJbqa6+FtoZkCUo0dkKWFwlMUb84qnqo9wxSe4lZDlWVJ
rHyr8dXooF9kFGs8jRMPmMZQMldUOgJP6eSTwlPZk5ZTo6S/dqW6hdFNFZS4vj6l
fUbNxVArnUZvtFwbufhzPLUaKuLpzRJPZW6dLp6+9Y7V72Q+RTlc1huRaKrjQU2E
KILm4dUjl1l9WdQ7xn1LpNm56qliU+zcFeNpsF+UDeVeMNh0ETxdxMuvaCYSse3K
YIJ4iqlRiKe4tnP3WxstkLjvGjHV5ak2bmSzFeEkYMvt06My0RUX/Qme0ljYLJ5i
bSkbbxPuX1pGiDa2EXjqHpzzq7vkiNYYEZ6eXD+beErG2cHTcn1i0+DyhP3G/s2H
bXsEqm1R3qSK+HLx1JUJEE/lxwni6Ut/PEcdmqinM7ENaMZeED9pDGJdhE1tWKfV
VlxYbORaPCeCqY3BELXVxdMb/TZRN01x/q3A06iwlAUkHcUUJIBaMQWd7C56htEd
0ZExwiaqarQQwtkT2VQVZ1i9elriqZWsm0JOmzk1d+6Pi1WNRFyLrbY/cC04KTx1
nfsqc19iYpIgDQTTRqC0rsBFZq9kmqx6GK/A1lZz0AlituyEty14qkoLqW0ykE2V
XymT09wcqYEg2/66G/KoVjIqPIs1VCWkqQDEY1NY6ozhaeQRDpclaRqc7R017pYl
t0f4G4noNqlRCT9CqIhT7Xi6Kee+wlO7qSni6cyzb3wISeyZClVS6qZyvivKVGwa
vdeNAVAkil/GRRlX4sGy/DcAVXnM3pywc1/FnqJPA0vY2tsbZyXhDR2EViYnZaAZ
RB5jsKlLnIqJI1G2cGGZpZGVTpFNZSSuKfZUrrsznVTpc7GE/TU0dzpUM+J08DRK
jXJ3jcLaC7jMsJ6+EWx62cuPGdRa1B37q0i1VVKcNvEmL6qKp5ty7qs4DXHvKt/u
3DPosUhFURuKp2nW/1C0RTzF5a5LKjwqHwY8Ref+vNIfVpXqRBpfN43XAzmeRqNy
RZy6a2LTr/R1lBy/R+niH4GnG0iNeuwJ+l/wlKdX1yzPhnCPp8qtH0plQSa1GxuK
6OlKqpGzXgGowmL8MSIkd1Xp0EyPqqc7RcV4ejyl1Cjc1FRFEgsmKYOm8FSMW4Kn
+reBiz/SRyONNkrCUUfaYywaqYXHWvHUSqc7vVQ2CE8dTXQ9wGo/Iv5cNyFDumGC
eGoLS9mN2mf9aHaNwmWGmi3yWNKqAopT0QBqiVPLk6lOyajyYog4Xtr+BPFUstxs
7KlMacUe6w3xpuraJj9Wu8lX7OK+k/tEfit956incWEplb1x9vAUq966eIqF3PXK
xFx5dZEHEaT7lurYjDwk1UWv6no9I/aVbofi6fGmCks14CnqbZIXlanIFv68jSrc
oECFqvawJjyNnM5ulGSfXiP86ob7C5jKrlF2zyEXTzdbWCpyayhMcgOWIiKUvqb/
5YIrBTTP6LcG034Qvy6hkvJ9kojHw75OfB6EWhBqWcJ2MJ4+9czzXVn+/6Yh9PIr
56vOfbfebBTqvo0tShYWX4ZaH+C1Fk7l5/QrMlIrxVMsyy94qlKjNJ72Kw27SQmu
N5JUpxYkdWFoic1+ip0UMaZN4thwqlOGUmxlgaddWf714ykDCtY9VTX5bZCGLsIw
XM7UywMbBrCk/ooCNpRJsesKt+9QkjnqM/pP+v1pZcBOGU/v3btHfzjhqVuW35Yi
Ur4sXdO0b0NdGer4aj8OxdwqsLqqOebGHcGOtTek4neZGiU6jfJlc+wpXcA1O/dp
OL/4B42nFwP1lK6YvfkV80XsiHwZ4WYjhkY+elc3zVqv4dl4qpMy7BXjUE/xFHZp
R46xeEoXatV4SmxKpESYxKoBz7DclUyoBZ72VaV2+qhT5CJ05UvPJvKnK5FGMaNu
MCsipsVN9y389SyeiuCKgHTcb/fgsGkce3rU7aAhK0z6sYKnateoR3ia46mrnm4K
T//9p7/AXaOG4qnVIF02Heq7XxGbRniqZkSFp2pBefbwtAg2HQ2mDXi6SBe3oIzF
lEd42oin2CkWNxsHbAKsCisj6GxkUwupygeKctEAPO1Tv88annrBpo3cmSOpFVDt
8fK8CU8NWq0ETy9fWTOeono6Ak/FmiXhnjmbJk2ppAKyVnaV5xGeKp++S7RoitVd
tHQ8ffERnrbgKc52U8BTOu1un7m/CJ5eulzB00QxdeGjlYRyPGpmHVef2y2LszyE
eDqMIFvwdGgbCKkunlb77mHG0yK+Ii5MOwhSW1p+zkYqtYSa9Ttkpkd4Ov8RSruf
YTy1bv1cMc3BFK9VlVYzPEUkBbpScQgJnopDX5hGsEYC52g4rxNPxbn/0h/PqdjT
QXgaZSNdUyWcTOxpS5Nz4qkSv38Lm6pAcFtEwt5UJ7hH1FLwlHNFH+HpQ4GnIL0g
nmKH7kL+fqKODNPPRvBNG+604KmNY5s+nmKWW4SnRYGwRfDU7a/yRxtpWskWH7jM
0P79KHO5AU+5B3HA0mDcdjylrrexp0n14p00hNTFylxbbTw4UVVzQlV4emAq8z+8
eOqF+iV4qoTPQXiav72unhot0M6nx2X4KYYq5ni6EfUUY0/H4GlPFwoH5wDqXTT7
ujpAQacNRZXDEvW0qpuqIgNuRLjFU86FWgBP73wpqVGMpy2FpR7h6aTwdHDsKVfm
L/H0kgncHOTTHwej9SI4C+Cpde6fJTxV+aEJnsrzHErCvhslaY/AX6XGKTxV2VEP
OZ6qqlI5nuYLy+hOsEuFEWroUOlUzSZujT8ljT+EeKrIcoSPPjlyFXiKTufl4+m6
Yk8Xx9P9fusvLZ2OwtNcPY0o1nX02x9zPI1mUrxPZHguBU9/15S5b5jmEZ5OFU/P
j8BTlFsGxZuOoFK3LcipLp5GicBbjKeS7bsRPHUhdWFylV6T50mNoat9FvBD6Nxv
x9NEv2xsVdUzl0IbqdTaGcl0RjwV5/7DjKcuYjYSaiOYus59l1nb8fRqmQYkg1cR
qtDMBPF0hHP/Up+2b/G0wMcGPHWvZwGIKsbXi1uNULWKp6opd5YN2CjWGxvE00Ln
eDjw9GiqqVGEp03O/QBPpTcRT92Jra6HDaTSQS2H1J0yKWQezfbw4SlSaYKnle4z
eOquIoY59+F1+2WQjZLyUo/wFPFUuqCdF6P7wa0/VV3eNDJuBKbK1Nh6cMoaJ3h6
fIZTo4x0OlQctRjqvl6VYFFGzWNPLU61CKhTztxvT42yeMqEenj1yEHJIGC3mhpl
SVQ9vxqUCLhq4lDzpChXTD28Oh08TbeMegjxFG3ipvB0cOypwdNZKaJybhuGp2Pl
0qXjKdJPgqc4qLYdT7EwO47KRnqoS9Tuj829n4Av3m+z+wqKSFwuUwpcPJVee4Sn
9pJG3o8cT3OabJdFo3NG5U4jPEVnqEzkdTw9k4WlGnaHSvBU7JvCUIWkNjhVJj4b
XRDiqSHUQXh6o4anJ7Br1GQLS1XxNG+uMlporsfZhlJCpRJg6jJohKeHXlWpdjw9
WZZzP0mNOh1CtdjTYg9JYVN8Um6mvDSOXBYN93YwwVPlRkH19HpfGvp4Q2X56bRc
ll+c+9SJLXjq1pZyJxWXSoUnEBmRIwWbUOBRTUrK233D7Sby6oTqnPbrycJJ7kwc
aa6V5L6bFJ7ipqZ2yyjc0xJZsE6lLmgadTN7vY1Ki88KDohkPJtSYKOdpOOkvyI8
Pen4lE5CV48u3a3bt1fXlSMehKf0Jz/3wu8ET9mHaPGURjECDdbkl9teMWKCjyM8
8i1Qu1OGl6AKa1FVJWLa5H01Zo/7wGLkUWoyNSbO/YNu16j1leX/xeOdanBOplfe
ZMHdNeqdfpMhvvOL5bQnnaqJKUFMNHERuVajApBHj7usLHTWz53UJZ76+TqeNCC9
dsOU5edfOXi6Mef+LHxOKvPL0pEss5TU2DE1+RM81SEQ5U5Rygtv9dTkhIpZET3l
hCqAyqZAHZpcfvy2eBOqDr3p4anMsPQjP6Fbgq4bPfnhhx/G4ynPiEqg0ngaQOR0
8FR2FcMfq+rpNPFUxZ6Ow1OkOpw8NM3AkYKnSt1UQGnhkpuiUtuq58xUuv5vcTfy
Pkt4WlSVKpNaNI8OrVda01MrEcPBOaPlhCUeWy/QEuoIPGV5Yxvx9GKCp2VAS5VQ
W/C0ZZGTc6p6xR7mKqk4YHFVKfOudPdW4Cn9346n8ztfzUQxnuahqLmvP48QsM0G
mFoktYSkCFWJPoLIKjtqangqzn2MPR2Ep4562l86J0J3SEaU2yzXunhqlVHcczVS
T9XG73YhVFVPEU9Put3+6LrRjwupp3OmAZqxS4SCIBs4Ul0XhY+j6VMBqL309ldO
/Xa4jaaGpyNjT2Fr0wIyyj5lPFUYqlhQgWPk0EehFFuVTS2eqi8ctUKEM9lRW4Sn
1JVVPFXZipHsbeE1osMQVau6abBacF+xcIPPlWUfhKdiIn3n/tnCU8EaVCLVbSCD
2mJiUt64kVMtoapUJ9eDHzW7y858zMJcWOBpualpEns6QTyVTU2lH9WGFFHOfsSs
izSc6Zqc+EGqfhLmiHgqX7tgGsDTeWrUxPAUdxsWPGVSSvAUOxR99PnVw18hyLow
ajFUvPzqRevKV3SU42lhkL0NF/zCUt2PLp7SRaMf6YIvA09hOvTVU8OmLm5GYJq3
RA3F66tetJde/eiUsAH/hRtdse14Ktt2qyz+AlPs7upGRVNamkuoVkBN1FPLqfqD
jPaGk7FMdeIjRl/hWcBTryz/jonKUBjaqKJFatngloacJgRjnbxD8RTx5aziKYaP
70Bik+pTlxotI0abGCdRpy0qLDbZLTlpasrQ6inEdWDcf4GncezphvD0ZYw9xU0W
FJ6ic39PtmI2vOiipGVTK45WhVKEzgRMnePTiEmr+Kgv6eBpKblNB095huV+lHah
r/fHeCqLRmXHDrHWqdGYrSPelZ9btNLD2p5PeXPfi4TqqHilIh7iaTdUEU95LDOe
0ivj1VPrTMS5RFmWRgZNShhYtbmx5WdweVTdBIWTorzu08TTYalRPZ5Kh6pubQ0x
rDWXUCNadSNNQzY1Cpyad/lujBBnW/D03J9eHYSneUBnI0MM4tSq/9eq2i0qmtgT
5WZCh8ZDhacXYEcGtWeYssaXjVfdXuoWTIxo1b1PqtlOLp5qD1sJpriexDF7DCmq
W4SnL79yXm0Ch54Q6cedPjVKAQ3iYKJ0utgn0aX4I75uCbWim5ZORTGk7Yk++C6L
p8g0NwyeHpeZ+9Snm8VTnmereMqefRRBQ3XZBJ46F9BTWCP1VEGnAtl2bD30do2a
hXmUu5u6XSmrDjyGxzL9z3g6JvZUZe5jrBuaJ5dQkQsbqbQFT93jD72SXfRi9JYW
NkWImSaetmfuiwqOAqreubvdhzsKT4cKpWGAI+CR8lzb9ZKDOFuLpwIozpD0CDWh
zwQ7WoizSsBWxot0XIVN2HGRdDrOuc/zx+3bn6yoH8c9XDzFzP0LpvcTPE24H630
UDDNffTRGewJHcU0ljPmeAp5OejcFzy93lBYat14+tgTI/B0tyythfe81TVzxdSF
URtvmkcF5G79enMPS/H0ZomnLMWJWRZxbp14KqlRCk+lDoPF00uX5yE3Ya20IIHM
uvXdMN9GPTVqcuQBpOQrH7LVZRWbKreGWGPuIzc1CvGUnzCeLhR7inOhIlSNp946
uF3CdEXmiEdbpOmcR/VNYNaF7mL0DOCpil+sJLuU3GkxNHq9UT21PFrB050iT0uR
kFosqYG3XXhKXXkBqkpZPJ0zShmeYTEiF73aBVT1Ee3qbKR2K9EUbcgI9VSoVJ6c
dHxKb9w6PEVfsOCphLhhQSI0xeKst7CIl1etByJUjYC1UYWNmDWfL3jKTPC0qOUH
iVATSo1qxlMVpCGuA8RTNSW5ummumFoMxUtabfYLqNDJCrDGQQJFdlRfT6rAU/AI
i0a+Njztd416cSE83S/w9PBqHU/9C+ixqTqDVTpzPLWsFeGpcuhbNj1SxTfj1Cge
qkvGUyRUFfbk+GvaCLWF9Ntb+5kraxRvM1lZgJ4lPFW5SlVMzDFUvc5RrW40aqKY
2mMiPHXZVN+NsHKl/88AnmJ2VOTTSCTSXAmrMqt6V67UWnKK5LdkiesKqI/wVPDU
+rIUCEZ4Wlxq42pXEDkURpNXCj9bDU8Pr2rnvgxV4dFp4in3ZiOeyjARPFX3fBVP
5W53tdJEQHUBNPqtUkAVrV5TRTpj0cdlGvTpTw1Ppe4pYpLFU4kkVh1qNcg8urTw
nsdyaU6cLmhGn8jNvusAClHZnhX9DqVTH08hNUpMtIenX9zpy/L/vlqW39Y9VcFk
he07yPz71sVvydKKySMaXkQVmVGX0D03BGqoss7L8XQ9u0ZZPJVa7gmeom6KlZ4Q
DXVcYymU2hJRikqlVR39LuAWPxqfchTOqKVTQzkzPO07F612gqd0DdeAp4898eRv
n35WpUZhqi9PaTIYsYNchwbG/EXomXhyFUrm1JuLanhwLsJZ9VTwVPmScLoVcUh+
hVMa20d27tOlm2BZfuo1mgV7PD2nyvLbmvw4eKt4OrfPBw50huVWRregckv4uWay
UL4vJFShmbl62s188yHcT4SCMtyo0+lUdBnXiadslqmRWUY8LVICjHNfLpSOmC8h
FceC67JXSGrZ1BLqIBnVRVI787rS6TVTkEiYxmbuSyyHzK3rjD3t8XTm3MeBqTL3
1Y6MiKdXynphCntcxFTwmgeeJm5991eJeIdxNfYtVtZV+r3cdYin0pvXobCUjM1r
fd3T8XjqBrq5eBpppVEMaPs1zZk1g85qNIxZnrqDvIiS2UI8tYRqiz0l6mbkoHex
sqqPRi5+R7JN4x1V4KmVTv0sYMBTVMSniadqmxnsO8QUpVPmOmiEpCNCEhvZ1DKT
elHDTZe/7E7SzChKGToreKp3jdLWWIUdGzusWN+VThNGVC26H1rem1FvyqYqBg5N
tHgG0bkv9tniKf8vu0ZNAU8vBoWldjnwFG5+IRUHT410ovDUjTrF4136dMm1gNE4
AjXE09IXrPBUE2qf4n1jGnjqpkYJnmJVDdnOzWFTE34aqZ6umpazaa6GWsq0aige
GX1JNMIOXJm7ETEJtfAl46kKdJtjRKSexhVJXcW0epXzqx+RqP96nIGIQ9Edqxh4
er2h7ul08bTM35emij0lHOmGAbi+/kY8jY6JXPmIp1kMtGHTq9d8PM2d+5PCU3+f
4Z1dBeg5ViZu2dyNWz2V9Q6r493XHYcvWIwcT8WnedztZ3OG8VTqNmCZPwyfUL54
7aMHCmyFy0HcmR8Zzwtu0Jfj1+qaWGAVeyrYOnE8xVgdwVNZXiqhp7BapX88cpRb
PE2c+xZS5fUIf10pVE277o/FXxF4JtnqzpgGPMITwNMXcVNTNsvi3Bc8xUjiKAvC
xdPDIIM+Ahurr7m6XqKSRgirvobyY2jiMgEhuCiSGEgZlSgGKTxdwLlfim3Rqr0Q
P4wZUgtid5XQwqCNeFoMCXiSBNDgSlGNybOGp2UKv+Bpy2ZOUTJTxKYtYaZJi0JO
VeZ+ch+24Om2qKfUgzKroVsQC72FUplLEm0eW5c7HXe8QszuSCuRKqez4id3QYvW
UDy8iKc8gZ1JPNXRiuUefg6bAuIrg4wIqDg1KpMyFDqd97bhqfKqaYkBbLKYWYw9
FTxVsacTx1NZZqjedJz7Hp66hGoZFKFBYWsCuNEBCZ66GmqoELl42sulWJwIzfKa
8ZTYtMTT8wme8kz6drm5plJPI21SOQ1wtmqkHbcXEg+z/XTLpvKKi6ci52EPIiAJ
nt4oU6OWiqdxGXBHAgm0UhVX2s6j0XUPD86LX+CL6fB2h7TqgK3DU0uoEZ66+VJD
vfYuzuYvujEDs3JX8X6Y6LN28RSd+2LuUVSYMp663gxVTEOV1qp6UQvyKAlm3+xn
kclmqcBmQTaSbHNwEWsoDfFUIm3kV2cST5VwruywxlPvYtq5R/rXhl2pbIG8AIs9
3v0C7eppISDBFHgEOUAzX3BPMC6enkwv9tTFUw00vaAzD7w2eJpPWMimCOtJi1A1
IuMcTxNJSARU5OATCJzDJvPs1PBUj02VEqC21/bGoKtZuoqpGwNgW6SVJs0dxe7r
vnrq9eNJv52b7coV4ikmwYR4GiwUXEKPBFG96sqJ0410SYaTF0ZTXYDiBd1qPC0I
tV/wKUi10ajIlFVtNTrATZ/CH618+w4k/WCwaVTqyI0zwbtRbhjVy1PHUwMomCVq
E0UzoTR12g7z/FZdumkCeJO+CyXK3TWkTGkSp3GW8FTkc5V+0Y6nuN5AV51Czwg3
cwyNXm+/r3LV9qDfPEmtTGYjVAS2jkdRcps4njp1T80Q1lbLm62samVhFCVJdWSj
mIqfMptPS7nnqnHo+xyjjvfw1BLqdPC02y9jhqdu7Cm6s7ReUE5GibfdAk9VtrNq
aFUKjNg0MQX2hNKndo0k60bsx1XhqYTICGREeKpypFxDhn+nz5exO6CqZitl1A45
l1ajhSN6lLYaT7EpDVXY1C3aj01esRTrpu2/fckJCGEp1OZChe8CXWG33Dp8Z1eX
l0Ljbgn1sKx7qvp3sngaCajoEMQ8/SgAsQ6Fxqc/4l35GaIQ1RBS9x1MkaF9AhFO
IqCeMTwtsoNVvVu7ubSHp3IZh7nvN9Hm32p/3vXXykRv5dmf/w+btotxPukLS03E
uW+3qKUOfcdU3kCVx7VaET7K8+MyTcryqNVT1RogwtYESS0qWRFKScL2S6qsmmng
6WlqlI+npVm2XZnIJVabjHz6CjdDYS7Ylcr17Ks1Kv+454UAuW6Nwz53SLkiozVG
jqfXx6dGxZn7KukB7aCL3nqVoLzt1gVvRdAanuL6A/E0kU6vmdheG7VjV5/bhaec
WlEsOd58W6IYZ80wawSp1NQBUWEpQVhxQAuhFv76Musf3yUlVyQDHbddjcyBDa2b
2cQgE25b8BSjD+n68MVxyw/nLvUiq9Ri4sH8RXWGBEAbW0FRfXxqRMNi3HE+k6GN
M9lDgae9u0Pw1Cl9UKqV/CQJophmm1P1/pxQ1dwmkx9ugKnw9HiCsaemhvHcU3R5
5g7e85z7ucgyex2OxJku12V876InD/FHREgUKXlKsdszC07BUxnUSDnXN58apfF0
7tkohTwV/VhoJca3zPy31zsKBAeRHV1pEy9vPRzLrP1cLwe/rr6hG9UjnytHYgSO
YqQxeEoWEPEUy/IrqcYpLFWigGsZ8bK6YRMRm1q+bNE+9XngdVn8hW8EkLXrSMup
ePX5V1hs9ka/FwIZKYYGmn5WMXIYT3/1m6d+8rPHbFn+GZv2XiQBU1thyuZIuY7+
av5+NZDU8qhqLtqKQIjbFNlQVFX+nW5I1yK4S3ZhmuuwpwV35QcffiR4uopO5Icq
y89BTii3YOlThadukmLkTG9nx1z1xF+5nzUOW/3vczDnV+pEtoPHfRIx+gSx+66b
TU2p6xnvpoan9+/fp7/u2ef/g/qf9xnCTRm4We3c2QlTSc4NURPb0bqvTV1PI1dZ
YF5PMq+IZ//mlJz7tNR88Q/neHrlPYqlkLuUYmA3yNtd8r7N4lCTJqpf2tlY1kO1
Lvikub5jy6BqKm8JZESiQhqTu5HOjKqQ/G9DEQRSBU/pbOva1PTFHk9n60Yakiyg
Um+Kisf+fZmzpB/n3gCDSU1jthy/ikErPpChLq8D8xGlmlB8Ym//2TKj6I5+LfxR
kElep3cxntIFr+NpVFhKBQIOxdMoasGOE4uYw/DUCKJJ0PdRXKFDxZ7iLKicDluB
p5pNzQ5S1SDUcS1K8K++JYk9TbKjCi3fDOmDchtrNItV9XQVnciPdjyVeDVMjVIS
2iK+eCuLahXTQ9XoLctqaGHEDh73+5SIhMYL8a3DU7IPdN8+89wLOZ5i5r5YY2qi
0GwxgEbTaskxvLbEZWTh1scc4W3DUxnIGKWzV9aWUu3ATVWxmfJtLQlPtE75PBzZ
ho5oVa8c3SiNK2uM8tvU8HSeGlU6tTDwZu5SPgi9T2PagR4a1dXdyPOrT7G/hbew
ZxIjNBQmqZGr8JSeZOopDR667tYB4Xj2Uzy1bKrwtGnAxBpnBU+D4HEXPauOkiMv
cFstCzaLp9GmpoKn4tnXeVGedGq99uPwFN8YCatRGamwttRlHW8a7RoV5eqJ38SG
y1g8vd4lBW8WT13nvk2NkmX6EvHUVU83gqdWteX5TEwe5k+cbTx1M/dtqYqC7ba3
qUmxH8U8BYrhxZ1pMOJNxZ5OGU9xR0YxcafdCtUYI51SPbcykJVdk4YBeI3K6LBo
5mBoy5oTnb9zPO03w9wInj71zPMunrqxp2q3YVFJWhxWe0O8T/b4xH4OOv9Q4zzv
xwN2cGghT4VKrgpPLZvaEjbIpmFW2lA2dSNQY36tNjcS3GKufZd17ud4yqvhKeBp
5NaP5NJoTylEz0Y8TQpUubqpdfq7RU8jPFWciqobhs5IF09WPRVAcfAUNxm+PK9d
styWF/DPa/uv6Gtw8DHPZypiGEPGtw5POfa06twXPOWRy3sxoKPAXTMs2sZh5Qqa
zIIi0sxzL2B7IVXCZop42kXpcJN0NxUBJXiaSJUWE938lQg3c+98wqaDqdS7K5QZ
EbhRcagnfdkBgRvEU3rXOlOj7KamNvYUUwL4r4sMadXAJs0e0GKolS2ttsTgu6fl
TpRIOcum49VTdu4jnuIe3yrq1C2vWGVT7bhvkEvb8TRx3Ddiqz1e+fdVZEyOpzQj
rhRP7969K3j6H7//r8S5L3lRWIchd+VHrRFPsaktqaLyqPJihqcerbrVT108FfOK
/n3EUxW4vdnY0whPZ2uMbkhiQYOHpInlYQ2VxRX05G4jnop6iqlRrnMfc71ZNU9m
pqW0cRC5lM91n9Pfyxqq6GoSe4rAimuVqeNpH60xi0DtVh1XoFJm1WkuFKjiEXFG
Tk41qLUvSFTfKeixJLTXOYiPoDhDjqd0MTeIp+jcx7qNMjbFXqGf2bVmIwzgImeo
nt89J77oHsMv7s2CxG+gE0MtOcbjqaqzyHhqdyjZNXVMIjb1ffoBfVZbVRNN8qga
Q06tTx+nPQzyvQH7Pid4uqLMfYOn57BosIo9lbnN7gHWzqYtOVKRkhodPwBGa2Kq
ikBVU53opujcRzzFwXOiUqNee306zn0psMeOXbF6kb1YKSauoeFfJ89nquHB4Smg
9oxi7eBZwlMexdToT6B7ctcIM+r5Spl1Dc26I7nt9ihD4/cGJOzP8RT2GZo+nooA
hOVNrpS6j6ZAFb8RO3P18S0CebreUD/miKOaVRDQQIkfgONQRSwQL/+m8LSPPa3j
6bywVO/Wjy5RFI22LQ0nWXyRoZxDNdRCUVYdS8BTng5xLwSpCiSGz2XTqMhW1YOf
e+0btc9IEE2E0vZIgK3DU0z35q5ENk0c8cvFU3VMVW2NYlKrXn6bHSUTNgqoEZ46
zv1N46mbGsVDEtnUFSdW3eynrw5T8PzyN7LCdOrkhzlsG/EUM/dz9ZRHMY1BVimE
1ZAbVudbn0670muoItLwdt7XYaN2JShMGU9xj2IyZVeMcmwxsX1gjhvaEY5UGfRy
um1KtJcKv2smv3UOYsmwkXn2qN8obgp4KpZZmWWav9Cx3HJtlVlbkTkdYa6j2SSZ
aPh1nm2P+gJ/bIqXhqccVCHRThjilrNpBU+D/HphxEYwHaSwHpsSUTm2JkEFR0Ga
1DTxVFUjov9V/VqLp42oGtFkEofqcidm8buJUzog1SBpNXlf4elenwnbkholsaf0
BaaDpxZQZuPxwDGFayaGtXEJ/717HZztlb6kbYw9pd5vwVMWUE9DTi+bSlLYJpLS
tMQvpk7S/c93AvXpSV+c/6SvMEV9vS14WiR9dy4R5jP5A68McY679LOINmZJdLl4
ivkDWJhFwotFCTo+2RiePvNchqe8Py33I49NvkXt0iI3a3h8br2veCuWZPWyF+jf
2Tg1Z7OfmH9Duj0k101m1RMoR50WlrrzJV3oX9Nk+MLvOjw9HT/sTOSLzoRK1lwV
3kcwVaEtrkO/0E2bcXO0UKpynlx3fyKOtp+c63pc6+vwoYwqLon3P/hwpWX5AU9/
bsvyM83IrMa+YFXxPo86HSRz8i5QriIbvT1K0h/m9PfUU4w/UWxq8VScwiiHo3q6
Bjx98OABXSjBU5rSXvrjOQYURag0Jun77HZ+beEz16Aoe4SDdxy8JucfdPzQ1kKr
1KHKCahSgGkwXu3L8t+6PS08ZfWUTDGX5acbQKwxs6nkAxDBsOfXTmYD+rQdKxc/
sgVbh35QP/vw865u5nWbGnUCCazUpCz/Z5+vD0/pfx7Lov5IpUxmUx7RdFuezrUg
nbrj1FWq2psFXHWSpASKe55G332jeqq8/Jz7KDXCMPFjzZn7BElPPfM8YZJk7tPA
FIPMXspT9eetd7j7Vm0nh9rtvQB/h37ciO+JdTaOyuRyWXXQEzqGrt5cPb3z5Vdq
1yg2iDx++H8yhbOVnGdKbOR1a5J+VBCqmiBVg1f8VQvm5qxsX5w/PzqmP5NB56iv
vLhRPPV3jRKgebMjGl6tVt3rQzOfcqd88nERcQ7A09i/72ZHccPw0xbn/kbwFGNP
2QjSE/oac920R1KxHe3mqXr8IDO6rONHfB98wpgiK3KV9vvue+9vC55ijiPZYcFT
juiwF1C/sgp1c0GmbDl+kJjaP7kC+TTXpeQfxJ4q9ZQW6mvD058/9ksyyzScWf3h
paakdrBb/2KXHsCiviuKuxg6LmZR+dDlR/ewlma984lEmni9LBBL3M5RH4Qqs6po
5GvL3Gc8pQmWSEmZZR6eF7u1xWxp4Xmxxtm9Jdrb0fZ/EVzmm5k7EalUObh8PH35
lfOIp/SjZO7TFaeRQ7cIT+TWQFg2jdz6jeV/w5Sp6itRitUQ3h3QunMym+7127Lh
pLhOPJWy/BZPRQKn/6kr3+lcDmxBXM3S7tWUx5i6RNtIq/YT1Y8RHzfWmXJ9/fNR
pCJQewFVdBcUXdbm3Gc8Pd3UtMRTtdKgMbxnNmvVc3YjBAwCgmm2vjdlSmBXr8xh
gqcnHZ9uHZ6yNebhzAb5SrcXWlLBZ1nZ2W5K+PjM7vQMQ7+/HIbv4kSp2SITYk9V
atQ68VQ59wVPZ3pb59S62K08RRR3kbSdF3NMVL9Semc7Vra2gY4vG5q1tz8LQsWy
/Iina3PuC56+9MdzaJZRyMtv/jXZw2RZuG8OHnragd9nBq99vTCZYSVOQ0hJnPt9
7Gnn3P/t08/2zv3TTYEJTzmugn36+/1+FZERwUJobgW1ZJ80n1AjVbWROAdW+B/H
prJ5hlwE2cNG8JQv/RrwlLofd40iI8geYXYFMtaQESTA2sH9lnCrei8AtJEvq1Db
/t4kZmCchoomT+HpXkmoR1CkDfH0ZI11TyM8Fd8u9SP1IhOYDEncwSXZysWWRbTj
t6VFuLCs40c3GY88GNUynbtyu/BUnPscsEhDmGPalnINW2pethwfHTPuvhr6/dVt
z27EWawb7BolwsEGYk9/8TibZc4KsJnHIp2SEduHrT5dxTRSQ9ubq7yOixltDCp1
DXLi39cxhAdzPMXeXLNzn1OjxLnPjCROZoYltjwH3Yb1Q1eAQ+3n2uzwgp/rqng0
MK16Sr+i6Q9iT7+4Qxe6w9NT9ZSnQyZUut4c1spnT756DqMOgAJB+tpqFTqXK4Uu
oJ4qKyxuYgx7Wj+eSkaF2EGJOpXt8rT5WKSuU1uL8HRodOlo6dT69xHvUENVPkHE
05Xm07jOfXbvcleybqqWRoKqYhwfqiZj8Gq/xyNfCilMgyuNKTv37927t9ulRgme
crQi3wB079G9baeEESAo162dTe3xYs+Xdf6h7Srsril7HR2Uq02MbxM83e9iT9eM
p6yeCp7ycJbYU7ohRQk6sPvRew5WGz86qO02ZHBXY1jtMRHyVnEZv8Dc79znsF7r
Ihf9wlKXrxAc0kVbZ+wpm2UWUK2Qd9Dh6cYN40Sa2GSxV8osS+wpvf72pR368UdM
jaK5kEYR79ZFQ4jIhsYM3RwMgjLso63PKm76SMUcqnEOxdMFiqo2nl9dioN+FyJ0
E68HT9m5T3iKZflp2DDWUG8SxkkgiIqIry6ac9/N8p1BVWKurcgT84fS6UG54YpM
bJjiJqEaG8FTal0M/nkWUJlNUShCQBExeG1q5QTbfu/z5eeooXKf3piwesp1TzFz
n5mGep+GcCebFn+p/duX0tebumfatR97HZB9ZZ0mNeNEOxc8pYG8Njz9+WO/pP95
bsVNGTlKhz1FHEFH37kA05JQh8aYJljpImYEplWsVJPIUCE24lT0bslSk1HG4ikd
s2o8pYFJZpkWGpyzSDMsa0Ds05AASDE+i4y7Rcbgcs+z+Ofa8+DqUeEpTX/049y5
L6lRRDa8LGBTyAlAwpqHXlH9OonmTaFnjq3jQJYPq0Kte/Io5rV/0ZK6pNqIar02
PH3y178t8fQ820EyxMRVPFUfdBBjV+TKZo1wGK3CN5S7paoW0y70rWdfrAmORqW7
bEQ9pWU6oUmPp68Km/Jdd1B68wcpUok3dkGVa0E1rtqqH31QIrvoLuJO4v+3BE9/
1yXTvPynV/9C37aTZuZ22F6WJaqSi/T7ps7pXpBDSHwUT+IG1NPHnuA6DKyFs+R2
octu3O0y0w86pZ9uVOabPUjVjyTMReywtZnLMuNDhQx8l/16bvwVBpRvEE+5K2mG
ZScz96C4sDY4GBuHiTtwcns7eoxjDyr/hvgqUzx9+lm69OyAoMHDPn16Aw8YJDDF
o5XE/AArw3cBAjapsHGzb6+eqlX6hVMpPOUb9IAX7v1m0OvE03JT0/O0tvvLhdeo
vztv8Gzw7GP0cFwvbVkr9fU0+50HZBd2MiqOOl5dYAzx2vCUprQOT38teMreDAKU
vX4bFbzx1KKoGldzVtu1PhZcxuZB7/zldlpMo8vjnrhzH/G0i9N5hb7q6T1pFsPy
5KCXl1Z6hSMvGX/0Ru695CupcSEa6kZiT3/688fpf5ZO2RlCdvl0RPf7krOfjb7n
HtTJwuyoy10yXISnkVVsgddFVE8Lu0sRI5QZZ/vM7WqHJS6eHqzeud/j6YtS8u+v
F/9GX1i5Uvn5gedttvenuleH3v+DzqN+NfoTh74LjfNVhZF9zIZk7r/59iXA0y/u
sHr6zHMvENnQREiXm94gPv2rgGKW4Vq+VvSinFY+Zdwf735EFUBHnGdQT4hN5HA3
HrpksFYxcmhYinpKSwyJwf/zXy9e2tnlbyJ3hlXdl58hmDdzBg2OC2YmDmyot3GT
u93ZNWrFePr999/T+PzF46epUb//r5fIFNJk9vobp2zKtcxaxt2j5g5MLvdG8xld
Rt4R+/Ynn66uK0c8Hjx4QAOWZsEnnvwNrU9oFqTvKcYELaSrFIxew6tTWTtcnfbc
37Z8+lDjbP/w/AxIqLy6o4G8v5a6p/fv3zexp6fBxOf//FdZcoisi0F01ajTQRGi
u2PrT9k3Rl54FSTWck73SF9NAAcX9ybGXNFwJrP8lwuvrQJPCZLkOX0cDcmuQPx/
8t439KE0p7uRftNs7iBdnLhG4/XVcpIV9ZSe/8ixp59//gUNGFqs/+apZ19+5ZRN
ceswHD+qXj2+EnnM3fr2uN+SOuE1KDJarY2vvlhLOX31xsaDVRnUa2kVVbkg6E66
0a3wqN27d2+544cfNCxpDP/qN0/9v5/8jEYO+wTJCL59aec0Wq2f2NTNtMGmvknu
qrOtxcE34vvIgJk/7ysJkxH86ONbdD3/9vc36ckPP/wg9kueL+VBU9obb73z+C+p
M0/3J6E5jdYYZLh5ZlUT88btnbU1yY8b/27i4qcfT/c3f+ud27c/kSu/3H4c8aAv
wOopTYE/f+yXxDP0DemrSjVyNizWcFWtWRLUZI35CDtp7XD7V8JXBhnt6EPzSYfL
8hP0XHjt9U8+/ezHEkGW+6CxTHaD8JTr/RGenv4796c33nx7r9vp8bD0TDpKgakf
aUNFc59S5GhqSZxKyNLF0wV9Xw6bGu1AzPIR5x93G4PRxLqeuqei4lGfEizR585G
5SSt8VY0vnRHfTY5PS8KS9EKkmiGlgU0C9Kvv/jiDgErjdvbn3xKtvvWbXp8ctro
x+6V5TQ+W39O+ZT5x406j/86NPfPyT5UnaHh+9Cl46s3u4b9ExpsdDevyLlPw/LK
aeb+0z/9+eky/ff/9dK5P71KLCW6y1VPWl/WvbW4Sr2p75MrOrPn3STKqVG0sGM8
ffDgwSr68cdOP6PxSXRCfEoDkwum8CJH7KDM66E01R5gnR8/NmUw+3EVLVHpynhx
NoKH3aamdJ1p7K+OTtofQsaEp5d2dn/79LM0C9KTj2/dJmtMjc0UNzSbrQYztoeF
SRxnhIfb4ab3Qpt9pRYjrOy8aZ9+9vmdL7+im+Hi3/6+au38u+++IzwlmuHUKDLL
xKb0uTyirdmpLr8PykDzloOXsoZviWXMD4u+cOPnKh1BhHDew5ad+/srLixFXfab
p57lkhrsZBZ/tLZC1VyX9djh6HPzVxYxv8PfeNRvb3Stm9Goi4vYU7J9dK2pdwlM
uRtQGZKHfWXxh5yQPtF+ljyW+6H4EUs/rfwh/IT/588iO0XLu2+//XYVI6fP3H/6
//3kZ08/+wJZwTfeeufw6mwYI5BZsXDNLVcuJ9JkzpCvR5bovfc/YPWUmeZfq8Ea
wlP6iP/77z+jlTohFH0yYfEHH35En/7ue+/zNuL8fIJNfbFJfU+6dNToK9HFpKtK
1/bvb7610jiNEQ8ayATNf3j5FVptiqeF7rTvv/8+sV0/LsOU4WmVQU5eXOfD/uFD
3y5TGw1hwotVx57SWKb7jfD0Z794nMiGnlx87XUVpZMv5u3iOVpFr9oebsQOJ9jK
lpk3gXvn0uU///XiqvGUeo06kZaOr5z/M30BMh3vf/DhadzeBx9u3LhtaZPpjNrN
7kqeXL9BBnC+a9QXd74kXCVyOl2jf/Ipm2/6nw6lRs/5yRoafxb9j23ESZJ3ub8a
8Sl8QW2Ta80XkM5MbEFX9cuvvqJxRPf36jY1pR58/Je//l//+//853+/RKtJXlZi
aTF5jk2qX0UHjGvqtNU29DzL+p5Rwy0QxbnP6ulfLrxGT1bRifz47rvviJxopUGj
9Ot//pMmVJrkiFTudg96cv/+/XtTfeB3u989Nvhl5Dvw1+ALSM8J9Wg80gRDV5hG
qFz5f01ARqX5lWZZGr9kQD77/HOiKPqGbFUiy4amUhnPEVZ0nNVFozfuUwa9Pbfb
7nnkUnz08S2a6egJwc0qYk/xLqLBS333zHMvcMwVsSlx3k2zTUC7RVWWfOnGEPfW
mkJLDD7Pp/Qr6m4yy3969S+rTo2ij3v62Rdee/2NTz79jM0I2RNaT97z7N7GTd9W
PGiyowvIZpl/pCFJiw26CWns/Bv9TGOVNVWyibQEoZXBuT+92tX0Ov/yK69COy+v
0AHU5Ff8o9vMSfSp1Bnig6P2qnue+PvYc+af4p+85SvRYVxAhKt0kTUkm3hvNbGn
1MH0EYSnv/rNU9SVtOS48+VXHKdB/S3t089Om3rx9IXOgWhfP/ONL4j7Oj6h/+li
/uPrr7lcIjLN0h+8wwJDME11NEK/+eYb6l+yvDyS6X96fjd9fPvo0T3kUuB1I9yn
5zSr0YqOLjJNM6vrzaEP6mtiKYIYugf+9vc3yXqQGfnDy6/wJnC9pXpVWZvAcra3
8GzGLOfWWM8RLQ3OXLWr1VdOGxektHaePosghua4ty/tsHudBvXS1yQYwUy31o13
3yOm+cXjT9Kke/uTT8mG0IeyEVaWBy0w2yXb1GGNRlvM+3ItPP8V6svkLfo+0ZGu
uebrQHMcv5GWmjS3rjpz/7Qrb75L45FWFz92ujhbFZrQ2TKLnXlkhNsfdPXI4vET
+p8mu6//+c9rxyd0kU/xlF6lzmZv1xtvvcPbc/FeCLYxb1GjQY6v8w6oUUvOI2+X
5h7cePL8PO5pGw8b1/gMdD15j2y64nSpqQ9WMR1Sp9Lq4j//+yXqRBZo2UqyV+uH
8iGvLNFxph4/1B7JYYPOk7x36PdUv/qxT3viB18fQgfqytu3P5FO/NdSpzc67Vf/
+AfZQc6F2ts/fPPtS1wCif7nRrfT62+89cabb1OTF9fc6Au4jX8rX4xf2eD3tN+Z
riSBAtcOO7l+g2a46eAp3Us0kG/dvk1fjG4zWgiR9SAbImvdERYst2Pqt8q8t1tU
9WXkXVW7rfC3/W9p/628wns1/fXi3956Z4djZmgNT5yx3CGMD449pdUFfSh9Fr8o
9oSffN89qnbMtZzjjOSIh/2G/PixNJKjH0MnDjVmacjwZrCrw1MiJbphrvRbSbNZ
Zsssz8X6Ld3i5fZ29AlHf+4iH63Oz1eMriH78Dl5/+Nbt6mL/43+0bChH2i4UgfT
tSabSGPp4muvX/Aa7xEsjXBWdg1OjndfkZNUD+Zd46vfJzpmkTbutPg3vvb6G5w+
/977HxCeinN/uTaRZjUaM9TNrNFyfUeegFucOEt3sifHX+93tOd6ovwiFnNYxG8V
ZfKOdnVxRiFX12M3K3Xl7U8+vX///hK7Tx5kf7/86quPPr5FH72ze4Vm0z+e+xO3
l/54jhpNdS/+4RxXhKbnUeODF28jzs9SH389+TH5qoPOP+J49YT3quCMeFpsfHHn
y9VluQ19kE2gWZCImYYGzbX0JWkpwqb4YmnuLng/jrZUiZWOLH/S2j/9Ipx8uXbY
ziz8hKwxGUkaWTSoaZFJY21Fvc/mnaw9GQ2aemmxQZPszW6T8chkRfazxa5GzTV9
iT1MDLvYbTw//6jOmVRUsH9pYp/zK8PGmesw0NxK0x99mRXhKfXmN998Q9M3Tay8
bmQ9nuwJlxhXBgqt30rt82h7npvTxu851Kq7ja4Vz2ivdBvj0fRKF/mTTz8jS3ga
e8oGkUYOdTBd+mRjdLU9Or6Sv+XstWRfeN6hTi4RmUKOhSc79dU//rEiqeYfX3/9
fhdWTB9HNE89zeEZcgcgIgjx9CEcq2rVD8IDqt8Hj7FvzFtyzvz79G9/lTffosFD
I4XGy4qCNNgO3rp9m8wurdRpKqUpnDr0z3+9uNJGH+G2ZZ1w1d8/b7y5OX8NYhRa
r9O15TU6DZzpqKc/dk5DshIffvTxteMTshu8oY4yOyPsFVkkfLv8mB+vPlFenE6L
jHByPHU9rUxudlPgijIB5EG0RPBEY5m6klYatC4Sm6PscLsZXGeTiSP6Vupru1PM
CPtsTb09s2yLSGaZ1xs0ar7tM4+XrojTmemGYQ5+650dVvHWZoeX1VbxVRc/Cdtn
YlMaodeOjomUvrjz5f3790/xlKwzjaIvvrjDYfh5si1nv+Jz+fGhavK3q2YvEec0
0J1NK/UVSW4/duop2cEbXXEAmn1p5LA/jkbvRhrdcI0vTrPR1eP/+Qmz6ZtvX2Kf
4OpElx/75SLdPAeH1whN6EMn4hxvd9ZMp6GjjZ/T9aSrun949cbNd1e3zFjk8d13
39ENdvv2J3SnSbkG17wMzZBNbLhrypKTrM5+rvo8ZI3p2tJ8R7PeDyuudEsG/9PP
PqfPJCCmG4+FAzHL22IP2QZuxJ7TR7ifwpaZN4Z94613aDifMs0Xd1Y3nKkr73z5
FQ1J9muxWZa2cUO3wbaIu38WpdYFSNDSkVZxvMz4x9df/4sz93/sXIqcQvXNN9/Q
L2j5HjWym/icW3L8WW3yt6vmHkyXlG7ulQY53b17V5iGliDU5dTxNHIJqvzWedZO
W/T6gk2dMPqx+n1afrtIC745seipX7V/TheTd8cmpuH8BsbTVXQonZMmTlrPsByO
BWg2UCdvdAG8Bb/bsuq59jUIr8LOlpztS/1I5m5S0qk8xBpH1mbjBnAibZAd5kYr
eU7CWJ015se/urxGZhq668h80DRMloTsCVlmCTZw29LscNU+D50gVmqNh3wEXSUu
XXy6b1OnGnxx58vVDecfui0ziIA/vnX7xrvvcezB3LZs3PCuwZ5HdngBg394dT61
8abTdHlZOv2Rd43C4YR5IY8eW/Rgprl1+zaXHOctN8btYjfBJvuULL49SctWKPQR
vAf0pcun//Mr3d5bN9jvsGrJjWMQaR7l8gtJJi/vATGdJttSLNiG/r3J8Xz18Bh6
hS7sGsSzR4+pPdY8wdEHEQqzgErm43S30m7nJ7Y59By390y2+pxIE9sr33D9X1g+
jv+na0h0+O5779OgXmlVKX4QNpFZ5toL8xoCX9zZuOFdUUvs6lImIK7SIIaa5la6
vLLx+7/lnfHosS0PXqmfjpw7XxIifPTxLWpcdRXLH6ofVct/u6JGHxp9rn2dD171
9+SPoAuIT2hVR6OIhfDVrdH/VRZNpA968ODBd/HjwRl9DP17k+M54ZeecIo0P1lR
9z16PHrI41/9RgB379798quvaAK+ffsTMiNYgVUMmmrrt8PJFMAvrvSLjTszXcBb
t2/zNmC0DHiwlhxHKS9AZoQsDPtFz+ojsavf948Fzy//S2UGuc6P8HRND7zuq3vQ
Rzzo6rH9T/dI6o39T/mIXh/9cE/V/rnRVx1dX23E98f3cm22B4ZsHvkZHj2W8njk
szrbD7L/Yk++6R9LtLfLeiTW0tpSfr4UOxwdEL0Xr+G9e/ce9IFzKx1Ej5wta378
f4NEYR4y9xGxAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.12,0,-0,.11998016,-1374.812,-621.5487)" src="data:image/png;base64,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">
<p style="top:259.2pt;left:120.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mmarizing the main &#xfb01;ndings of this systematic review. In 66 studies, MSCs (mesenchymal stem cells) and NSCs</span></p>
<p style="top:268.7pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">roven to be the most commonly used cell types among all stem cell lines, whereas the IV (intravenous) together with</span></p>
<p style="top:278.2pt;left:125.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">iques are the most preferred routes for cell delivery.</span></p>
<p style="top:301.4pt;left:119.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">maru and colleagues proposed the</span></p>
<p style="top:313.4pt;left:123.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">r than MSCs that usually takes</span></p>
<p style="top:325.3pt;left:127.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for preparation. Therefore, they</span></p>
<p style="top:337.3pt;left:119.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">w mononuclear cells (BMMNCs),</span></p>
<p style="top:349.2pt;left:122.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ed such culture time, containing</span></p>
<p style="top:361.2pt;left:121.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with other forms of cells [28].</span></p>
<p style="top:373.1pt;left:126.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">these cells lines unwanted pro-</span></p>
<p style="top:385.1pt;left:123.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rentiation, and the need for irra-</span></p>
<p style="top:397.1pt;left:124.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mes other toxic preconditioning</span></p>
<p style="top:409.0pt;left:122.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">er engraftment [29]. Neverthe-</span></p>
<p style="top:421.0pt;left:122.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">concerns regarding severe side</span></p>
<p style="top:432.9pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">from MSCs use, such as imm-</span></p>
<p style="top:444.9pt;left:122.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">otential tumourgenicity [30, 31].</span></p>
<p style="top:456.8pt;left:125.6pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">ells.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Notwithstanding the remark-</span></p>
<p style="top:468.8pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ed with the use of MSCs, research</span></p>
<p style="top:480.7pt;left:124.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">generative diseases have pointed</span></p>
<p style="top:492.7pt;left:125.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SCs. Indeed, NSCs transplanta-</span></p>
<p style="top:504.7pt;left:126.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of the main lines used for AD</span></p>
<p style="top:516.6pt;left:124.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The robust migratory capacity of</span></p>
<p style="top:528.6pt;left:128.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compelling approach to deliver</span></p>
<p style="top:540.5pt;left:123.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ffect to the brain. The subventric-</span></p>
<p style="top:552.5pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ateral ventricles is considered the</span></p>
<p style="top:564.4pt;left:125.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SCs in the adult mammalian brain</span></p>
<p style="top:576.4pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">proved in multiple settings to be</span></p>
<p style="top:588.3pt;left:128.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">when transplanted into the hip-</span></p>
<p style="top:600.3pt;left:121.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ving cognitive functions, synaptic</span></p>
<p style="top:612.2pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">euronal survival in animal models</span></p>
<p style="top:624.2pt;left:123.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tically modi&#xfb01;ed NSCs expressing</span></p>
<p style="top:636.2pt;left:121.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">zyme neprilysin that underlies the</span></p>
<p style="top:648.1pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dation of A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">, led to marked and</span></p>
<p style="top:660.1pt;left:122.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on in the pathology of A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP trans-</span></p>
<p style="top:672.0pt;left:121.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">or concern, particularly in the study</span></p>
<p style="top:684.0pt;left:121.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and colleagues, was the long-term</span></p>
<p style="top:301.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">side effects associated with the vector assisted deliv-</span></p>
<p style="top:313.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ery method (lentivirus, adenovirus, or herpes simplex</span></p>
<p style="top:325.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">virus) they used to deliver the neprilysin to the target</span></p>
<p style="top:337.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">areas. It was also unclear the reason of the adenovirus</span></p>
<p style="top:349.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">delivered neprilysin localization at the presynaptic</span></p>
<p style="top:361.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sites, whereas the lentivirus localization was in the</span></p>
<p style="top:373.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cell soma and the endoplasmic reticulum [34&#x2013;36].</span></p>
<p style="top:385.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Transplantation of neuronal precursor cells (NPCs),</span></p>
<p style="top:397.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">derived from mouse embryonic stem cells (ESCs),</span></p>
<p style="top:409.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was shown to promote behavioral recovery in a nbM-</span></p>
<p style="top:421.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lesioned rats AD model following commitment to a</span></p>
<p style="top:432.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cholinergic cell phenotype [37]. Unlike other pre-</span></p>
<p style="top:444.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vious studies, it clearly showed an increase in the</span></p>
<p style="top:456.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">number of cholinergic neurons after treatment. Still,</span></p>
<p style="top:468.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the question whether NPCs is only a cholinergic sur-</span></p>
<p style="top:480.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vival factor or also contributes to differentiation of</span></p>
<p style="top:492.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cholinergic neurons is yet to be elucidated.</span></p>
<p style="top:504.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In an</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vitro</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> induction study, the combined effect</span></p>
<p style="top:516.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of both nerve growth factor and brain derived neu-</span></p>
<p style="top:528.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rotropic factor (BDNF) on NSCs differentiation led</span></p>
<p style="top:540.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to increased neurogenesis rate, which may be inter-</span></p>
<p style="top:552.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">esting for future clinical applications, especially for</span></p>
<p style="top:564.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dosage optimization [38]. In addition, NSCs showed</span></p>
<p style="top:576.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">signi&#xfb01;cant neuroprotective effect against AD in&#xfb02;am-</span></p>
<p style="top:588.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mation by suppressing glial and toll-like receptor-4</span></p>
<p style="top:600.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(TLR4) mediated in&#xfb02;ammatory pathway activation,</span></p>
<p style="top:612.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">leading to down-regulation of the proin&#xfb02;ammatory</span></p>
<p style="top:624.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mediators [interleukin-1 (IL-1), IL-6, tumor necro-</span></p>
<p style="top:636.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sis factor alpha (TNF</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">)] in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP/PS1 mouse model,</span></p>
<p style="top:648.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">thus ameliorating the cognitive de&#xfb01;cits, but with no</span></p>
<p style="top:660.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">change in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> concentration [39]. It is worth noticing</span></p>
<p style="top:672.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the amelioration of cognitive de&#xfb01;cits without differ-</span></p>
<p style="top:684.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ence in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> concentration, but associated with the</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1221</span></p>
<p style="top:74.6pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n&#xfb02;ammatory response, which war-</span></p>
<p style="top:86.5pt;left:125.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">igation.</span></p>
<p style="top:98.5pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">s regarding NSCs mechanism of</span></p>
<p style="top:110.5pt;left:122.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">r ability to enhance mitochondrial</span></p>
<p style="top:122.4pt;left:124.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reasing the number of mitochon-</span></p>
<p style="top:134.4pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ndrial proteins (dynamin related</span></p>
<p style="top:146.3pt;left:124.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ndrial &#xfb01;ssion 1 protein, optic atro-</span></p>
<p style="top:158.3pt;left:127.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP/PS1 mice models, thus</span></p>
<p style="top:170.2pt;left:123.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">itive outcome [40]. These results</span></p>
<p style="top:182.2pt;left:122.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">evance as mitochondrial bioener-</span></p>
<p style="top:194.1pt;left:125.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ly precede AD pathogenesis, thus</span></p>
<p style="top:206.1pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mitochondria through NSC trans-</span></p>
<p style="top:218.1pt;left:127.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">a promising therapeutic strategy.</span></p>
<p style="top:230.0pt;left:125.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">es showed that NSCs transplan-</span></p>
<p style="top:242.0pt;left:130.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stages of the disease improved</span></p>
<p style="top:253.9pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">memory ability and reduced A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span></p>
<p style="top:265.9pt;left:122.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">u hyperphosphorylation in Tg2576</span></p>
<p style="top:277.8pt;left:129.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">NSCs transplantation decreased</span></p>
<p style="top:289.8pt;left:125.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on [41]. However, it should be</span></p>
<p style="top:301.7pt;left:128.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">advanced stages of the disease,</span></p>
<p style="top:313.7pt;left:125.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tore behavioral/cognitive de&#xfb01;cits,</span></p>
<p style="top:325.6pt;left:120.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">well with previous results in older</span></p>
<p style="top:337.6pt;left:123.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">se.</span></p>
<p style="top:349.6pt;left:123.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">o identify a suitable line for clin-</span></p>
<p style="top:361.5pt;left:130.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study used human neural stem</span></p>
<p style="top:373.5pt;left:123.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">uCNS-SCs) transplantation in ani-</span></p>
<p style="top:385.4pt;left:122.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rodegeneration. In 3xTg-AD mice,</span></p>
<p style="top:397.4pt;left:122.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ed to ameliorate context and place</span></p>
<p style="top:409.3pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">g (tested using the novel subject</span></p>
<p style="top:421.3pt;left:123.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n addition, HuCNS-SCs improved</span></p>
<p style="top:433.2pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nd memory impairments (tested</span></p>
<p style="top:445.2pt;left:121.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ater maze test, MWM) with proper</span></p>
<p style="top:457.2pt;left:125.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">graftment detected by immuno&#xfb02;u-</span></p>
<p style="top:469.1pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">focal microscopy. The intriguing</span></p>
<p style="top:481.1pt;left:123.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">he improvement in MWM probe</span></p>
<p style="top:493.0pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ject recognition test performance,</span></p>
<p style="top:505.0pt;left:122.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n MWM acquisition, suggesting</span></p>
<p style="top:516.9pt;left:129.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">processes involved in memory</span></p>
<p style="top:528.9pt;left:124.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nsolidation. Moreover, cognitive</span></p>
<p style="top:540.8pt;left:122.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">re not associated with altered A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span></p>
<p style="top:552.8pt;left:125.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ather, human NSC transplantation</span></p>
<p style="top:564.8pt;left:127.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cognition by enhancing endoge-</span></p>
<p style="top:576.7pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is [42].</span></p>
<p style="top:588.7pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">o highlight that despite NSCs and</span></p>
<p style="top:600.6pt;left:121.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">verlap to a certain degree in terms</span></p>
<p style="top:612.6pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">, they can be clearly distinguished</span></p>
<p style="top:624.5pt;left:123.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ces in notch signaling and func-</span></p>
<p style="top:636.5pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PCs collectively describe a mixed</span></p>
<p style="top:648.4pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">NSCs and neural progenitor cells.</span></p>
<p style="top:660.4pt;left:124.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cells are generally capable of lim-</span></p>
<p style="top:672.3pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">enewal with generation of one type</span></p>
<p style="top:684.3pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to the highly plastic NSCs that can</span></p>
<p style="top:74.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">maintain unlimited lifetime differentiation along the</span></p>
<p style="top:86.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">three known cell lineages (multipotent) [43].</span></p>
<p style="top:98.5pt;left:294.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Human umbilical cord blood cells (HUCBCs).</span></i></p>
<p style="top:110.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">HUCBCs transplantation has been therapeutically</span></p>
<p style="top:122.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bene&#xfb01;cial in many neurodegenerative disorders [44].</span></p>
<p style="top:134.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Despite acknowledged as clinical waste, HUCBCs</span></p>
<p style="top:146.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">provide an alternative source for plenty of MSCs [45].</span></p>
<p style="top:158.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">They have been suggested to modulate the periph-</span></p>
<p style="top:170.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eral in&#xfb02;ammatory processes, which in turn affect</span></p>
<p style="top:182.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in&#xfb02;ammation in the brain parenchyma, and the mobi-</span></p>
<p style="top:194.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lization of adult stem cells from the bone marrow,</span></p>
<p style="top:206.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">leading to extension of the lifespan in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP mice [46,</span></p>
<p style="top:218.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">47]. Multiple low doses of HUCBCs were shown to</span></p>
<p style="top:230.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improve cognitive impairment, reduce A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">-associated</span></p>
<p style="top:242.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuropathology, and improve the motor skills in long</span></p>
<p style="top:253.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">term treated AD mice [48]. Despite the usage of mul-</span></p>
<p style="top:265.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tiple doses to detect the optimum one in those studies,</span></p>
<p style="top:277.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the problem of dose optimization is yet to be solved.</span></p>
<p style="top:289.8pt;left:294.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Adiposetissuederivedstemcells(ADSCs).</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">ADSCs</span></p>
<p style="top:301.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">appeared as a new attractive source for stem cells in</span></p>
<p style="top:313.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">regenerativetherapyastheyarereadilyabundant,eas-</span></p>
<p style="top:325.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ily accessible, with a detected lower senescence ratio</span></p>
<p style="top:337.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compared to bone marrow-MSCs [49]. In addition,</span></p>
<p style="top:349.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">they are known for their ability to differentiate into</span></p>
<p style="top:361.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mesenchymal and non-mesenchymal lineages [50].</span></p>
<p style="top:373.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">One study proposed ADSCs as a safe stem cell source</span></p>
<p style="top:385.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for intravenous (IV) injections, owing to the absence</span></p>
<p style="top:397.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of immune rejections, ethical problems or tumorigen-</span></p>
<p style="top:409.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">esis. [51]. Long term follow-up (up to 26 months post</span></p>
<p style="top:421.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injection) to determine their potential tumorigenicity</span></p>
<p style="top:433.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in nude mice showed ADSCs to be safe even with</span></p>
<p style="top:445.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">high doses.</span></p>
<p style="top:457.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In AD, intracerebral (IC) transplanted or intra-</span></p>
<p style="top:469.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">venous (IV) administered ADSCs showed dramatic</span></p>
<p style="top:481.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement of impaired memory and neuropathol-</span></p>
<p style="top:493.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ogy in A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP/PS1 mice models, with huge reduction</span></p>
<p style="top:505.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> peptide deposition with microglial activation,</span></p>
<p style="top:516.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">thus suggesting that they have a high therapeutic</span></p>
<p style="top:528.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">potential for AD [17, 52]. It was very interest-</span></p>
<p style="top:540.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing to show that in cases of IV ADSC delivery,</span></p>
<p style="top:552.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the labeled &#xfb02;uorescence magnetic nanoparticles for</span></p>
<p style="top:564.8pt;left:284.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> live tracking were demonstrated in all brain</span></p>
<p style="top:576.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">regions except the olfactory bulb in Tg2576 model</span></p>
<p style="top:588.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[53]. This study highlights once more the importance</span></p>
<p style="top:600.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of the early detection and intervention in AD, as the</span></p>
<p style="top:612.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">early onset injected cells produced major changes in</span></p>
<p style="top:624.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the disease progress and pathology, while late onset</span></p>
<p style="top:636.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment was minimally effective.</span></p>
<p style="top:648.4pt;left:294.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Hair follicle stem cells = Epidermal neural crest</span></i></p>
<p style="top:660.4pt;left:284.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">derived stem cells (Epi-NCSCs).</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> A very interesting</span></p>
<p style="top:672.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study assessed the ability of Epi-NCSCs derived from</span></p>
<p style="top:684.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hair follicles, which are the multipotent remnants of</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:74.6pt;left:125.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">l differentiation for the &#xfb01;rst time.</span></p>
<p style="top:86.5pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tic transplantation of the cells into</span></p>
<p style="top:98.5pt;left:124.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:7.6pt">40</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> induced AD rat model,</span></p>
<p style="top:110.5pt;left:125.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">olleagues showed that Epi-NCSC</span></p>
<p style="top:122.4pt;left:121.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nto neurons</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">, offering them</span></p>
<p style="top:134.4pt;left:125.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eating neurological diseases with</span></p>
<p style="top:146.3pt;left:122.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ages over other NSCs sources, as</span></p>
<p style="top:158.3pt;left:121.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ccessible, with no risks of obtain-</span></p>
<p style="top:170.2pt;left:124.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">e brain, and provide a renewable</span></p>
<p style="top:182.2pt;left:123.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ologous transplantation [54]. Yet,</span></p>
<p style="top:194.1pt;left:124.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">needed to determine the fate of the</span></p>
<p style="top:206.1pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">d neurons.</span></p>
<p style="top:218.1pt;left:124.3pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">tent stem cells (iPSCs).</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Since their</span></p>
<p style="top:230.0pt;left:126.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by Yamanka and Takahashi [55],</span></p>
<p style="top:242.0pt;left:125.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">used on induced pluripotent stem</span></p>
<p style="top:253.9pt;left:125.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">arious reasons, such as their high</span></p>
<p style="top:265.9pt;left:123.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">g up and the potential ability to get</span></p>
<p style="top:277.8pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hereby reducing or eliminating the</span></p>
<p style="top:289.8pt;left:125.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">suppression. Recently, xeno-free</span></p>
<p style="top:301.7pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cs have been generated, moving</span></p>
<p style="top:313.7pt;left:125.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ral steps closer to clinical reality</span></p>
<p style="top:325.6pt;left:124.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ntioning that iPSCs exhibit molec-</span></p>
<p style="top:337.6pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">l characteristic similar to those of</span></p>
<p style="top:349.6pt;left:121.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ke ESCs, iPSCs raise no major eth-</span></p>
<p style="top:361.5pt;left:123.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rding their source. Moreover, they</span></p>
<p style="top:373.5pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">s cells for cell-based therapies [57].</span></p>
<p style="top:385.4pt;left:123.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">e potential of iPSCs to reach ther-</span></p>
<p style="top:397.4pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">enerative disease, trials on iPSCs</span></p>
<p style="top:409.3pt;left:130.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the basic laboratory boundaries</span></p>
<p style="top:433.2pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hile progress has been made last</span></p>
<p style="top:445.2pt;left:123.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ll line to be used is still a point</span></p>
<p style="top:457.2pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">worthy, MSCs and NSCs together</span></p>
<p style="top:469.1pt;left:124.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ost 75% of the cases (37.9% and</span></p>
<p style="top:481.1pt;left:122.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">y). An important question arising</span></p>
<p style="top:493.0pt;left:122.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pathological nature of AD is:</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> when</span></i></p>
<p style="top:505.0pt;left:125.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Early injection proved to be more</span></p>
<p style="top:516.9pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cting and/or reversing the pathol-</span></p>
<p style="top:528.9pt;left:122.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">e stages management that is not as</span></p>
<p style="top:576.7pt;left:122.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hrough which stem cells can reach</span></p>
<p style="top:588.7pt;left:125.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ues for neurogenesis is still a mat-</span></p>
<p style="top:600.6pt;left:124.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">te numerous efforts in elucidating</span></p>
<p style="top:624.5pt;left:123.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2).</span><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">that over 70% of the studies used</span></sup></p>
<p style="top:636.5pt;left:121.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ve to assume that to deliver cells</span></p>
<p style="top:648.4pt;left:123.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">an, direct implantation techniques</span></p>
<p style="top:660.4pt;left:125.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">t. The safety and tolerability of</span></p>
<p style="top:672.3pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">istration was proven by a phase-</span></p>
<p style="top:684.3pt;left:126.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for gene delivery in AD patients</span></p>
<p style="top:74.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[60]. A recent phase-one clinical trial used the same</span></p>
<p style="top:86.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported successful stereotactic surgery to deliver</span></p>
<p style="top:98.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MSCs intracerebrally, directly into the hippocampus</span></p>
<p style="top:110.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and the precuneus, which was proven to be feasible,</span></p>
<p style="top:122.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">safe, and well tolerated [61]. Despite lacking a con-</span></p>
<p style="top:134.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trol group in both studies and the small study sample</span></p>
<p style="top:146.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(10 and 9, respectively), they both proved interven-</span></p>
<p style="top:158.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tional safety, thus opening the gate for future more</span></p>
<p style="top:170.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">controlled wide scale evidence-based clinical trials.</span></p>
<p style="top:182.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Choosing a cell delivery route for clinical trans-</span></p>
<p style="top:194.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lation is a huge challenge, since the human brain is</span></p>
<p style="top:206.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">considerably larger than the mouse brain (the most</span></p>
<p style="top:218.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">used animal model for AD). Peripheral delivery of</span></p>
<p style="top:230.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cells and proteins appears to be less effective than</span></p>
<p style="top:242.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">intracerebral injections. For instance, a study found</span></p>
<p style="top:253.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that IV delivery route could reduce plasma A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">, but</span></p>
<p style="top:265.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">failed to clear A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> plaques within the brain [62].</span></p>
<p style="top:277.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Kanamaru and colleagues rationally debated the</span></p>
<p style="top:289.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">need for other less invasive ways of cell delivery,</span></p>
<p style="top:301.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">particularly in humans [28]. Based on the theory</span></p>
<p style="top:313.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of blood-brain barrier disruption and leakage in AD</span></p>
<p style="top:325.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">patients [63, 64], lots of researchers have constructed</span></p>
<p style="top:337.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">their preclinical experiments using the IV route for</span></p>
<p style="top:349.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cell delivery, as an easier and less invasive method.</span></p>
<p style="top:361.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Although Lee and colleagues in 2008 postulated that</span></p>
<p style="top:373.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">NSCs are best delivered IV than IC, they also men-</span></p>
<p style="top:385.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tioned that in case of MSCs IV injection, most of the</span></p>
<p style="top:397.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injectedcellswerefoundinthesplenicmarginalzone,</span></p>
<p style="top:409.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rather than homing in the brain tissues [65]. This was</span></p>
<p style="top:421.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">also consistent with the results of IV injection of cord</span></p>
<p style="top:433.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">blood cells that were found all over the body of a</span></p>
<p style="top:445.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">murine model [66]. Moreover, Yang and colleagues</span></p>
<p style="top:457.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb01;rst reported that the IV injection of BMMNCs is</span></p>
<p style="top:469.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not inferior to the intra-arterial route. Interestingly,</span></p>
<p style="top:481.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Kanamaru and colleagues also reported the inability</span></p>
<p style="top:493.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to detect the IV injected cells in brain tissues after 3</span></p>
<p style="top:505.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">months of transplantation [28]. Such reports illustrate</span></p>
<p style="top:516.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the unpredictable fate of the IV route, and the min-</span></p>
<p style="top:528.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">imal percentage of localization of the injected cells</span></p>
<p style="top:540.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">centrally (in the brain), despite its apparent ef&#xfb01;cacy,</span></p>
<p style="top:552.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">which render this technique debatable.</span></p>
<p style="top:564.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Direct intra-arterial stem cells transplantation has</span></p>
<p style="top:576.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">been used mainly for stroke and ischemic diseases</span></p>
<p style="top:588.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to induce functional recovery in the acute therapeutic</span></p>
<p style="top:600.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">window [67, 68]. In 6-hydroxydopamine (6-OHDA)-</span></p>
<p style="top:612.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">induced animal model of Parkinson&#x2019;s disease, MSCs</span></p>
<p style="top:624.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were directly infused in the carotid artery. System-</span></p>
<p style="top:636.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ically injected cells could not ef&#xfb01;ciently cross the</span></p>
<p style="top:648.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">blood-brain barrier to home in the nigrostriatal region</span></p>
<p style="top:660.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">unless another agent is given with them facilitat-</span></p>
<p style="top:672.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing their permeability [69]. Such technique is not</span></p>
<p style="top:684.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">employed so far for stem cells delivery in AD.</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1223</span></p>
<p style="top:74.6pt;left:124.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cal trials used this route in AD</span></p>
<p style="top:86.5pt;left:119.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Monodisperse Iron Oxide Nanopar-</span></p>
<p style="top:98.5pt;left:122.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">geting the cerebrovascular amyloid</span></p>
<p style="top:110.5pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">found in approximately 90% of</span></p>
<p style="top:122.4pt;left:128.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[70]. The same research group</span></p>
<p style="top:134.4pt;left:121.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">delivery of antibody fragments for</span></p>
<p style="top:146.3pt;left:124.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1]. Still, this technique is far from</span></p>
<p style="top:158.3pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">inical practice.</span></p>
<p style="top:170.2pt;left:123.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">monly utilized routes were sugg-</span></p>
<p style="top:182.2pt;left:122.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ut a clear or convincing justi&#xfb01;ca-</span></p>
<p style="top:194.1pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">For instance, it was tried a direct</span></p>
<p style="top:206.1pt;left:125.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion in a trial to prove the sys-</span></p>
<p style="top:218.1pt;left:123.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">s as an alternate pathway for cells</span></p>
<p style="top:242.0pt;left:125.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ostulated the intranasal (IN) route</span></p>
<p style="top:253.9pt;left:125.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n this study, the authors showed</span></p>
<p style="top:265.9pt;left:122.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of IN application of MSCs, cells</span></p>
<p style="top:277.8pt;left:123.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tly distributed within the olfac-</span></p>
<p style="top:289.8pt;left:121.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ampus, cortex, and cerebellum in</span></p>
<p style="top:301.7pt;left:120.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mal models, a Thy1-h[A30P]</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">S</span></p>
<p style="top:313.7pt;left:122.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onism and an A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">PP/PS1 model of</span></p>
<p style="top:325.6pt;left:125.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ve functional improvement using</span></p>
<p style="top:337.6pt;left:124.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">osage, number of injections and</span></p>
<p style="top:349.6pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">should be further investigated for</span></p>
<p style="top:409.3pt;left:123.7pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">nism of action</span></i></p>
<p style="top:421.3pt;left:123.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">have shown that stem cells trigger</span></p>
<p style="top:433.2pt;left:127.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reactions that activate microglia</span></p>
<p style="top:445.2pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">icroglia was shown to increase</span></p>
<p style="top:457.2pt;left:127.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> degrading enzymes such as</span></p>
<p style="top:469.1pt;left:125.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rilysin, thus helping in improv-</span></p>
<p style="top:481.1pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tions [75]. One study postulated</span></p>
<p style="top:493.0pt;left:122.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">duced neurotrophic factor, namely</span></p>
<p style="top:505.0pt;left:123.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ible for the improvement in cog-</span></p>
<p style="top:516.9pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">D mice model [76]. It was very</span></p>
<p style="top:528.9pt;left:125.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tudy to show that the NSCs</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> per se</span></i></p>
<p style="top:540.8pt;left:127.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">direct cognitive bene&#xfb01;cial effects</span></p>
<p style="top:552.8pt;left:122.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> or tau pathology, as hypoth-</span></p>
<p style="top:564.8pt;left:127.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in literature. In contrast, NSCs</span></p>
<p style="top:576.7pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nthehippocampallevelsofBDNF,</span></p>
<p style="top:588.7pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ed synaptic density and restoring</span></p>
<p style="top:600.6pt;left:124.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ndent cognition.</span></p>
<p style="top:612.6pt;left:124.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dies, stem cells were shown to</span></p>
<p style="top:624.5pt;left:124.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">-in&#xfb02;ammatory cytokine IL-10 and</span></p>
<p style="top:636.5pt;left:124.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">o-in&#xfb02;ammatory cytokines (TNF</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span></p>
<p style="top:648.4pt;left:128.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">IL-12) [77&#x2013;79], in addition to</span></p>
<p style="top:660.4pt;left:125.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n of vascular endothelial growth</span></p>
<p style="top:672.3pt;left:123.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n to have neuroprotective and neu-</span></p>
<p style="top:74.6pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">A more recent explanation to stem cells&#x2019; effects</span></p>
<p style="top:86.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is the role of the extracellular vesicles as key com-</span></p>
<p style="top:98.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ponents of their paracrine effect. Various types of</span></p>
<p style="top:110.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stem cells release &#x2018;secretomes&#x2019;. Studies have shown</span></p>
<p style="top:122.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that they deliver bio-active cargo to the neighboring</span></p>
<p style="top:134.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">diseased or injured cells, modifying the cellu-</span></p>
<p style="top:146.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lar receptors function, inducing anti-in&#xfb02;ammatory,</span></p>
<p style="top:158.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">immune modulation, angiogenesis, neurogenesis and</span></p>
<p style="top:170.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">synaptogenesis [81&#x2013;84]. Moreover, recent reports</span></p>
<p style="top:182.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">linked them as mediators to intercellular communica-</span></p>
<p style="top:194.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion in cancer [85], which warrants more elucidation</span></p>
<p style="top:206.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on their mechanism of action.</span></p>
<p style="top:218.1pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In spite of the numerous trials along the past</span></p>
<p style="top:230.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decade to unravel the actual mechanism by which</span></p>
<p style="top:242.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stem cells induce their effect, to date, it is still largely</span></p>
<p style="top:253.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">unknown and mostly hypothetical. Furthermore,</span></p>
<p style="top:265.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">despite their promise, secretomes clinical application</span></p>
<p style="top:277.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">still faces several challenges, including their iso-</span></p>
<p style="top:289.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lation and production techniques (time consuming</span></p>
<p style="top:301.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ultracentrifugation is the only available technique so</span></p>
<p style="top:313.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">far) and heterogeneity.</span></p>
<p style="top:337.6pt;left:285.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">In vivo stem cell tracking</span></i></p>
<p style="top:349.6pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">One of the biggest challenges that face all sorts of</span></p>
<p style="top:361.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stemcellstherapiesisthelackofreliable</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">invivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">imag-</span></p>
<p style="top:373.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing methods to evaluate the biological interactions of</span></p>
<p style="top:385.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">transplanted cells [86].</span></p>
<p style="top:397.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Nanomedicine and nanoparticles-based delivery</span></p>
<p style="top:409.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">systems for stem cells are very interesting. Super-</span></p>
<p style="top:421.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">paramagnetic iron oxide has been used for decades</span></p>
<p style="top:433.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to track stem cells</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> after</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vitro</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> labeling.</span></p>
<p style="top:445.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Nanotechnologies revolutionized the high resolution</span></p>
<p style="top:457.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> imaging for cell tracking [87]. Magnetic</span></p>
<p style="top:469.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resonance imaging (MRI), positron emission tomog-</span></p>
<p style="top:481.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">raphy (PET), or single-photon emission computed</span></p>
<p style="top:493.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tomography are used to visualize the labeled stem</span></p>
<p style="top:505.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cells</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">. MRI imaging has the advantage of high</span></p>
<p style="top:516.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">spatial resolution and anatomical information but its</span></p>
<p style="top:528.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">major drawback is the limited sensitivity [88&#x2013;90].</span></p>
<p style="top:540.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PET scans are highly sensitive but have low spa-</span></p>
<p style="top:552.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tial resolution, poor in anatomical delineation, with</span></p>
<p style="top:564.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">notable short half-life of the radioisotopes [91, 92].</span></p>
<p style="top:576.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Fluorescence imaging is another noninvasive imag-</span></p>
<p style="top:588.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing method for</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> tracking. It is also highly</span></p>
<p style="top:600.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sensitive with good resolution at the subcellular level,</span></p>
<p style="top:612.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">but suffers from limited penetration power even with</span></p>
<p style="top:624.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the prolonged release dye techniques [93, 94]. Near-</span></p>
<p style="top:636.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">infrared &#xfb02;uorescence imaging (NIRFI) using NIR</span></p>
<p style="top:648.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb02;uorophores improved penetration depth and pro-</span></p>
<p style="top:660.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vided more speci&#xfb01;c signals, but still has a major</span></p>
<p style="top:672.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">drawback of photobleaching [95, 96]. Several mul-</span></p>
<p style="top:684.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">timodal imaging techniques have been developed</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:74.6pt;left:124.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">imitations of each single method</span></p>
<p style="top:98.5pt;left:122.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">g the advances achieved in nan-</span></p>
<p style="top:110.5pt;left:124.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">still proper methods of</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> cell</span></p>
<p style="top:122.4pt;left:124.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ting are far from optimization for</span></p>
<p style="top:134.4pt;left:119.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">man subjects.</span></p>
<p style="top:182.2pt;left:123.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">s use small animal models (mice</span></p>
<p style="top:194.1pt;left:123.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">odels, the most commonly used</span></p>
<p style="top:206.1pt;left:123.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on the overexpression of familial</span></p>
<p style="top:218.1pt;left:119.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mutant genes, particularly amy-</span></p>
<p style="top:230.0pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ein, presenilin-1, and presenilin-2</span></p>
<p style="top:242.0pt;left:124.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">shown that the expected outcomes</span></p>
<p style="top:253.9pt;left:124.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vious preclinical trials are not con-</span></p>
<p style="top:265.9pt;left:125.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nical studies. This was attributed</span></p>
<p style="top:277.8pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">crepancies including the anatom-</span></p>
<p style="top:289.8pt;left:125.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ogical and micro-environmental</span></p>
<p style="top:301.7pt;left:122.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dition to the divergent reporting</span></p>
<p style="top:313.7pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n humans compared with animals</span></p>
<p style="top:337.6pt;left:127.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">particular gave momentum to the</span></p>
<p style="top:349.6pt;left:123.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">delingtechnologies.Israelandcol-</span></p>
<p style="top:361.5pt;left:123.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the initial iPSCs based</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vitro</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> AD</span></p>
<p style="top:373.5pt;left:121.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">using on replicating already known</span></p>
<p style="top:385.4pt;left:125.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dic aspects of the disease [103].</span></p>
<p style="top:397.4pt;left:124.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nabled the creation of patient spe-</span></p>
<p style="top:409.3pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ell lines. &#x2018;Alzheimer&#x2019;s in a dish</span></p>
<p style="top:421.3pt;left:127.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by Choi and colleagues marked</span></p>
<p style="top:433.2pt;left:121.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gress in AD modeling [104, 105].</span></p>
<p style="top:445.2pt;left:121.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onal of the 3D model, Zhang and</span></p>
<p style="top:457.2pt;left:122.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ped a 3D-iPSCs derived neuronal</span></p>
<p style="top:469.1pt;left:125.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6]. The importance of 3D-iPSCs</span></p>
<p style="top:481.1pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stems from their ability to differ-</span></p>
<p style="top:493.0pt;left:125.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">le neurologic cell types. As these</span></p>
<p style="top:505.0pt;left:127.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">all the information packed in the</span></p>
<p style="top:516.9pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ient from where they are derived,</span></p>
<p style="top:528.9pt;left:125.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">testing, drug screening and possi-</span></p>
<p style="top:540.8pt;left:124.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dalities, in addition to predicting</span></p>
<p style="top:552.8pt;left:125.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nt&#x2019;s interaction with treatments.</span></p>
<p style="top:564.8pt;left:120.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">C-AD modelling trials have con-</span></p>
<p style="top:576.7pt;left:123.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bryoid body/neurosphere or small</span></p>
<p style="top:588.7pt;left:122.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">euronal differentiation known for</span></p>
<p style="top:600.6pt;left:124.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ical forebrain neuron generation.</span></p>
<p style="top:612.6pt;left:124.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and neuronal marker expression,</span></p>
<p style="top:624.5pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on cultures comprise a mixture of</span></p>
<p style="top:636.5pt;left:122.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">s of variable maturity levels, such</span></p>
<p style="top:648.4pt;left:124.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ytes, oligodendrocytes, and other</span></p>
<p style="top:660.4pt;left:125.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">. As these diverse cells carry the</span></p>
<p style="top:672.3pt;left:126.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ts with AD, most closely resem-</span></p>
<p style="top:684.3pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">n fetal neurons, expressing AD</span></p>
<p style="top:74.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">phenotypes such as increased A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:7.6pt">42</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> production and</span></p>
<p style="top:86.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tau-phosphorylation changes, they are very important</span></p>
<p style="top:98.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vitro</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> study models. Very interestingly, com-</span></p>
<p style="top:110.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pounds that inhibit gamma-secretase activity were</span></p>
<p style="top:122.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effective at reducing A</span><span style="font-family:MathematicalPi,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> production in AD iPSC-</span></p>
<p style="top:134.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">derived neuronal cultures, a concept used in drug</span></p>
<p style="top:146.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">screening studies. This will hopefully lead to ratio-</span></p>
<p style="top:158.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nal selection of the most successful pharmacological</span></p>
<p style="top:170.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">strategy for preventing early AD changes [107].</span></p>
<p style="top:182.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Thisnewstemcellsfrontierwillenablescientiststo</span></p>
<p style="top:194.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">genuinely study human-based AD pathology and its</span></p>
<p style="top:206.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">response to genetic and pharmacologic manipulation,</span></p>
<p style="top:218.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for more effective future clinical applications.</span></p>
<p style="top:244.0pt;left:284.8pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">CONCLUSION AND FUTURE</span></b></p>
<p style="top:255.9pt;left:284.8pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">PERSPECTIVES</span></b></p>
<p style="top:277.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cell based therapies offer promising results, but</span></p>
<p style="top:289.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">it is clear that they still need more research to opti-</span></p>
<p style="top:301.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mize lots of hanging problems around them. On one</span></p>
<p style="top:313.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hand, the potential of regeneration of brain tissue</span></p>
<p style="top:325.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">using stem cells is sure. On the other hand, we still</span></p>
<p style="top:337.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">do not know the best way to deliver these cells to the</span></p>
<p style="top:349.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">brain. The complexity of neurodegenerative diseases</span></p>
<p style="top:361.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">results in dif&#xfb01;culty in optimizing a single direct cell</span></p>
<p style="top:373.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">based therapy to reverse all the effects, particularly</span></p>
<p style="top:385.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">AD, in which there is no uniform disease progression</span></p>
<p style="top:397.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with multiple levels of pathological changes incorpo-</span></p>
<p style="top:409.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rated along different time points (early, intermediate,</span></p>
<p style="top:421.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and late courses). This is one of the major hurdles</span></p>
<p style="top:433.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that face a potential cell based therapy to such com-</span></p>
<p style="top:445.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">plex disease process. NSCs, claimed to be the best</span></p>
<p style="top:457.2pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and most effective type for AD management, need</span></p>
<p style="top:469.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">proper optimization regarding doses and mode of</span></p>
<p style="top:481.1pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">delivery and whether a concomitant treatment should</span></p>
<p style="top:493.0pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">be administered or not.</span></p>
<p style="top:505.0pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In addition, we learned that stem cells are effec-</span></p>
<p style="top:516.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tive, but we are still incapable of clearly identifying</span></p>
<p style="top:528.9pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">their mechanistic effects as well as detect them</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in</span></i></p>
<p style="top:540.8pt;left:284.8pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> after transplantation, which is in our opinion the</span></p>
<p style="top:552.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ultimate hurdle facing their clinical applications. It is</span></p>
<p style="top:564.8pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">paramount to be able to trace your treatment, to detect</span></p>
<p style="top:576.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">its dosage level, its toxicity and cellular interactions,</span></p>
<p style="top:588.7pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not just administer it and applauding an outcome that</span></p>
<p style="top:600.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we are not sure of its cellular level biochemical pro-</span></p>
<p style="top:612.6pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cesses yet.</span></p>
<p style="top:624.5pt;left:294.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In iPSCs based therapy, the &#xfb01;rst landmark clini-</span></p>
<p style="top:636.5pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cal trial on humans was launched in 2014 to treat</span></p>
<p style="top:648.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">macular degeneration [108, 109]. Even though it</span></p>
<p style="top:660.4pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">started favorably with their &#xfb01;rst patient, an unde&#xfb01;ned</span></p>
<p style="top:672.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">genomic mutation occurred with the iPSCs of the</span></p>
<p style="top:684.3pt;left:284.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">second patient, which forced them last year to</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1225</span></p>
<p style="top:74.6pt;left:127.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the trial till further notice. This</span></p>
<p style="top:86.5pt;left:123.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">he point of the real comprehensive</span></p>
<p style="top:98.5pt;left:123.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">he cellular level based interactions</span></p>
<p style="top:122.4pt;left:123.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ature of the human brain and its</span></p>
<p style="top:134.4pt;left:122.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cuit of neurons make it unlikely for</span></p>
<p style="top:146.3pt;left:125.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cell type or other current manage-</span></p>
<p style="top:158.3pt;left:122.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">be fully effective in AD treatment</span></p>
<p style="top:170.2pt;left:120.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Most likely, a future cure will be</span></p>
<p style="top:182.2pt;left:121.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">odal approach at different intervals,</span></p>
<p style="top:194.1pt;left:125.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">e collective bene&#xfb01;ts of optimized</span></p>
<p style="top:206.1pt;left:121.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ogy, probably via their medically</span></p>
<p style="top:218.1pt;left:122.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mes, in addition to the advances in</span></p>
<p style="top:230.0pt;left:123.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ction.</span></p>
<p style="top:257.9pt;left:123.8pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">TATEMENT</span></b></p>
<p style="top:281.8pt;left:122.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sures available online (http://j-alz.</span></p>
<p style="top:293.8pt;left:123.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">isclosures/16-0250r2).</span></p>
<p style="top:345.2pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">dhi V, Nanda A (2014) From the cell of</span></p>
<p style="top:354.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">chwannoma: A century&#x2019;s fruition.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> World</span></i></p>
<p style="top:364.1pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">906-911.</span></p>
<p style="top:373.6pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">kop AR (2008) Cell division screens and</span></p>
<p style="top:383.0pt;left:123.3pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">hem Soc Trans</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 36</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 431-435.</span></p>
<p style="top:392.5pt;left:127.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(2010) Cell theory, speci&#xfb01;city, and repro-</span></p>
<p style="top:402.0pt;left:123.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1870.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stud Hist Philos Biol Biomed Sci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 41</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:420.9pt;left:123.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">bert CW, Porteous DD, Aexanian R (1964)</span></p>
<p style="top:430.4pt;left:123.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">one-marrow stem-cell population.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Ann N Y</span></i></p>
<p style="top:439.8pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">742-752.</span></p>
<p style="top:449.3pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">asso R, Reverberi D, Cilli M, Pfeffer U,</span></p>
<p style="top:458.8pt;left:126.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">015) Identi&#xfb01;cation of a new cell popula-</span></p>
<p style="top:468.2pt;left:125.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ely circulating in healthy conditions and</span></p>
<p style="top:477.7pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">a homing ability toward injured sites.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Sci</span></i></p>
<p style="top:496.6pt;left:124.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hansky L, Blumenthal J, Barash H, War-</span></p>
<p style="top:506.1pt;left:125.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">azor Y, Shtrichman R (2014) Cell-based</span></p>
<p style="top:515.5pt;left:123.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">aches: The hope for incurable diseases.</span></p>
<p style="top:525.0pt;left:122.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">649-672.</span></p>
<p style="top:534.5pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">S, Park YS (2016) Regenerative applica-</span></p>
<p style="top:543.9pt;left:126.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">th derived stem cells in other than tooth</span></p>
<p style="top:553.4pt;left:122.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A literature review.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells Int</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 2016</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:572.3pt;left:125.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">H, Kobeissy FH, Itani M, Nokkari A, Wang</span></p>
<p style="top:581.8pt;left:126.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tem cells in neuroinjury and neurodegen-</span></p>
<p style="top:591.3pt;left:123.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">rs: Challenges and future neurotherapeutic</span></p>
<p style="top:600.7pt;left:123.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">ral Regen Res</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 9</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 901-906.</span></p>
<p style="top:610.2pt;left:119.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Weuve J, Scherr PA, Evans DA (2013)</span></p>
<p style="top:619.6pt;left:125.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ase in the United States (2010&#x2013;2050) esti-</span></p>
<p style="top:629.1pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">e 2010 census.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurology</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 80</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1778-1783.</span></p>
<p style="top:638.6pt;left:125.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">2015) Stem cell treatments for neurode-</span></p>
<p style="top:648.0pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ases: Challenges from a science, business</span></p>
<p style="top:657.5pt;left:126.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">perspective.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurodegener Dis Manag</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 5</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:676.4pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">3) Neuropathologic changes in Alzheimer&#x2019;s</span></p>
<p style="top:685.9pt;left:125.2pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Psychiatry</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 64</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Suppl 9), 7-10.</span></p>
<p style="top:76.2pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[12]</span></p>
<p style="top:76.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Burns A, Iliffe S (2009) Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> BMJ</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 338</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:85.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">b158.</span></p>
<p style="top:95.4pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[13]</span></p>
<p style="top:95.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glaston-</span></p>
<p style="top:104.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">bury CM, Weiner MW, Schmansky NJ, Greve DN, Salat</span></p>
<p style="top:114.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">DH, Buckner RL, Fischl B, Alzheimer&#x2019;s Disease Neu-</span></p>
<p style="top:123.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">roimaging Initiative. (2009) Automated MRI measures</span></p>
<p style="top:133.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">identify individuals with mild cognitive impairment and</span></p>
<p style="top:142.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Brain</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 132</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 2048-2057.</span></p>
<p style="top:152.5pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[14]</span></p>
<p style="top:152.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kimbrel EA, Lanza R (2015) Current status of pluripotent</span></p>
<p style="top:162.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">stem cells: Moving the &#xfb01;rst therapies to the clinic.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Nat Rev</span></i></p>
<p style="top:171.4pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Drug Discov</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 14</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 681-692.</span></p>
<p style="top:181.2pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[15]</span></p>
<p style="top:181.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Peng Y, Huang S, Cheng B, Nie X, Enhe J, Feng C, Fu</span></p>
<p style="top:190.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">X (2013) Mesenchymal stem cells: A revolution in thera-</span></p>
<p style="top:200.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">peutic strategies of age-related diseases.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Ageing Res Rev</span></i></p>
<p style="top:209.6pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">12</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 103-115.</span></p>
<p style="top:219.3pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[16]</span></p>
<p style="top:219.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Bash D, Song L, Tuan RS (2004) Adult mesenchymal stem</span></p>
<p style="top:228.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells: Characterization, differentiation, and application in</span></p>
<p style="top:238.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cell and gene therapy.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Cell Mol Med</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 8</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 301-316.</span></p>
<p style="top:248.0pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[17]</span></p>
<p style="top:248.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chang KA, Kim HJ, Joo Y, Ha S, Suh YH (2014) The</span></p>
<p style="top:257.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">therapeutic effects of human adipose-derived stem cells in</span></p>
<p style="top:267.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease mouse models.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurodegener Dis</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 13</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:276.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">99-102.</span></p>
<p style="top:286.2pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[18]</span></p>
<p style="top:286.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Marei HES, Althani A, A&#xfb01;&#xfb01; N, Abd-Elmaksoud A,</span></p>
<p style="top:295.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Bernardini CFM, Pescatori M, Maira G, Paldino E, Manni</span></p>
<p style="top:305.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">L, Casalbore P, Cenciarelli C (2013) Over-expression of</span></p>
<p style="top:314.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hNGF in adult human olfactory bulb neural stem cells pro-</span></p>
<p style="top:324.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">motes cell growth and oligodendrocytic differentiation.</span></p>
<p style="top:333.5pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">PLoS One</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 8</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, e82206.</span></p>
<p style="top:343.3pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[19]</span></p>
<p style="top:343.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yun HM, Kim HS, Park KR, Shin JM, Kang AR, il Lee K,</span></p>
<p style="top:352.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Song S, Kim YB, Han SB, Chung HM, Hong JT (2013)</span></p>
<p style="top:362.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Placenta-derived mesenchymal stem cells improve mem-</span></p>
<p style="top:371.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ory dysfunction in an A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">1-42-infused mouse model of</span></p>
<p style="top:381.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell Death Dis</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 4</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, e958.</span></p>
<p style="top:390.9pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[20]</span></p>
<p style="top:390.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yang H, Yang H, Xie Z, Wei L, Bi J (2013) Systemic</span></p>
<p style="top:400.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation of human umbilical cord derived mes-</span></p>
<p style="top:409.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">enchymal stem cells-educated T regulatory cells improved</span></p>
<p style="top:419.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the impaired cognition in A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PPswe/PS1dE9 transgenic</span></p>
<p style="top:428.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> PLoS One</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 8</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, e69129.</span></p>
<p style="top:438.5pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[21]</span></p>
<p style="top:438.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim KS, Kim HS, Park JM, Kim HW, Park MK, Lee HS,</span></p>
<p style="top:448.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lim DS, Lee TH, Chopp M, Moon J (2013) Long-term</span></p>
<p style="top:457.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">immunomodulatory effect of amniotic stem cells in an</span></p>
<p style="top:466.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurobiol Aging</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 34</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 2408-</span></p>
<p style="top:476.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">2420.</span></p>
<p style="top:486.1pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[22]</span></p>
<p style="top:486.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Majka SM, Jackson KA, Kienstra KA, Majesky MW,</span></p>
<p style="top:495.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Goodell MA, Hirschi KK (2003) Distinct progenitor pop-</span></p>
<p style="top:505.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ulations in skeletal muscle are bone marrow derived and</span></p>
<p style="top:514.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">exhibit different cell fates during vascular regeneration.</span></p>
<p style="top:524.0pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">J Clin Invest</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 111</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 71-79.</span></p>
<p style="top:533.5pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[23]</span></p>
<p style="top:533.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Birch AM, Katsouri L, Sastre M (2014) Modulation of</span></p>
<p style="top:542.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in&#xfb02;ammation in transgenic models of Alzheimer&#x2019;s disease.</span></p>
<p style="top:552.4pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Neuroin&#xfb02;ammation</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 11</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 25.</span></p>
<p style="top:561.9pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[24]</span></p>
<p style="top:561.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee HJ, Lee JK, Lee H, Carter JE, Chang JW, Oh W, Yang</span></p>
<p style="top:571.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">YS, Suh JG, Lee BH, Jin HK, Bae JS (2012) Human</span></p>
<p style="top:580.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">umbilical cord blood-derived mesenchymal stem cells</span></p>
<p style="top:590.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">improve neuropathology and cognitive impairment in an</span></p>
<p style="top:599.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease mouse model through modulation of</span></p>
<p style="top:609.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neuroin&#xfb02;ammation.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurobiol Aging</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 33</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 588-602.</span></p>
<p style="top:618.7pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[25]</span></p>
<p style="top:618.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Oh SH, Kim HN, Park HJ, Shin JY, Lee PH (2015) Mes-</span></p>
<p style="top:628.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">enchymal stem cells increase hippocampal neurogenesis</span></p>
<p style="top:637.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and neuronal differentiation by enhancing the Wnt sig-</span></p>
<p style="top:647.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">naling pathway in an Alzheimer&#x2019;s disease model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell</span></i></p>
<p style="top:656.5pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Transplant</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 24</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1097-1109.</span></p>
<p style="top:666.0pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[26]</span></p>
<p style="top:666.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Garcia KO, Ornellas FL, Martin PK, Patti CL, Mello LE,</span></p>
<p style="top:675.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Frussa-Filho R, Han SW, Longo BM (2014) Therapeu-</span></p>
<p style="top:684.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tic effects of the transplantation of VEGF overexpressing</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:76.2pt;left:122.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mesenchymal stem cells in the hippocam-</span></p>
<p style="top:85.7pt;left:122.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">model of Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Front Aging</span></i></p>
<p style="top:104.6pt;left:125.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">, Lee JK, Richardson JC, Carter JE (2013)</span></p>
<p style="top:114.0pt;left:122.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">derived mesenchymal stem cells contribute</span></p>
<p style="top:123.5pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">n of amyloid-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposits and the improve-</span></p>
<p style="top:133.0pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ptic transmission in a mouse model of</span></p>
<p style="top:142.4pt;left:125.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">lzheimer&#x2019;sdisease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">CurrAlzheimerRes</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">10</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:161.4pt;left:120.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kamimura N, Yokota T, Nishimaki K, Iuchi</span></p>
<p style="top:170.8pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ami S, Akashiba H, Shitaka Y, Ueda M,</span></p>
<p style="top:180.3pt;left:122.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mura K, Ohta S (2015) Intravenous trans-</span></p>
<p style="top:189.8pt;left:124.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">bone marrow-derived mononuclear cells</span></p>
<p style="top:199.2pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ry impairment in transgenic mouse models</span></p>
<p style="top:208.7pt;left:126.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Brain Res</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 1605</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 49-58.</span></p>
<p style="top:218.2pt;left:126.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">JK, Lee JE, Min WK, Schuchman EH,</span></p>
<p style="top:227.6pt;left:123.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">S (2011) Combined effects of hematopoi-</span></p>
<p style="top:237.1pt;left:128.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cell mobilization from bone marrow by</span></p>
<p style="top:246.5pt;left:122.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">olony stimulating factor and AMD3100</span></p>
<p style="top:256.0pt;left:124.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">s into the brain using stromal cell-derived</span></p>
<p style="top:265.5pt;left:128.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease mouse model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem</span></i></p>
<p style="top:274.9pt;left:125.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1089.</span></p>
<p style="top:284.4pt;left:123.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ory E, Jekerle V, Lucas-Samuel S, Ahnert</span></p>
<p style="top:293.7pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#xa8;uscher D, Fibbe W, Foussat A, Kwa M,</span></p>
<p style="top:303.3pt;left:122.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ciulaitis R, Palom&#xa8;aki T, Schneider CK,</span></p>
<p style="top:312.8pt;left:122.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">chdjian G, Tarte K, Tosca L, Salmikangas</span></p>
<p style="top:322.3pt;left:124.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">zalez V, Lavell E, Qui&#x2dc;nones-Hinojosa A,</span></p>
<p style="top:331.7pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">res H (2015) Regulation of subventricular</span></p>
<p style="top:341.2pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ells migration in the adult brain.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Adv Exp</span></i></p>
<p style="top:350.7pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1-21.</span></p>
<p style="top:360.1pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">t B (2014) Mesenchymal stem and progen-</span></p>
<p style="top:369.6pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">lems, potential and promise.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Stem Cells</span></i></p>
<p style="top:379.0pt;left:126.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">106.</span></p>
<p style="top:388.5pt;left:125.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ez V, Herranz-P&#xb4;erez V, Garc</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#xb4;</span></sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">ia-Verdugo</span></p>
<p style="top:398.0pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">e aged brain: Genesis and fate of resid-</span></p>
<p style="top:416.9pt;left:123.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">5.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells in the subventricular zone.</span></sup><sup><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Front Cell</span></i></sup></p>
<p style="top:426.4pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">, Webber DJ, Bilican B, Goedert M,</span></p>
<p style="top:435.8pt;left:120.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">G, Chandran S (2010) Cell-mediated neu-</span></p>
<p style="top:445.3pt;left:122.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">n a mouse model of human tauopathy.</span></p>
<p style="top:454.8pt;left:124.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">9973-9983.</span></p>
<p style="top:464.2pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">arr RA, Rockenstein E, Crews L, Adame</span></p>
<p style="top:473.7pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">atrick C, Gage FH, Verma IM, Masliah E</span></p>
<p style="top:483.2pt;left:122.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">erm neprilysin gene transfer is associated</span></p>
<p style="top:492.6pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">evels of intracellular Abeta and behavioral</span></p>
<p style="top:502.1pt;left:124.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">n APP transgenic mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> BMC Neurosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 9</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:521.0pt;left:127.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cisse M, Ho K, Wu T, Esposito LA,</span></p>
<p style="top:530.5pt;left:125.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">K, Cheng IH, Yu GQ, Mucke L (2009)</span></p>
<p style="top:539.9pt;left:124.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">rexpression inhibits plaque formation but</span></p>
<p style="top:549.4pt;left:127.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">pathogenic Abeta oligomers and associ-</span></p>
<p style="top:558.9pt;left:122.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">de&#xfb01;cits in human amyloid precursor protein</span></p>
<p style="top:568.3pt;left:123.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">e.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neurosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 29</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1977-1986.</span></p>
<p style="top:577.8pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M, Spencer B, Michael S, Castello NA,</span></p>
<p style="top:587.3pt;left:127.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Davis JL, M&#xa8;uller FJ, Loring JF, Masliah E,</span></p>
<p style="top:596.7pt;left:122.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">014) Neural stem cells genetically-modi&#xfb01;ed</span></p>
<p style="top:606.2pt;left:126.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">lysin reduce pathology in Alzheimer trans-</span></p>
<p style="top:615.7pt;left:123.2pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Stem Cell Res Ther</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 5</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 46.</span></p>
<p style="top:625.1pt;left:120.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">H, Alaie H, Karbalaie K, Tanhaei S, Nasr</span></p>
<p style="top:634.6pt;left:126.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Baharvand H (2009) Transplantation of</span></p>
<p style="top:644.1pt;left:125.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">imed mouse embryonic stem cell-derived</span></p>
<p style="top:653.5pt;left:124.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">or cells improves cognitive function in</span></p>
<p style="top:663.0pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ats.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Differentiation</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 78</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 59-68.</span></p>
<p style="top:672.4pt;left:128.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chen Y, Zhang J, Xu L, Yan Q, Long D</span></p>
<p style="top:681.9pt;left:125.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ed effect of nerve growth factor and brain-</span></p>
<p style="top:76.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">derived neurotrophic factor on neuronal differentiation of</span></p>
<p style="top:85.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neural stem cells and the potential molecular mechanisms.</span></p>
<p style="top:95.1pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Mol Med Rep</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 10</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1739-1745.</span></p>
<p style="top:104.6pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[39]</span></p>
<p style="top:104.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang Q, Wu HH, Wang Y, Gu GJ, Zhang W, Xia R</span></p>
<p style="top:114.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(2016) Neural stem cell transplantation decreases neuroin-</span></p>
<p style="top:123.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#xfb02;ammation in a transgenic mouse model of Alzheimer&#x2019;s</span></p>
<p style="top:133.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neurochem</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 136</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 815-825.</span></p>
<p style="top:142.4pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[40]</span></p>
<p style="top:142.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang W, Gu GJ, Shen X, Zhang Q, Wang GM, Wang PJ</span></p>
<p style="top:151.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(2015) Neural stem cell transplantation enhances mito-</span></p>
<p style="top:161.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">chondrial biogenesis in a transgenic mouse model of</span></p>
<p style="top:170.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease-like pathology.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurobiol Aging</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 36</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:180.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1282-1292.</span></p>
<p style="top:189.8pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[41]</span></p>
<p style="top:189.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim JA, Ha S, Shin KY, Kim S, Lee KJ, Chong YH,</span></p>
<p style="top:199.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chang KA, Suh YH (2015) Neural stem cell transplan-</span></p>
<p style="top:208.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tation at critical period improves learning and memory</span></p>
<p style="top:218.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">through restoring synaptic impairment in Alzheimer&#x2019;s dis-</span></p>
<p style="top:227.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ease mouse model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell Death Dis</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 6</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, e1789.</span></p>
<p style="top:237.1pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[42]</span></p>
<p style="top:237.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ager RR, Davis JL, Agazaryan A, Benavente F, Poon</span></p>
<p style="top:246.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">WW, LaFerla FM, Blurton-Jones M (2015) Human neu-</span></p>
<p style="top:256.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ral stem cells improve cognition and promote synaptic</span></p>
<p style="top:265.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">growth in two complementary transgenic models of</span></p>
<p style="top:274.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease and neuronal loss.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Hippocampus</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 25</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:284.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">813-826.</span></p>
<p style="top:293.9pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[43]</span></p>
<p style="top:293.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Seaberg RM, van der Kooy D (2003) Stem and progeni-</span></p>
<p style="top:303.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tor cells: The premature desertion of rigorous de&#xfb01;nitions.</span></p>
<p style="top:312.8pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Trends Neurosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 26</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 125-131.</span></p>
<p style="top:322.3pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[44]</span></p>
<p style="top:322.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo</span></p>
<p style="top:331.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">E, Town T, Tan J (2008) In&#xfb02;ammaging as a prodrome to</span></p>
<p style="top:341.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neuroin&#xfb02;ammation</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 5</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 51.</span></p>
<p style="top:350.7pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[45]</span></p>
<p style="top:350.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Romanov YA, Svintsitskaya VA, Smirnov VN (2003)</span></p>
<p style="top:360.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Searching for alternative sources of postnatal human mes-</span></p>
<p style="top:369.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">enchymal stem cells: Candidate MSC-like cells from</span></p>
<p style="top:379.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">umbilical cord.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 21</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 105-110.</span></p>
<p style="top:388.5pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[46]</span></p>
<p style="top:388.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ende N, Chen R, Ende-Harris D (2001) Human umbil-</span></p>
<p style="top:398.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ical cord blood cells ameliorate Alzheimer&#x2019;s disease in</span></p>
<p style="top:407.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transgenic mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Med</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 32</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 241-247.</span></p>
<p style="top:416.9pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[47]</span></p>
<p style="top:416.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Vendrame M, Cassady J, Newcomb J, Butler T, Penny-</span></p>
<p style="top:426.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">packer KR, Zigova T, Sanberg CD, Sanberg PR, Willing</span></p>
<p style="top:435.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">AE (2004) Infusion of human umbilical cord blood cells</span></p>
<p style="top:445.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in a rat model of stroke dose-dependently rescues behav-</span></p>
<p style="top:454.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ioral de&#xfb01;cits and reduces infarct volume.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stroke</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 35</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:464.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">2390-2395.</span></p>
<p style="top:473.7pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[48]</span></p>
<p style="top:473.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Darlington D, Deng J, Giunta B, Hou H, Sanberg CD,</span></p>
<p style="top:483.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kuzmin-Nichols N, Zhou HD, Mori T, Ehrhart J, Sanberg</span></p>
<p style="top:492.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">PR, Tan J (2013) Multiple low-dose infusions of human</span></p>
<p style="top:502.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">umbilical cord blood cells improve cognitive impair-</span></p>
<p style="top:511.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ments and reduce amyloid-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">-associated neuropathology</span></p>
<p style="top:521.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in Alzheimer mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells Dev</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 22</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 412-421.</span></p>
<p style="top:530.5pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[49]</span></p>
<p style="top:530.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Huang T, He D, Kleiner G, Kuluz J (2007) Neuron-like</span></p>
<p style="top:539.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">differentiation of adipose-derived stem cells from infant</span></p>
<p style="top:549.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">piglets</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vitro</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Spinal Cord Med</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 30</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Suppl 1), S35-S40.</span></p>
<p style="top:558.9pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[50]</span></p>
<p style="top:558.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Anghileri E, Marconi S, Pignatelli A, Cifelli P, Gali&#xb4;e M,</span></p>
<p style="top:568.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Sbarbati A, Krampera M, Belluzzi O, Bonetti B (2008)</span></p>
<p style="top:577.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Neuronal differentiation potential of human adipose-</span></p>
<p style="top:587.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">derived mesenchymal stem cells.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells Dev</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 17</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:596.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">909-916.</span></p>
<p style="top:606.2pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[51]</span></p>
<p style="top:606.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY,</span></p>
<p style="top:615.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E (2011) Safety of</span></p>
<p style="top:625.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">intravenousinfusionofhumanadiposetissue-derivedmes-</span></p>
<p style="top:634.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">enchymal stem cells in animals and humans.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells</span></i></p>
<p style="top:644.1pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Dev</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 20</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1297-1308.</span></p>
<p style="top:653.5pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[52]</span></p>
<p style="top:653.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ma T, Gong K, Ao Q, Yan Y, Song B, Huang H, Zhang X,</span></p>
<p style="top:663.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Gong Y (2013) Intracerebral transplantation of adipose-</span></p>
<p style="top:672.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">derived mesenchymal stem cells alternatively activates</span></p>
<p style="top:681.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">microglia and ameliorates neuropathological de&#xfb01;cits in</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1227</span></p>
<p style="top:76.2pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">sease mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell Transplant</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 22</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Suppl 1),</span></p>
<p style="top:95.1pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">KA, Kim Ja, Park HG, Ra JC, Kim HS, Suh</span></p>
<p style="top:104.6pt;left:126.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">preventive and therapeutic effects of intra-</span></p>
<p style="top:114.0pt;left:125.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">adipose-derived stem cells in Alzheimer&#x2019;s</span></p>
<p style="top:123.5pt;left:121.4pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">PLoS One</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 7</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, e45757.</span></p>
<p style="top:133.0pt;left:122.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">B, Nobakht M, Joghataei MT, Rahbar</span></p>
<p style="top:142.4pt;left:129.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Rasouli H, Samadi Kuchaksaraei A,</span></p>
<p style="top:151.9pt;left:126.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Najafzade N, Asalgoo S, Hejazian LB,</span></p>
<p style="top:161.4pt;left:123.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">oghi F (2012) Delivery of epidermal neural</span></p>
<p style="top:170.8pt;left:126.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(EPI-NCSC) to hippocamp in Alzheimer&#x2019;s</span></p>
<p style="top:180.3pt;left:122.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">del.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Iran Biomed J</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 16</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1-9.</span></p>
<p style="top:189.8pt;left:122.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yamanaka S (2006) Induction of pluripo-</span></p>
<p style="top:199.2pt;left:123.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">from mouse embryonic and adult &#xfb01;broblast</span></p>
<p style="top:208.7pt;left:126.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ned factors.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 126</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 663-676.</span></p>
<p style="top:218.2pt;left:122.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">C, Ramathal C, Vega-Crespo A, Durruthy-</span></p>
<p style="top:227.6pt;left:123.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ooper A, Karumbayaram S, Lowry WE,</span></p>
<p style="top:237.1pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">k JA, Sebastiano V, Kohn DB, Pyle AD,</span></p>
<p style="top:246.5pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ipshutz GS, Phelps PE, Pera RA, Byrne</span></p>
<p style="top:256.0pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">eration and characterization of transgene-</span></p>
<p style="top:265.5pt;left:124.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">uced pluripotent stem cells and conversion</span></p>
<p style="top:274.9pt;left:125.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">nical-grade status.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cell Res Ther</span></i></p>
<p style="top:293.9pt;left:125.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">lendra S, Renda A, Longaker M, Quarto</span></p>
<p style="top:303.3pt;left:124.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">verview of direct somatic reprogramming:</span></p>
<p style="top:312.8pt;left:124.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ts of iPSCs.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Int J Mol Sci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 17</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">. pii, E141.</span></p>
<p style="top:322.3pt;left:123.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada</span></p>
<p style="top:331.7pt;left:127.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Egawa N, Yahata N, Okita K, Takahashi</span></p>
<p style="top:341.2pt;left:125.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">i T, Watanabe A, Watanabe K, Kadoya C,</span></p>
<p style="top:350.7pt;left:125.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tanabe D, Maruyama K, Hori O, Hibino</span></p>
<p style="top:360.1pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">akahata T, Hioki H, Kaneko T, Naitoh M,</span></p>
<p style="top:369.6pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yamawaki S, Suzuki S, Hata R, Ueno S,</span></p>
<p style="top:379.0pt;left:122.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ashi K, Toda T, Murakami K, Irie K, Klein</span></p>
<p style="top:388.5pt;left:124.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">sada T, Takahashi R, Iwata N, Yamanaka S,</span></p>
<p style="top:398.0pt;left:126.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Modeling Alzheimer&#x2019;s disease with iPSCs</span></p>
<p style="top:407.4pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">henotypes associated with intracellular A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:416.9pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">l drug responsiveness.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell Stem Cell</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 12</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:435.8pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M, Zhang CL, Zheng JC (2016) The ther-</span></p>
<p style="top:445.3pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">al of cell identity reprogramming for the</span></p>
<p style="top:454.8pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ging-related neurodegenerative disorders.</span></p>
<p style="top:464.2pt;left:124.2pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">l</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">. doi: 10.1016/j.pneurobio.2016.01.006</span></p>
<p style="top:473.7pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mann TL, Bakay RA, Ostrove JM, Siffert</span></p>
<p style="top:483.2pt;left:125.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Herzog CD, Barba D, Pay M, Salmon DP,</span></p>
<p style="top:492.6pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">er JH, Bishop K, Keator D, Potkin S, Bartus</span></p>
<p style="top:502.1pt;left:122.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hase1 study of stereotactic gene delivery of</span></p>
<p style="top:511.6pt;left:124.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">r Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Alzheimers Dement</span></i></p>
<p style="top:530.5pt;left:122.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">W, Chang JW, Lee JI, Kim CH, Chin J, Choi</span></p>
<p style="top:539.9pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">un HJ, Lee JM, Kim ST, Choe YS, Lee KH,</span></p>
<p style="top:549.4pt;left:126.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tereotactic brain injection of human umbil-</span></p>
<p style="top:558.9pt;left:128.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mesenchymal stem cells in patients with</span></p>
<p style="top:568.3pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">sease dementia: A phase 1 clinical trial.</span></p>
<p style="top:577.8pt;left:123.6pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">ment (N Y)</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 1</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 95-102.</span></p>
<p style="top:587.3pt;left:122.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">coma R, Watson J, Ou W, Alves J, Mason</span></p>
<p style="top:596.7pt;left:125.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">, Urbina HD, Welzel G, Althage A, Liu</span></p>
<p style="top:606.2pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Jacobson LH, Harris JL, Schumacher AM</span></p>
<p style="top:615.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ed proteolytic clearance of plasma A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> by</span></p>
<p style="top:625.1pt;left:122.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">dministered neprilysin does not result in</span></p>
<p style="top:634.6pt;left:124.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of brain A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neurosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 33</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 2457-</span></p>
<p style="top:653.5pt;left:124.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">anson CE, Gonzalez L, Berzin TM, Tavares</span></p>
<p style="top:663.0pt;left:126.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Vitek MP, Hovanesian V, Stopa EG (2007)</span></p>
<p style="top:672.4pt;left:125.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">injury and blood-brain barrier leakage in</span></p>
<p style="top:681.9pt;left:124.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">sease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurobiol Aging</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 28</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 977-986.</span></p>
<p style="top:76.2pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[64]</span></p>
<p style="top:76.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Jeynes B, Provias J (2011) The case for blood-brain barrier</span></p>
<p style="top:85.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">dysfunction in the pathogenesis of Alzheimer&#x2019;s disease.</span></p>
<p style="top:95.1pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">J Neurosci Res</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 89</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 22-28.</span></p>
<p style="top:104.6pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[65]</span></p>
<p style="top:104.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee ST, Chu K, Jung KH, Kim SJ, Kim DH, Kang KM,</span></p>
<p style="top:114.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Hong NH, Kim JH, Ban JJ, Park HK, Kim SU, Park CG,</span></p>
<p style="top:123.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee SK, Kim M, Roh JK (2008) Anti-in&#xfb02;ammatory mech-</span></p>
<p style="top:133.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">anism of intravascular neural stem cell transplantation in</span></p>
<p style="top:142.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hemorrhagic stroke.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Brain</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 131</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 616-629.</span></p>
<p style="top:151.9pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[66]</span></p>
<p style="top:151.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ehrhart J, Darlington D, Kuzmin-Nichols N, Sanberg</span></p>
<p style="top:161.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">CD, Sawmiller DR, Sanberg PR, Tan J (2016) Biodis-</span></p>
<p style="top:170.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tribution of infused human umbilical cord blood cells in</span></p>
<p style="top:180.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease-like murine model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell Transplant</span></i></p>
<p style="top:189.8pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">25</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 195-199.</span></p>
<p style="top:199.2pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[67]</span></p>
<p style="top:199.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kamiya N, Ueda M, Igarashi H, Nishiyama Y, Suda S,</span></p>
<p style="top:208.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Okubo S, Inaba T, Katayama Y (2013)</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> In vivo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> monitor-</span></p>
<p style="top:218.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ing of arterially transplanted bone marrow mononuclear</span></p>
<p style="top:227.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells in a rat transient focal brain ischemia model</span></p>
<p style="top:237.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">using magnetic resonance imaging.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurol Res</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 35</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:246.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">573-579.</span></p>
<p style="top:256.0pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[68]</span></p>
<p style="top:256.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Toyoshima A, Yasuhara T, Kameda M, Morimoto J,</span></p>
<p style="top:265.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Takeuchi H, Wang F, Sasaki T, Sasada S, Shinko A,</span></p>
<p style="top:274.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wakamori T, Okazaki M, Kondo A, Agari T, Borlongan</span></p>
<p style="top:284.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">CV, Date I (2015) Intra-arterial transplantation of allo-</span></p>
<p style="top:293.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">geneic mesenchymal stem cells mounts neuroprotective</span></p>
<p style="top:303.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">effects in a transient ischemic stroke model in rats: Analy-</span></p>
<p style="top:312.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ses of therapeutic time window and its mechanisms.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> PLoS</span></i></p>
<p style="top:322.3pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">One</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 10</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, e0127302.</span></p>
<p style="top:331.7pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[69]</span></p>
<p style="top:331.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cerri S, Greco R, Levandis G, Ghezzi C, Mangione</span></p>
<p style="top:341.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">AS, Fuzzati-Armentero MT, Bonizzi A, Avanzini MA,</span></p>
<p style="top:350.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Maccario R, Blandini F (2015) Intracarotid infusion of</span></p>
<p style="top:360.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mesenchymal stem cells in an animal model of Parkinson&#x2019;s</span></p>
<p style="top:369.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease, focusing on cell distribution and neuroprotective</span></p>
<p style="top:379.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and behavioral effects.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells Transl Med</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 4</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1073-</span></p>
<p style="top:388.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1085.</span></p>
<p style="top:398.0pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[70]</span></p>
<p style="top:398.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Poduslo JF, Hultman KL, Curran GL, Preboske GM,</span></p>
<p style="top:407.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chamberlain R, Marja&#xb4;nska M, Garwood M, Jack CR Jr,</span></p>
<p style="top:416.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wengenack TM (2011) Targeting vascular amyloid in arte-</span></p>
<p style="top:426.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">rioles of Alzheimer disease transgenic mice with amyloid</span></p>
<p style="top:435.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> protein antibody-coated nanoparticles.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neuropathol</span></i></p>
<p style="top:445.3pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Exp Neurol</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 70</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 653-661.</span></p>
<p style="top:454.8pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[71]</span></p>
<p style="top:454.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-</span></p>
<p style="top:464.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alvarado M, Kandimalla KK, Gilles EJ, Curran GL,</span></p>
<p style="top:473.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wengenack TM (2007)</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> In vivo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> targeting of antibody</span></p>
<p style="top:483.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">fragments to the nervous system for Alzheimer&#x2019;s dis-</span></p>
<p style="top:492.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ease immunotherapy and molecular imaging of amyloid</span></p>
<p style="top:502.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">plaques.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neurochem</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 102</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 420-433.</span></p>
<p style="top:511.6pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[72]</span></p>
<p style="top:511.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Danielyan L, Beer-Hammer S, Stolzing A, Sch&#xa8;afer R,</span></p>
<p style="top:521.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Siegel G, Fabian C, Kahle P, Biedermann T, Lourhmati</span></p>
<p style="top:530.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A, Buadze M, Novakovic A, Proksch B, Gleiter CH,</span></p>
<p style="top:539.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Frey WH, Schwab M (2014) Intranasal delivery of bone</span></p>
<p style="top:549.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">marrow-derived mesenchymal stem cells, macrophages,</span></p>
<p style="top:558.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and microglia to the brain in mouse models of Alzheimer&#x2019;s</span></p>
<p style="top:568.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and Parkinson&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell Transplant</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 23</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Suppl 1),</span></p>
<p style="top:577.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">S123-S139.</span></p>
<p style="top:587.3pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[73]</span></p>
<p style="top:587.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee JK, Jin HK, Bae JS (2009) Bone marrow-derived mes-</span></p>
<p style="top:596.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">enchymal stem cells reduce brain amyloid-beta deposition</span></p>
<p style="top:606.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and accelerate the activation of microglia in an acutely</span></p>
<p style="top:615.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">induced Alzheimer&#x2019;s disease mouse model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurosci Lett</span></i></p>
<p style="top:625.1pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">450</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 136-141.</span></p>
<p style="top:634.6pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[74]</span></p>
<p style="top:634.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae</span></p>
<p style="top:644.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">JS (2010) Intracerebral transplantation of bone marrow-</span></p>
<p style="top:653.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">derived mesenchymal stem cells reduces amyloid-beta</span></p>
<p style="top:663.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">deposition and rescues memory de&#xfb01;cits in Alzheimer&#x2019;s</span></p>
<p style="top:672.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease mice by modulation of immune responses.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem</span></i></p>
<p style="top:681.9pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Cells</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 28</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 329-343.</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:76.2pt;left:121.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Allison EK, El Khoury J (2008) Microglial</span></p>
<p style="top:85.7pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">d defective beta-amyloid clearance path-</span></p>
<p style="top:95.1pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neurosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 28</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:114.0pt;left:128.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M,</span></p>
<p style="top:114.0pt;left:143.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kitazawa</span></p>
<p style="top:114.0pt;left:180.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M,</span></p>
<p style="top:114.0pt;left:195.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Martinez-Coria</span></p>
<p style="top:114.0pt;left:251.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">H,</span></p>
<p style="top:123.5pt;left:121.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M&#xa8;uller FJ, Loring JF, Yamasaki TR, Poon</span></p>
<p style="top:133.0pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">N, LaFerla FM (2009) Neural stem cells</span></p>
<p style="top:142.4pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tion via BDNF in a transgenic model of</span></p>
<p style="top:151.9pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ase.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Proc Natl Acad Sci U S A</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 106</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 13594-</span></p>
<p style="top:170.8pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A, Bartholomew A (2013) Stem cells and</span></p>
<p style="top:180.3pt;left:124.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">t on in&#xfb02;ammation.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Adv Wound Care (New</span></i></p>
<p style="top:189.8pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">9-378.</span></p>
<p style="top:199.2pt;left:122.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">u Y, Yan K, Chen L, Chen XR, Li</span></p>
<p style="top:208.7pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">iang XD (2013) Anti-in&#xfb02;ammatory and</span></p>
<p style="top:218.2pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">atory mechanisms of mesenchymal stem</span></p>
<p style="top:227.6pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tion in experimental traumatic brain injury.</span></p>
<p style="top:237.1pt;left:122.0pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">mation</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 10</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 106.</span></p>
<p style="top:246.5pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Bochev I, Ivanova-Todorova E, Mourdjeva</span></p>
<p style="top:256.0pt;left:126.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">T, Belemezova K, Kyurkchiev S (2014)</span></p>
<p style="top:265.5pt;left:121.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mmunoregulatory cytokines by mesenchy-</span></p>
<p style="top:274.9pt;left:126.5pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">World J Stem Cells</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 6</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 552-570.</span></p>
<p style="top:284.4pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">odovar C, Lambrechts D, Mazzone M,</span></p>
<p style="top:293.9pt;left:123.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">2009) Role and therapeutic potential of</span></p>
<p style="top:303.3pt;left:123.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ervous system.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Physiol Rev</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 89</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 607-648.</span></p>
<p style="top:312.8pt;left:124.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">simov</span></p>
<p style="top:312.8pt;left:150.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">SV</span></p>
<p style="top:312.8pt;left:166.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(2013)</span></p>
<p style="top:312.8pt;left:194.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">The</span></p>
<p style="top:312.8pt;left:213.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">secretome</span></p>
<p style="top:312.8pt;left:252.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of</span></p>
<p style="top:322.3pt;left:123.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">stem cells: Potential implications for neu-</span></p>
<p style="top:331.7pt;left:127.3pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Biochimie</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 95</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 2246-2256.</span></p>
<p style="top:341.2pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Liu L, Jiang H, Shen Y, Xu X, Li J, Zhang</span></p>
<p style="top:350.7pt;left:125.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">n Z, Xiong N, Wang T (2016) Exosomes</span></p>
<p style="top:360.1pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">peutic potentials of stem cells.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells</span></i></p>
<p style="top:369.6pt;left:123.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">489.</span></p>
<p style="top:379.0pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">amidi MK, Bhonde R, Das AK, Pocham-</span></p>
<p style="top:388.5pt;left:123.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">R (2016) The current landscape of the</span></p>
<p style="top:398.0pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tromal cell secretome: A new paradigm for</span></p>
<p style="top:407.4pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">eration.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cytotherapy</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 18</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 13-24.</span></p>
<p style="top:416.9pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">dell R (2016) The use of umbilical stem</span></p>
<p style="top:426.4pt;left:124.5pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">athol</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 6</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 41-56.</span></p>
<p style="top:435.8pt;left:123.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">rama</span></p>
<p style="top:435.8pt;left:146.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">I,</span></p>
<p style="top:435.8pt;left:158.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Romero-Cordoba</span></p>
<p style="top:435.8pt;left:221.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">S,</span></p>
<p style="top:435.8pt;left:234.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Peralta-</span></p>
<p style="top:445.3pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">idalgo-Miranda A, Rodr&#xb4;&#x131;guez-Dorantes M</span></p>
<p style="top:454.8pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NAs transported by exosomes in body &#xfb02;u-</span></p>
<p style="top:464.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">s of intercellular communication in cancer.</span></p>
<p style="top:473.7pt;left:121.4pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ther</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 7</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1327-1338.</span></p>
<p style="top:483.2pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">PC (2010) Molecular imaging of stem cell</span></p>
<p style="top:492.6pt;left:127.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in myocardial disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Curr Cardiovasc</span></i></p>
<p style="top:502.1pt;left:127.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">106-112.</span></p>
<p style="top:511.6pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">olasco P, Moscatelli D, Silani V, Cova L</span></p>
<p style="top:521.0pt;left:123.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ependent side effect of superparamagnetic</span></p>
<p style="top:530.5pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">oparticle labeling on cell motility in two</span></p>
<p style="top:539.9pt;left:123.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">populations.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> PLoS One</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 8</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, e78435.</span></p>
<p style="top:549.4pt;left:124.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">o S, Razini P, Farini A, Meregalli M, Belic-</span></p>
<p style="top:558.9pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">e Y (2011)</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> In vivo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> tracking of stem cell by</span></p>
<p style="top:568.3pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ies: Future prospects for mouse to human</span></p>
<p style="top:577.8pt;left:123.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">sue Eng Part B Rev</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 17</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1-11.</span></p>
<p style="top:587.3pt;left:124.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">i D, Wen X (2015) Particle systems for stem</span></p>
<p style="top:596.7pt;left:125.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">s.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Biomed Nanotechnol</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 11</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1107-1123.</span></p>
<p style="top:606.2pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">D, Tsai HM, Morshed RA, Kanojia D, Lo</span></p>
<p style="top:615.7pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Govind Y, Zhang L, Aboody KS, Lesniak</span></p>
<p style="top:625.1pt;left:126.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Balyasnikova IV (2015) Dynamic</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vivo</span></i></p>
<p style="top:634.6pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">g of neural stem cells functionalized with</span></p>
<p style="top:644.1pt;left:123.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">anoparticles for tracking of glioblastoma.</span></p>
<p style="top:653.5pt;left:127.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">279-284.</span></p>
<p style="top:663.0pt;left:125.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">YH, Kim JH, Kang KW, Tae EL, Youn</span></p>
<p style="top:672.4pt;left:121.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">m SK, Kwon JT, Cho MH, Lee YS, Jeong</span></p>
<p style="top:681.9pt;left:128.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lee DS (2012) Development and</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vivo</span></i></p>
<p style="top:76.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">imaging of a PET/MRI nanoprobe with enhanced NIR &#xfb02;u-</span></p>
<p style="top:85.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">orescence by dye encapsulation.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Nanomedicine (Lond)</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 7</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:95.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">219-229.</span></p>
<p style="top:104.6pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[92]</span></p>
<p style="top:104.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yang B, Brahmbhatt A, Nieves Torres E, Thielen B,</span></p>
<p style="top:114.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">McCall DL, Engel S, Bansal A, Pandey MK, Dietz AB,</span></p>
<p style="top:123.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Leof EB, DeGrado TR, Mukhopadhyay D, Misra S (2016)</span></p>
<p style="top:133.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Tracking and therapeutic value of human adipose tissue-</span></p>
<p style="top:142.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">derivedmesenchymalstemcelltransplantationinreducing</span></p>
<p style="top:151.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">venous neointimal hyperplasia associated with arteriove-</span></p>
<p style="top:161.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">nous &#xfb01;stula.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Radiology</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 279</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 513-522.</span></p>
<p style="top:170.8pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[93]</span></p>
<p style="top:170.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Nagarajan S, Zhang Y (2011) Upconversion &#xfb02;uorescent</span></p>
<p style="top:180.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">nanoparticles as a potential tool for in-depth imaging.</span></p>
<p style="top:189.8pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Nanotechnology</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 22</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 395101.</span></p>
<p style="top:199.2pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[94]</span></p>
<p style="top:199.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Rosenholm JM, Gulin-Sarfraz T, Mamaeva V, Niemi R,</span></p>
<p style="top:206.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#xa8;Ozliseli E, Desai D, Antfolk D, von Haartman E, Lindberg</span></p>
<p style="top:218.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">D, Prabhakar N, N&#xa8;areoja T, Sahlgren C (2016) Prolonged</span></p>
<p style="top:227.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">dye release from mesoporous silica-based imaging probes</span></p>
<p style="top:237.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">facilitates long-term optical tracking of cell populations</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in</span></i></p>
<p style="top:246.5pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">vivo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Small</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 12</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1578-1592.</span></p>
<p style="top:256.0pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[95]</span></p>
<p style="top:256.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Page MJ, Lourenc&#xb8;o AL, David T, LeBeau AM, Cat-</span></p>
<p style="top:265.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">taruzza F, Castro HC, VanBrocklin HF, Coughlin SR,</span></p>
<p style="top:274.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Craik CS (2015) Non-invasive imaging and cellular track-</span></p>
<p style="top:284.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ingofpulmonaryembolibynear-infrared&#xfb02;uorescenceand</span></p>
<p style="top:293.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">positron-emission tomography.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Nat Commun</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 6</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 8448.</span></p>
<p style="top:303.3pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[96]</span></p>
<p style="top:303.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lehtivuori H, Bhattacharya S, Angenent-Mari NM,</span></p>
<p style="top:312.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Satyshur KA, Forest KT (2015) Removal of chromophore-</span></p>
<p style="top:322.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">proximal polar atoms decreases water content and</span></p>
<p style="top:331.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">increases &#xfb02;uorescence in a near infrared phyto&#xfb02;uor.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Front</span></i></p>
<p style="top:341.2pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Mol Biosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 2</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 65.</span></p>
<p style="top:350.7pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[97]</span></p>
<p style="top:350.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wegner KD, Hildebrandt N (2015) Quantum dots: Bright</span></p>
<p style="top:360.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and versatile</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vitro</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> and</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vivo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> &#xfb02;uorescence imaging</span></p>
<p style="top:369.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">biosensors.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Chem Soc Rev</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 44</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 4792-4834.</span></p>
<p style="top:379.0pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[98]</span></p>
<p style="top:379.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Von der Haar K, Lavrentieva A, Stahl F, Scheper T, Blume</span></p>
<p style="top:388.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">C (2015) Lost signature: Progress and failures in</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vivo</span></i></p>
<p style="top:398.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tracking of implanted stem cells.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Appl Microbiol Biotech-</span></i></p>
<p style="top:407.4pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">nol</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 99</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 9907-9922.</span></p>
<p style="top:416.9pt;left:289.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[99]</span></p>
<p style="top:416.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhao JY, Chen G, Gu YP, Cui R, Zhang ZL, Yu ZL, Tang</span></p>
<p style="top:426.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">B, Zhao YF, Pang DW (2016) Ultrasmall magnetically</span></p>
<p style="top:435.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">engineered Ag2Se quantum dots for instant ef&#xfb01;cient label-</span></p>
<p style="top:445.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ing and whole-body high-resolution multimodal real-time</span></p>
<p style="top:454.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">tracking of cell-derived microvesicles.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Am Chem Soc</span></i></p>
<p style="top:464.2pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">138</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1893-1903.</span></p>
<p style="top:473.7pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[100]</span></p>
<p style="top:473.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D,</span></p>
<p style="top:483.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Jones E (2011) Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Lancet</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 377</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1019-</span></p>
<p style="top:492.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1031.</span></p>
<p style="top:502.1pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[101]</span></p>
<p style="top:502.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis</span></p>
<p style="top:511.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W,</span></p>
<p style="top:521.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton</span></p>
<p style="top:530.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">RL, DeKosky ST (2008) Post-mortem correlates of</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> in vivo</span></i></p>
<p style="top:539.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s</span></p>
<p style="top:549.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Brain</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 131</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">(Pt 6), 1630-1645.</span></p>
<p style="top:558.9pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[102]</span></p>
<p style="top:558.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kitazawa M, Medeiros R, Laferla FM (2012) Transgenic</span></p>
<p style="top:568.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mouse models of Alzheimer disease: Developing a better</span></p>
<p style="top:577.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">model as a tool for therapeutic interventions.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Curr Pharm</span></i></p>
<p style="top:587.3pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Des</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 18</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1131-1147.</span></p>
<p style="top:596.7pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[103]</span></p>
<p style="top:596.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera</span></p>
<p style="top:606.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Car-</span></p>
<p style="top:615.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">son CT, Laurent LC, Marsala M, Gage FH, Remes AM,</span></p>
<p style="top:625.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Koo EH, Goldstein LS (2012) Probing sporadic and famil-</span></p>
<p style="top:634.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ial Alzheimer&#x2019;s disease using induced pluripotent stem</span></p>
<p style="top:644.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Nature</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 482</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 216-220.</span></p>
<p style="top:653.5pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[104]</span></p>
<p style="top:653.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S,</span></p>
<p style="top:663.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">D&#x2019;Avanzo C, Chen H, Hooli B, Asselin C, Muffat J,</span></p>
<p style="top:672.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM,</span></p>
<p style="top:681.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Woolf CJ, Wagner SL, Tanzi RE, Kim DY (2014) A</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:50.2pt;left:477.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1229</span></p>
<p style="top:76.2pt;left:124.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">nal human neural cell culture model of</span></p>
<p style="top:85.7pt;left:124.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">sease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Nature</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 515</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 274-278.</span></p>
<p style="top:95.1pt;left:122.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Aronson J, Kim YH, Choi SH, Tanzi RE,</span></p>
<p style="top:104.6pt;left:122.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">5) Alzheimer&#x2019;s in 3D culture: Challenges</span></p>
<p style="top:114.0pt;left:122.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">es.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Bioessays</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 37</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 1139-1148.</span></p>
<p style="top:123.5pt;left:123.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">kanen-Mattila M, Shahsavani M, Falk A,</span></p>
<p style="top:133.0pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">erland A (2014) A 3D Alzheimer&#x2019;s disease</span></p>
<p style="top:142.4pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and the induction of P21-activated kinase</span></p>
<p style="top:151.9pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ng in iPSC derived neurons.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Biomaterials</span></i></p>
<p style="top:170.8pt;left:128.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Reyna S, Woodruff G (2015) Probing</span></p>
<p style="top:180.3pt;left:122.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease using human-induced</span></p>
<p style="top:189.8pt;left:123.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">m cell technology.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurotherapeutics</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 12</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:208.7pt;left:125.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">lipsMJ,PinillaI,HeiD,GammDM(2014)</span></p>
<p style="top:218.2pt;left:123.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">otent stem cells as custom therapeutics for</span></p>
<p style="top:227.6pt;left:123.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Progress and rationale.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Exp Eye Res</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 123</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:246.5pt;left:129.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M, Borah BR, Nakano I (2014) Ethics</span></p>
<p style="top:256.0pt;left:126.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">clinical research for age-related macular</span></p>
<p style="top:265.5pt;left:122.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Patient-centered risk-bene&#xfb01;t analysis.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem</span></i></p>
<p style="top:274.9pt;left:126.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">3-752.</span></p>
<p style="top:284.4pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ijewicz-Nawrot M, Rodrigez-Arellano JJ,</span></p>
<p style="top:293.9pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ykova E (2016) Mesenchymal stem cells</span></p>
<p style="top:303.3pt;left:124.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ng memory in the 3xTg-AD mouse model</span></p>
<p style="top:312.8pt;left:126.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease,</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Int J Mol Sci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 17</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> pii, E152.</span></p>
<p style="top:322.3pt;left:127.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang XR, Yang H, Wei LF, Wang Y, Xu</span></p>
<p style="top:331.7pt;left:123.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">C, Bi JZ, Wang XY (2016) Wharton&#x2019;s Jelly-</span></p>
<p style="top:341.2pt;left:125.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">hymal stem cells alleviate memory de&#xfb01;cits</span></p>
<p style="top:350.7pt;left:124.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">amyloid-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> deposition in an APP/PS1 trans-</span></p>
<p style="top:360.1pt;left:125.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">odel.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Clin Exp Med</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 16</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 89-98.</span></p>
<p style="top:369.6pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">imizu J, Takai K, Arimitsu N, Ueda Y, Wak-</span></p>
<p style="top:379.0pt;left:126.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">T, Suzuki N (2015) Cellular and molecular</span></p>
<p style="top:388.5pt;left:127.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the restoration of human APP transgenic</span></p>
<p style="top:398.0pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">e dysfunction after transplant of human iPS</span></p>
<p style="top:407.4pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ural cells.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Exp Neurol</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 271</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 423-431.</span></p>
<p style="top:416.9pt;left:124.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">D, Chang EH, Kim JH, Hwang JW, Kim</span></p>
<p style="top:426.4pt;left:125.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim SH, Oh JS, Shim SM, Na DL, Oh W,</span></p>
<p style="top:435.8pt;left:123.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">15) GDF-15 secreted from human umbili-</span></p>
<p style="top:445.3pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mesenchymal stem cells delivered through</span></p>
<p style="top:454.8pt;left:125.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">al &#xfb02;uid promotes hippocampal neurogene-</span></p>
<p style="top:464.2pt;left:123.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">c activity in an Alzheimer&#x2019;s disease model.</span></p>
<p style="top:473.7pt;left:127.5pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">24</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 2378-2390.</span></p>
<p style="top:483.2pt;left:120.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">K, Kim IS, Lee H, Kim M, Yun S, Hwang</span></p>
<p style="top:492.6pt;left:125.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">k KI (2015) Human neural stem cells alle-</span></p>
<p style="top:502.1pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">er-like pathology in a mouse model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Mol</span></i></p>
<p style="top:511.6pt;left:123.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">10</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 38.</span></p>
<p style="top:521.0pt;left:121.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">C, Xuan A, Xu L, Bao G, Liu F, Fang J,</span></p>
<p style="top:530.5pt;left:127.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Treatment ef&#xfb01;cacy of NGF nanoparticles</span></p>
<p style="top:539.9pt;left:123.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ral stem cell transplantation on Alzheimer&#x2019;s</span></p>
<p style="top:549.4pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">rats.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Med Sci Monit</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 21</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 3608-3615.</span></p>
<p style="top:558.9pt;left:124.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">med HH, Atta HM, Ghazy MA, Aglan HA</span></p>
<p style="top:568.3pt;left:122.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">al of bone marrow mesenchymal stem cells</span></p>
<p style="top:577.8pt;left:126.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of Alzheimer&#x2019;s disease in female rats.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell</span></i></p>
<p style="top:587.3pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">67-1383.</span></p>
<p style="top:596.7pt;left:121.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim S, Joo Y, Chong YH, Suh YH, Chang</span></p>
<p style="top:606.2pt;left:125.7pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">vo</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> imaging of human adipose-derived stem</span></p>
<p style="top:615.7pt;left:123.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mer&#x2019;s disease animal model.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Biomed Opt</span></i></p>
<p style="top:634.6pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Q, Shen YY, Wang PY, Li MH, Teng GY</span></p>
<p style="top:644.1pt;left:127.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">stem cell transplantation improves spa-</span></p>
<p style="top:653.5pt;left:123.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">nd memory via neuronal regeneration in</span></p>
<p style="top:663.0pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cursor protein/presenilin 1/tau triple trans-</span></p>
<p style="top:672.4pt;left:125.5pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">m J Alzheimers Dis Other Demen</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 29</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:76.2pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[119]</span></p>
<p style="top:76.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yan Y, Ma T, Gong K, Ao Q, Zhang X, Gong Y (2014)</span></p>
<p style="top:85.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Adipose-derived mesenchymal stem cell transplantation</span></p>
<p style="top:95.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">promotes adult neurogenesis in the brains of Alzheimer&#x2019;s</span></p>
<p style="top:104.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neural Regen Res</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 9</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 798-805.</span></p>
<p style="top:114.0pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[120]</span></p>
<p style="top:114.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Khairallah M, Kassem LA, Yassin NA, El Din MA,</span></p>
<p style="top:123.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zekri M, Attia M (2014) The hematopoietic growth factor</span></p>
<p style="top:133.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x201c;erythropoietin&#x201d; enhances the therapeutic effect of mes-</span></p>
<p style="top:142.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">enchymal stem cells in Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Pak J Biol Sci</span></i></p>
<p style="top:151.9pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">17</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 9-21.</span></p>
<p style="top:161.4pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[121]</span></p>
<p style="top:161.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Gu G, Wang P, Zhang W, Li M (2014) Effects of trans-</span></p>
<p style="top:170.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">planted neural stem cells on synaptogenesis in APP/PS1</span></p>
<p style="top:180.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Zhonghua Yi Xue Za Zhi</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 94</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 539-543.</span></p>
<p style="top:189.8pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[122]</span></p>
<p style="top:189.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang W, Wang PJ, Sha HY, Ni J, Li MH, Gu GJ (2014)</span></p>
<p style="top:199.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Neural stem cell transplants improve cognitive function</span></p>
<p style="top:208.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">without altering amyloid pathology in an APP/PS1 double</span></p>
<p style="top:218.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transgenic model of Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Mol Neurobiol</span></i></p>
<p style="top:227.6pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">50</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 423-437.</span></p>
<p style="top:237.1pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[123]</span></p>
<p style="top:237.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang W, Wang GM, Wang PJ, Zhang Q, Sha SH (2014)</span></p>
<p style="top:246.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Effects of neural stem cells on synaptic proteins and mem-</span></p>
<p style="top:256.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ory in a mouse model of Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neurosci</span></i></p>
<p style="top:265.5pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Res</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 92</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 185-194.</span></p>
<p style="top:274.9pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[124]</span></p>
<p style="top:274.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ben-Menachem-Zidon O, Ben-Menahem Y1, Ben-Hur</span></p>
<p style="top:284.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">T2, Yirmiya R (2014) Intra-hippocampal transplantation</span></p>
<p style="top:293.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of neural precursor cells with transgenic over-expression</span></p>
<p style="top:303.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">of IL-1 receptor antagonist rescues memory and neuro-</span></p>
<p style="top:312.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">genesis impairments in an Alzheimer&#x2019;s disease model.</span></p>
<p style="top:322.3pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Neuropsychopharmacology</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 39</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 401-414.</span></p>
<p style="top:331.7pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[125]</span></p>
<p style="top:331.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Bobkova NV, Poltavtseva RA, Samokhin AN, Sukhikh</span></p>
<p style="top:341.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">GT (2013) Therapeutic effect of mesenchymal multipotent</span></p>
<p style="top:350.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">stromal cells on memory in animals with Alzheimer-type</span></p>
<p style="top:360.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neurodegeneration.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Bull Exp Biol Med</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 156</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 119-121.</span></p>
<p style="top:369.6pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[126]</span></p>
<p style="top:369.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhang W, Wang PJ, Gu GJ1, Li MH1, Gao XL (2013)</span></p>
<p style="top:379.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Effects of neural stem cells transplanted into an animal</span></p>
<p style="top:388.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">model of Alzheimer disease on A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> plaques.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Zhonghua Yi</span></i></p>
<p style="top:398.0pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Xue Za Zhi</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 93</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 3636-3639.</span></p>
<p style="top:407.4pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[127]</span></p>
<p style="top:407.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Li WY, Jin RL, Hu XY (2012) Migration of PKH26-</span></p>
<p style="top:416.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">labeled mesenchymal stem cells in rats with Alzheimer&#x2019;s</span></p>
<p style="top:426.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Zhejiang Da Xue Xue Bao Yi Xue Ban</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 41</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:435.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">659-664.</span></p>
<p style="top:445.3pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[128]</span></p>
<p style="top:445.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kim JY, Kim DH, Kim JH, Lee D, Jeon HB, Kwon SJ, Kim</span></p>
<p style="top:454.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">SM, Yoo YJ, Lee EH, Choi SJ, Seo SW, Lee JI, Na DL,</span></p>
<p style="top:464.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yang YS, Oh W, Chang JW (2012) Soluble intracellular</span></p>
<p style="top:473.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">adhesion molecule-1 secreted by human umbilical cord</span></p>
<p style="top:483.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">blood-derived mesenchymal stem cell reduces amyloid-</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:492.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">plaques.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Cell Death Differ</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 19</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 680-691.</span></p>
<p style="top:502.1pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[129]</span></p>
<p style="top:502.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chen SQ, Cai Q, Shen YY, Wang PJ, Teng GJ, Li</span></p>
<p style="top:511.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">MH, Zhang W, Zang FC (2012) (1)H-MRS evaluation of</span></p>
<p style="top:521.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">therapeutic effect of neural stem cell transplantation on</span></p>
<p style="top:530.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease in A</span><span style="font-family:MathematicalPi,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">PP/PS1 double transgenic mice.</span></p>
<p style="top:539.9pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">J Alzheimers Dis</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 28</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 71-80.</span></p>
<p style="top:549.4pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[130]</span></p>
<p style="top:549.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Xue S, Chen C, Dong W, Hui G, Liu T, Guo L (2012)</span></p>
<p style="top:558.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Therapeutic effects of human amniotic epithelial cell</span></p>
<p style="top:568.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transplantation on double-transgenic mice co-expressing</span></p>
<p style="top:577.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">APPswe and PS1</span><i><span style="font-family:MTMI,serif;font-size:8.0pt">&#xfffd;</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">E9-deleted genes.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Sci China Life Sci</span></i></p>
<p style="top:587.3pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">55</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 132-140.</span></p>
<p style="top:596.7pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[131]</span></p>
<p style="top:596.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Park D, Lee HJ, Joo SS, Bae DK, Yang G, Yang YH,</span></p>
<p style="top:606.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Lim I, Matsuo A, Tooyama I, Kim YB, Kim SU (2012)</span></p>
<p style="top:615.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Human neural stem cells over-expressing choline acetyl-</span></p>
<p style="top:625.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">transferase restore cognition in rat model of cognitive</span></p>
<p style="top:634.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">dysfunction.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Exp Neurol</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 234</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 521-526.</span></p>
<p style="top:644.1pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[132]</span></p>
<p style="top:644.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Klinge PM, Harmening K, Miller MC, Heile A, Wallrapp</span></p>
<p style="top:653.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">C, Geigle P, Brinker T (2011) Encapsulated native and</span></p>
<p style="top:663.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">glucagon-like peptide-1 transfected human mesenchymal</span></p>
<p style="top:672.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">stem cells in a transgenic mouse model of Alzheimer&#x2019;s</span></p>
<p style="top:681.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurosci Lett</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 497</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 6-10.</span></p>


<p style="top:50.2pt;left:150.9pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">H. Salem et al. / Potential Innovative Role of Stem Cells in AD Management</span></i></p>
<p style="top:76.2pt;left:126.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">CF, Dong WL, Hui GZ, Liu TJ, Guo LH</span></p>
<p style="top:85.7pt;left:123.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">rebroventricular transplantation of human</span></p>
<p style="top:95.1pt;left:122.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">helial cells ameliorates spatial memory</span></p>
<p style="top:104.6pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">oubly transgenic mice coexpressing APP-</span></p>
<p style="top:114.0pt;left:124.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">E9-deleted genes.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Chin Med J (Engl)</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 124</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:133.0pt;left:121.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">P, Ren YJ, Liu GJ, Gong FC, Zhong H, Bi S</span></p>
<p style="top:142.4pt;left:125.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ion of</span><i><span style="font-family:MTMI,serif;font-size:8.0pt"> &#x3b4;</span></i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Np73 in hippocampus of APP/PS1</span></p>
<p style="top:151.9pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">e following GFP-BMSCs transplantation.</span></p>
<p style="top:161.4pt;left:126.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1109-1114.</span></p>
<p style="top:170.8pt;left:128.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Jiang W, Zhang Y, Chen L, Hou N, Liu</span></p>
<p style="top:180.3pt;left:124.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">n J, Li T (2011) Immortalized mesenchy-</span></p>
<p style="top:189.8pt;left:124.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">: An alternative to primary mesenchymal</span></p>
<p style="top:199.2pt;left:123.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">euronal differentiation and neuroregenera-</span></p>
<p style="top:208.7pt;left:126.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">studies.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Biomed Sci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 25</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 87.</span></p>
<p style="top:218.2pt;left:120.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">K, Lee H, Shin JW, Carter JE, Sakamoto T,</span></p>
<p style="top:227.6pt;left:126.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(2010) The therapeutic potential of human</span></p>
<p style="top:237.1pt;left:125.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">blood-derived mesenchymal stem cells in</span></p>
<p style="top:246.5pt;left:124.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">sease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurosci Lett</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 481</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 30-35.</span></p>
<p style="top:256.0pt;left:129.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">JM, Shen L, Yao TL, Tian JH (2010)</span></p>
<p style="top:265.5pt;left:126.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">on tomography imaging of cell transplan-</span></p>
<p style="top:274.9pt;left:120.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">model of Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Zhongguo Yi</span></i></p>
<p style="top:284.4pt;left:124.0pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">an Xue Bao</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 32</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 210-214.</span></p>
<p style="top:293.9pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">T, Wang YT, McLarnon JG (2009) Neu-</span></p>
<p style="top:303.3pt;left:122.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells attenuate in&#xfb02;ammatory reactivity and</span></p>
<p style="top:312.8pt;left:124.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">n an animal model of in&#xfb02;amed AD brain.</span></p>
<p style="top:322.3pt;left:122.0pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">mation</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 6</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 39.</span></p>
<p style="top:331.7pt;left:122.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">o M, Ji WD, Long DH (2009) Effects of</span></p>
<p style="top:341.2pt;left:124.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">al stem cells in Alzheimer&#x2019;s disease rats.</span></p>
<p style="top:350.7pt;left:125.7pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">50</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 167-171.</span></p>
<p style="top:360.1pt;left:125.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">g DH, Gu HG, Yang DD, Hong LP, Leng</span></p>
<p style="top:369.6pt;left:121.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">NF improves the effects of neural stem cells</span></p>
<p style="top:379.0pt;left:122.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">del of Alzheimer&#x2019;s disease with unilateral</span></p>
<p style="top:388.5pt;left:123.9pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ia-fornix.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neurosci Lett</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 440</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 331-335.</span></p>
<p style="top:398.0pt;left:123.2pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">A, Yoshimoto R, Kawahara Y, Manabe T,</span></p>
<p style="top:407.4pt;left:123.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ashima M, Yuge L (2008) Neural stem cells</span></p>
<p style="top:416.9pt;left:124.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ng and memory in rats with Alzheimer&#x2019;s</span></p>
<p style="top:426.4pt;left:122.3pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">biology</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 75</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 186-194.</span></p>
<p style="top:435.8pt;left:122.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">afauci G, Rubenstein R, Mazur-Kolecka</span></p>
<p style="top:445.3pt;left:129.7pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">W, Frackowiak J (2008) The effect of</span></p>
<p style="top:76.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">amyloidosis-beta and ageing on proliferation of neuronal</span></p>
<p style="top:85.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">progenitor cells in APP-transgenic mouse hippocampus</span></p>
<p style="top:95.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">and in culture.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Acta Neuropathol</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 116</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 419-424.</span></p>
<p style="top:104.6pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[143]</span></p>
<p style="top:104.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg</span></p>
<p style="top:114.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">CD, Zeng J, Luo D, Ehrhart J, Mori T, Sanberg PR, Tan</span></p>
<p style="top:123.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">J (2008) Peripherally administered human umbilical cord</span></p>
<p style="top:133.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">blood cells reduce parenchymal and vascular beta-amyloid</span></p>
<p style="top:142.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">deposits in Alzheimer mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Stem Cells Dev</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 17</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 423-439.</span></p>
<p style="top:151.9pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[144]</span></p>
<p style="top:151.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Li LY, Li JT, Wu QY, Li J, Feng ZT, Liu S, Wang TH</span></p>
<p style="top:161.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">(2008) Transplantation of NGF-gene-modi&#xfb01;ed bone mar-</span></p>
<p style="top:170.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">row stromal cells into a rat model of Alzheimer&#x2019; disease.</span></p>
<p style="top:180.3pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">J Mol Neurosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 34</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 157-163.</span></p>
<p style="top:189.8pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[145]</span></p>
<p style="top:189.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yamasaki</span></p>
<p style="top:189.8pt;left:349.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">TR,</span></p>
<p style="top:189.8pt;left:368.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Blurton-Jones</span></p>
<p style="top:189.8pt;left:420.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">M,</span></p>
<p style="top:189.8pt;left:436.5pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Morrissette</span></p>
<p style="top:189.8pt;left:480.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">DA,</span></p>
<p style="top:199.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kitazawa M, Oddo S, LaFerla FM (2007) Neural stem</span></p>
<p style="top:208.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cells improve memory in an inducible mouse model of</span></p>
<p style="top:218.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">neuronal loss.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Neurosci</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 27</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 11925-11933.</span></p>
<p style="top:227.6pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[146]</span></p>
<p style="top:227.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhan YQ, Wang FR, Li FG, Xing BZ, Fang X, Zhang</span></p>
<p style="top:237.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">SM (2007) Study on distribution of neural stem cells in</span></p>
<p style="top:246.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">the brain of Alzheimer disease transgenic mice through</span></p>
<p style="top:256.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">caudal vein transplantation.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Zhonghua Yi Xue Za Zhi</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 87</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">,</span></p>
<p style="top:265.5pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">1786-1788.</span></p>
<p style="top:274.9pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[147]</span></p>
<p style="top:274.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Yang C, Zhang Q, Wang SC, Qiao P, Zhang Z (2007)</span></p>
<p style="top:284.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Neural stem cells transplantation improved learning and</span></p>
<p style="top:293.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">memory abilities in Alzheimer&#x2019;s disease rat.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Zhongguo</span></i></p>
<p style="top:303.3pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Ying Yong Sheng Li Xue Za Zhi</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 23</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 159-161.</span></p>
<p style="top:312.8pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[148]</span></p>
<p style="top:312.8pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Wang Q, Matsumoto Y, Shindo T, Miyake K, Shindo A,</span></p>
<p style="top:322.3pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Kawanishi M, Kawai N, Tamiya T, Nagao S (2006) Neural</span></p>
<p style="top:331.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">stem cells transplantation in cortex in a mouse model of</span></p>
<p style="top:341.2pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Alzheimer&#x2019;s disease.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> J Med Invest</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 53</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 61-69.</span></p>
<p style="top:350.7pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[149]</span></p>
<p style="top:350.7pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Zhao Z, Hu H, Feng G (2006) Learning and memory</span></p>
<p style="top:360.1pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">amelioration of transplantation of the neural stem cells</span></p>
<p style="top:369.6pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">modi&#xfb01;ed with human brain-derived neurotrophic factor</span></p>
<p style="top:379.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">gene on Alzheimer disease model rat.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Zhongguo Xiu Fu</span></i></p>
<p style="top:388.5pt;left:310.8pt;line-height:8.0pt"><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">Chong Jian Wai Ke Za Zhi</span></i><b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> 19</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 331-334.</span></p>
<p style="top:398.0pt;left:285.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">[150]</span></p>
<p style="top:398.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori</span></p>
<p style="top:407.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">T, Cao C, Arendash GW (2009) Granulocyte colony stim-</span></p>
<p style="top:416.9pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">ulating factor decreases brain amyloid burden and reverses</span></p>
<p style="top:426.4pt;left:310.8pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">cognitive impairment in Alzheimer&#x2019;s mice.</span><i><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Neuroscience</span></i></p>
<p style="top:435.8pt;left:310.8pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">163</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt">, 55-72.</span></p>

</div>
